0001193125-18-311190.txt : 20181030 0001193125-18-311190.hdr.sgml : 20181030 20181030060808 ACCESSION NUMBER: 0001193125-18-311190 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 53 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181030 DATE AS OF CHANGE: 20181030 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UNIVERSAL BIOSENSORS INC CENTRAL INDEX KEY: 0001279695 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 980424072 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-52607 FILM NUMBER: 181145428 BUSINESS ADDRESS: STREET 1: 1 CORPORATE AVENUE STREET 2: ROWVILLE CITY: VICTORIA STATE: C3 ZIP: 3178 BUSINESS PHONE: 613-9213-9000 MAIL ADDRESS: STREET 1: 1 CORPORATE AVENUE STREET 2: ROWVILLE CITY: VICTORIA STATE: C3 ZIP: 3178 10-Q 1 d631294d10q.htm 10-Q 10-Q
Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 10-Q

 

 

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2018

Commission File Number: 000-52607

 

 

Universal Biosensors, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware     98-0424072

(State or other jurisdiction of

incorporation or organization)

   

(I.R.S. Employer

Identification Number)

Universal Biosensors, Inc.

1 Corporate Avenue,

Rowville, 3178, Victoria

Australia

    Not Applicable
(Address of principal executive offices)     (Zip Code)

Telephone: +61 3 9213 9000

(Registrant’s telephone number, including area code)

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  ☒    No  ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  ☒    No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large Accelerated Filer      Accelerated Filer  
Non-Accelerated Filer      Smaller reporting company  
Emerging growth company       

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 177,001,884 shares of Common Stock, U.S.$0.0001 par value, outstanding as of October 30, 2018.

 

 

 


Table of Contents

UNIVERSAL BIOSENSORS, INC.

TABLE OF CONTENTS

 

     Page  

PART I

  FINANCIAL INFORMATION   

Item 1

  Financial Statements   
  1)   Consolidated condensed balance sheets at September 30, 2018 and December 31, 2017 (unaudited)      2  
  2)   Consolidated condensed statements of comprehensive income/(loss) for the three and nine months ended September 30, 2018 and 2017 (unaudited)      3  
  3)   Consolidated condensed statements of changes in stockholder’s equity and comprehensive income/(loss) for the period ended September 30, 2018 and 2017 (unaudited)      4  
  4)   Consolidated condensed statements of cash flows for the nine months ended September 30, 2018 and 2017 (unaudited)      5  
  5)   Notes to consolidated condensed financial statements (unaudited)      6  

Item 2

  Management’s Discussion and Analysis of Financial Condition and Results of Operations      26  

Item 3

  Quantitative and Qualitative Disclosures About Market Risk      39  

Item 4

  Controls and Procedures      40  

PART II

  OTHER INFORMATION   

Item 1

  Legal Proceedings      41  

Item 1A

  Risk Factors      41  

Item 2

  Unregistered Sales of Equity Securities and Use of Proceeds      42  

Item 3

  Defaults Upon Senior Securities      42  

Item 4

  Mine Safety Disclosures      43  

Item 5

  Other Information      43  

Item 6

  Exhibits      43  
  Exhibit 31.1   
  Exhibit 31.2   
  Exhibit 32

Exhibit 101

  

SIGNATURES

     44  

Unless otherwise noted, references on this Form 10-Q to “Universal Biosensors”, the “Company,” “Group,” “we,” “our” or “us” means Universal Biosensors, Inc. (“UBI”) a Delaware corporation and, when applicable, its wholly owned Australian operating subsidiary, Universal Biosensors Pty Ltd (“UBS”) and UBS’ wholly owned Canadian operating subsidiary, Hemostasis Reference Laboratory Inc. (“HRL”). Unless otherwise noted, all references in this Form 10-Q to “$”, “A$” or “dollars” and dollar amounts are references to Australian dollars. References to “US$” are references to United States dollars. References to “CAD$” are references to Canadian dollars.

 

 

1


Table of Contents

Universal Biosensors, Inc.

 

Item 1 Financial Statements

Consolidated Condensed Balance Sheets (Unaudited)

 

     September 30,     December 31,  
     2018     2017  
     A$     A$  

ASSETS

    

Current assets:

    

Cash and cash equivalents

     28,531,432       26,259,918  

Inventories, net

     481,282       662,132  

Accounts receivable

     4,902,417       4,397,268  

Prepayments

     665,312       887,303  

Restricted cash

     2,915,949       15,309  

Other current assets

     43,331,479       860,254  
  

 

 

   

 

 

 

Total current assets

     80,827,871       33,082,184  

Non-current assets:

    

Property, plant and equipment

     37,359,123       37,224,442  

Less accumulated depreciation

     (28,790,321     (27,264,680
  

 

 

   

 

 

 

Property, plant and equipment - net

     8,568,802       9,959,762  
  

 

 

   

 

 

 

Restricted cash

     320,000       3,220,000  
  

 

 

   

 

 

 

Total non-current assets

     8,888,802       13,179,762  
  

 

 

   

 

 

 

Total assets

     89,716,673       46,261,946  
  

 

 

   

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

    

Current liabilities:

    

Accounts payable

     472,930       329,586  

Accrued expenses

     1,643,828       1,472,692  

Short term secured loan

     20,660,753       0  

Other liabilities

     2,836,614       2,626,413  

Deferred revenue

     2,356,583       2,356,583  

Employee entitlements liabilities

     1,278,714       1,550,182  
  

 

 

   

 

 

 

Total current liabilities

     29,249,422       8,335,456  

Non-current liabilities:

    

Asset retirement obligations

     2,600,000       2,600,000  

Employee entitlements liabilities

     50,538       64,358  

Long term secured loan

     0       19,029,076  

Deferred revenue

     3,463,737       3,463,737  
  

 

 

   

 

 

 

Total non-current liabilities

     6,114,275       25,157,171  
  

 

 

   

 

 

 

Total liabilities

     35,363,697       33,492,627  
  

 

 

   

 

 

 

Commitments and contingencies

     0       0  
  

 

 

   

 

 

 

Stockholders’ equity:

    

Preferred stock, US$0.01 par value. Authorized 1,000,000 shares;

    

issued and outstanding nil at September 30, 2018 (nil at December 31, 2017)

    

Common stock, US$0.0001 par value. Authorized 300,000,000 shares; issued and

    

outstanding 177,001,884 shares at September 30, 2018 (176,498,550 at December 31, 2017)

     17,700       17,650  

Additional paid-in capital

     93,678,895       93,450,721  

Accumulated deficit

     (80,397,343     (79,632,626

Current year income/( loss)

     41,391,958       (764,717

Accumulated other comprehensive loss

     (338,234     (301,709
  

 

 

   

 

 

 

Total stockholders’ equity

     54,352,976       12,769,319  
  

 

 

   

 

 

 

Total liabilities and stockholders’ equity

     89,716,673       46,261,946  
  

 

 

   

 

 

 

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

 

2


Table of Contents

Universal Biosensors, Inc.

 

Consolidated Condensed Statements of Comprehensive Income/(Loss) (Unaudited)

 

     Three Months Ended September 30,     Nine Months Ended September 30,  
     2018     2017     2018     2017  
     A$     A$     A$     A$  

Revenue

        

Revenue from products

     227,649       1,764,855       1,131,319       4,062,470  

Revenue from services

     47,007,376       4,580,751       59,593,955       16,610,487  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total revenue

     47,235,025       6,345,606       60,725,274       20,672,957  

Operating costs & expenses

        

Cost of goods sold

     186,515       998,674       1,055,534       2,913,808  

Cost of services

     217,313       254,330       644,508       737,135  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total cost of goods sold & services

     403,828       1,253,004       1,700,042       3,650,943  
  

 

 

   

 

 

   

 

 

   

 

 

 

Contribution from products & services

     46,831,197       5,092,602       59,025,232       17,022,014  

Other operating costs & expenses

        

Product support

     8,750       205,317       202,899       537,010  

Depreciation

     451,481       636,000       1,519,375       1,485,014  

Research and development

     2,759,664       3,197,146       9,452,609       7,626,210  

General and administrative

     1,360,040       1,624,974       5,110,134       4,855,136  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total operating costs & expenses

     4,579,935       5,663,437       16,285,017       14,503,370  
  

 

 

   

 

 

   

 

 

   

 

 

 

Profit/(loss) from operations

     42,251,262       (570,835     42,740,215       2,518,644  

Other income/(expense)

        

Interest income

     175,643       15,772       365,542       74,625  

Interest expense

     0       (1,922     0       (8,649

Financing costs

     (734,946     (685,613     (2,118,069     (2,089,328

Exchange gain

     183,395       61,873       412,768       703,420  

Other

     (9,758     0       (8,498     119,932  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total other income/(expense)

     (385,666     (609,890     (1,348,257     (1,200,000

Net income/(loss) before tax

     41,865,596       (1,180,725     41,391,958       1,318,644  

Income tax benefit/(expense)

     0       0       0       0  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income/( loss)

     41,865,596       (1,180,725     41,391,958       1,318,644  
  

 

 

   

 

 

   

 

 

   

 

 

 

Earnings per share

        

Basic net income/(loss) per share

     0.24       (0.01     0.23       0.01  

Average weighted number of shares—basic

     176,859,637       176,410,144       176,620,235       176,395,711  

Diluted net income/(loss) per share

     0.24       (0.01     0.23       0.01  

Average weighted number of shares—diluted

     177,329,518       176,410,144       177,096,693       177,602,842  

Other comprehensive gain/(loss), net of tax:

        

Foreign currency translation reserve

     (31,391     (4,451     (36,525     (5,497
  

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive gain/(loss)

     (31,391     (4,451     (36,525     (5,497
  

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive gain/(loss)

     41,834,205       (1,185,176     41,355,433       1,313,147  
  

 

 

   

 

 

   

 

 

   

 

 

 

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

 

3


Table of Contents

Universal Biosensors, Inc.

 

Consolidated Condensed Statements of Changes in Stockholders’ Equity and Comprehensive Income/(Loss) (Unaudited)

 

     Ordinary shares      Additional Paid-
in Capital
    Accumulated
Deficit
    Accumulated
Other
Comprehensive
Loss
    Total
Stockholders’
Equity
 
     Shares      Amount  
    

 

     A$      A$     A$     A$     A$  

Balances at January 1, 2017

     176,386,884        17,639        93,167,465       (79,632,626     (298,203     13,254,275  

Net income

     0        0        0       1,318,644       0       1,318,644  

Exercise of stock options issued to employees

     44,999        4        762       0       0       766  

Other comprehensive loss

     0        0        0       0       (5,497     (5,497

Stock option expense

     0        0        354,243       0       0       354,243  
  

 

 

    

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

Balances at September 30, 2017

     176,431,883        17,643        93,522,470       (78,313,982     (303,700     14,922,431  
  

 

 

    

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

Balances at January 1, 2018

     176,498,550        17,650        93,450,721       (80,397,343     (301,709     12,769,319  

Net income

     0        0        0       41,391,958       0       41,391,958  

Exercise of stock options issued to employees

     503,334        50        (50     0       0       0  

Other comprehensive loss

     0        0        0       0       (36,525     (36,525

Stock option expense

     0        0        228,224       0       0       228,224  
  

 

 

    

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

Balances at September 30, 2018

     177,001,884        17,700        93,678,895       (39,005,385     (338,234     54,352,976  
  

 

 

    

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

 

4


Table of Contents

Universal Biosensors, Inc.

 

Consolidated Condensed Statements of Cash Flows (Unaudited)

 

     Nine Months Ended September 30,  
     2018     2017  
     A$     A$  

Cash flows from operating activities:

    

Net income

     41,391,958       1,318,644  

Adjustments to reconcile net income to net cash provided by operating activities:

    

Depreciation and amortization

     1,680,323       1,929,451  

Share based payments expense

     228,224       354,243  

Loss on fixed assets disposal

     8,498       2,409  

Unrealized foreign exchange gains

     (442,639     (159,889

Financing costs—amortization of warrants

     104,096       158,672  

Change in assets and liabilities:

    

Inventory

     180,850       196,982  

Accounts receivables

     (505,149     (949,175

Prepaid expenses and other current assets

     (42,249,234     90,616  

Deferred revenue

     0       (546,655

Employee entitlements

     (321,814     105,655  

Accounts payable and accrued expenses

     789,318       (314,914
  

 

 

   

 

 

 

Net cash provided by operating activities

     864,431       2,186,039  
  

 

 

   

 

 

 

Cash flows from investing activities:

    

Proceeds from sale of property, plant and equipment

     2,582       0  

Purchases of property, plant and equipment

     (308,669     (997,503
  

 

 

   

 

 

 

Net cash used in investing activities

     (306,087     (997,503
  

 

 

   

 

 

 

Cash flows from financing activities:

    

Repayment of borrowings

     (256,410     (334,811

Proceeds from stock options exercised

     0       767  
  

 

 

   

 

 

 

Net cash used in financing activities

     (256,410     (334,044
  

 

 

   

 

 

 

Net increase in cash, cash equivalents and restricted cash

     301,934       854,492  

Cash, cash equivalents and restricted cash at beginning of period

     29,495,227       23,622,322  

Effect of exchange rate fluctuations on the balances of cash held in foreign currencies

     1,970,220       (1,409,047
  

 

 

   

 

 

 

Cash, cash equivalents and restricted cash at end of period

     31,767,381       23,067,767  
  

 

 

   

 

 

 

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

 

5


Table of Contents

Universal Biosensors, Inc.

 

Notes to Consolidated Condensed Financial Statements (Unaudited)

Organization of the Company

We are a specialist medical diagnostics company focused primarily on the research, development and manufacture of in vitro diagnostic test devices for consumer and professional point-of-care use. In addition, we own, manage and operate a hemostasis laboratory.

Key aspects of our strategy for increasing shareholder value include:

 

   

executing on our existing business activities, including undertaking research and development activities for our customers and partners, manufacturing products (test strips and analyzers) and providing development and support services including providing laboratory services, to our customers and partners;

 

   

extending and demonstrating the broader application of our technology and seeking to enter into collaborative, strategic or distribution arrangements with other life sciences companies or other industry participants with respect to specific tests or specific fields;

 

   

participating in healthcare markets across the globe; and

 

   

identifying and pursuing related opportunities for growth.

Our plan of operations over the remainder of the fiscal year ending December 2018 is to:

 

   

manufacture products;

 

   

undertake research and development work;

 

   

provide the necessary post-market support for our customers and partners;

 

   

provide laboratory services for our customers and partners;

 

   

demonstrate the broader application of our technology platform for markets with significant commercial potential; and

 

   

seek to enter into collaborative, strategic or distribution arrangements with other life sciences companies or other industry participants with respect to the development and commercialization of specific tests or specific fields.

The Company’s first global strategic partnership was established with LifeScan, Inc. (“LifeScan”) in diabetes care. We have developed a blood glucose product with LifeScan (“OneTouch Verio®”) which is now available in countries that represent over 90% of the world self-monitoring blood glucose market. Unless otherwise noted, references to “LifeScan” in this document are references collectively or individually to LifeScan, Inc., and/or LifeScan Europe, a division of Cilag GmbH International, both affiliates of Johnson and Johnson. During the current quarter, LifeScan gave notice and exercised its right to “convert” its obligation to pay quarterly service fees to Universal Biosensors.

We are working with Siemens Healthcare Diagnostics, Inc. (“Siemens”) in relation to a range of products for the point-of-care coagulation testing market, pursuant to a Collaboration Agreement with Siemens (“Collaboration Agreement”). The first such product developed with Siemens, the Xprecia Stride™ Coagulation Analyzer, is now available in the United States, Europe, the Middle East, Africa, Asia Pacific, Latin America and Canada. Under the terms of a supply agreement with Siemens (“Supply Agreement”), UBS is the manufacturer of test strips for this product and further tests still in development for Siemens.

In addition, UBS is engaged in point-of-care coagulation product development for the consumer, home testing market which could be distributed globally on its own account.

Interim Financial Statements

The accompanying unaudited consolidated condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and with the instructions to Form 10-Q and Article 10 of Regulation S-X for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the nine months ended September 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018. The accompanying unaudited consolidated condensed financial statements should be read in conjunction with the financial statements and footnotes thereto as of and for the year ended December 31, 2017, included in the Annual Report on Form 10-K of Universal Biosensors, Inc. filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 23, 2018 (the “Annual Report”).

 

 

6


Table of Contents

Universal Biosensors, Inc.

Notes to Consolidated Condensed Financial Statements (Unaudited)

 

The year-end consolidated condensed balance sheets data as at December 31, 2017 was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain prior year amounts in the consolidated condensed financial statements have been reclassified to conform to the current presentation.

Basis of Presentation

The Company’s consolidated condensed financial statements have been prepared assuming the Company will continue as a going concern. We rely largely on our existing cash and cash equivalents balance and operating cash flow to provide for the working capital needs of our operations. We believe we have sufficient cash and cash equivalents to fund our operations for at least the next twelve months. However, in the event our financing needs for the foreseeable future are not able to be met by our existing cash and cash equivalents balance and operating cash flow, we would seek to raise funds through public or private equity offerings, debt financings, and through other means to meet the financing requirements. There is no assurance that funding would be available at acceptable terms, if at all.

Summary of Significant Accounting Policies

Principles of Consolidation

The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries, UBS and HRL. All intercompany balances and transactions have been eliminated on consolidation.

Use of Estimates

The preparation of the consolidated financial statements requires management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Significant items subject to such estimates and assumptions include the recognition of revenue, carrying amount of property, plant and equipment, deferred income taxes, asset retirement obligations, liabilities related to employee benefits, warrants and research and development tax incentive income. Actual results could differ from those estimates.

Cash, Cash Equivalents and Restricted Cash

The Company considers all highly liquid investments purchased with an initial maturity of three months or less to be cash equivalents. For cash and cash equivalents, the carrying amount approximates fair value due to the short maturity of those instruments. The Company maintains cash and restricted cash, which includes tenant security deposits, credit card security deposits and cash collateral for its borrowings. As of September 30, 2018, the Company has not realized any losses in such cash accounts and believes it is not exposed to any significant risk of loss.

Short-Term Investments (Held-to-maturity)

Short-term investments constitute all highly liquid investments with term to maturity from three months to twelve months. The carrying amount of short-term investments is equivalent to their fair value.

Concentration of Credit Risk and Other Risks and Uncertainties

Cash and cash equivalents and accounts receivable consist of financial instruments that potentially subject the Company to concentration of credit risk to the extent of the amount recorded on the consolidated condensed balance sheets. The Company’s cash and cash equivalents are primarily invested with one of Australia’s largest banks. The Company is exposed to credit risk in the event of default by the banks holding the cash or cash equivalents to the extent of the amount recorded on the consolidated condensed balance sheets. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company has not identified any collectability issues with respect to receivables.

 

7


Table of Contents

Universal Biosensors, Inc.

Notes to Consolidated Condensed Financial Statements (Unaudited)

 

Derivative Instruments and Hedging Activities

Derivative financial instruments

The Company may use derivative financial instruments to hedge its exposure to foreign exchange arising from operating, investing and financing activities. The Company does not hold or issue derivative financial instruments for trading purposes. However, derivatives that do not qualify for hedge accounting are accounted for as trading instruments.

Derivative financial instruments are recognized initially at fair value. Subsequent to initial recognition, derivative financial instruments are stated at fair value. The gain or loss on remeasurement to fair value is recognized immediately in the income statement. However, where derivatives qualify for hedge accounting, recognition of any resultant gain or loss depends on the nature of the item being hedged.

Cash flow hedges

Exposure to foreign exchange risks arises in the normal course of the Company’s business and it is the Company’s policy to use forward exchange contracts to hedge anticipated sales and purchases in foreign currencies. The amount of forward cover taken is in accordance with approved policy and internal forecasts.

Where a derivative financial instrument is designated as a hedge of the variability in cash flows of a recognized asset or liability, or a highly probable forecast transaction, the effective part of any unrealized gain or loss on the derivative financial instrument is recognized directly in equity. When the forecast transaction subsequently results in the recognition of a non-financial asset or non-financial liability, the associated cumulative gain or loss is removed from equity and included in the initial cost or other carrying amount of the non-financial asset or liability.

For cash flow hedges, other than those covered by the preceding statement, the associated cumulative gain or loss is removed from equity and recognized in the consolidated condensed statements of comprehensive income in the same period or periods during which the hedged forecast transaction affects the consolidated condensed statements of comprehensive income and on the same line item as that hedged forecast transaction. The ineffective part of any gain or loss is recognized immediately in the consolidated condensed statements of comprehensive income.

When a hedging instrument expires or is sold, terminated or exercised, or the Company revokes designation of the hedge relationship but the hedged forecast transaction is still probable to occur, the cumulative gain or loss at that point remains in equity and is recognized in accordance with the above policy when the transaction occurs. If the hedged transaction is no longer expected to take place, then the cumulative unrealized gain or loss recognized in equity is recognized immediately in the consolidated condensed statements of comprehensive income.

Derivative Instruments and Hedging Activities

In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as consider our own and counterparty credit risk. For periods ended September 30, 2018 and December 31, 2017, we did not have any assets or liabilities that utilize Level 3 inputs. The valuation of our foreign exchange derivatives are based on the market approach using observable market inputs, such as forward rates and incorporate non-performance risk (the credit standing of the counterparty when the derivative is in a net asset position, and the credit standing of the Company when the derivative is in a net liability position). Our derivative assets are categorized as Level 2. The fair value methodologies described as Level 2 and 3 inputs are defined elsewhere in these notes to the consolidated condensed financial statements.

 

8


Table of Contents

Universal Biosensors, Inc.

Notes to Consolidated Condensed Financial Statements (Unaudited)

 

Fair Value of Financial Instruments

The carrying value of all current assets and current liabilities approximates fair value because of their short-term nature. The estimated fair value of all other amounts has been determined, depending on the nature and complexity of the assets or the liability, by using one or all of the following approaches:

 

   

Market approach – based on market prices and other information from market transactions involving identical or comparable assets or liabilities.

 

   

Cost approach – based on the cost to acquire or construct comparable assets less an allowance for functional and/or economic obsolescence.

 

   

Income approach – based on the present value of a future stream of net cash flows.

These fair value methodologies depend on the following types of inputs:

 

   

Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).

 

   

Quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in markets that are not active or are directly or indirectly observable (Level 2 inputs).

 

   

Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).

Inventory

Inventories are stated at the lower of cost or net realizable value. Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and estimated costs necessary to dispose. Inventories are principally determined under the average cost method which approximates cost. Cost comprises direct materials, direct labour and an appropriate portion of variable and fixed overhead expenditure, the latter being allocated on the basis of normal operating capacity. Cost also includes the transfer from equity of any gains/losses on qualifying cash flow hedges relating to purchases of raw material. Costs of purchased inventory are determined after deducting rebates and discounts.

 

     Nine Months Ended
September 30,
     Year Ended
December 31,
 
     2018      2017  
     A$      A$  

Raw materials

     322,399        380,540  

Work in progress

     158,883        253,483  

Finished goods

     0        28,109  
  

 

 

    

 

 

 
     481,282        662,132  
  

 

 

    

 

 

 

Receivables

Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the best estimate of the amount of probable credit losses in the existing accounts receivable. The allowance is determined based on a review of individual accounts for collectability, generally focusing on those accounts that are past due. The expense to adjust the allowance for doubtful accounts, if any, is recorded within general and administrative expenses in the consolidated condensed statements of comprehensive income. Account balances are charged against the allowance when it is probable the receivable will not be recovered.

 

9


Table of Contents

Universal Biosensors, Inc.

Notes to Consolidated Condensed Financial Statements (Unaudited)

 

     Nine Months Ended
September 30,
     Year Ended
December 31,
 
     2018      2017  
     A$      A$  

Accounts receivable

     4,902,417        4,397,268  

Allowance for doubtful debts

     0        0  
  

 

 

    

 

 

 
     4,902,417        4,397,268  
  

 

 

    

 

 

 

Property, Plant, and Equipment—net

Property, plant, and equipment are recorded at acquisition cost, less accumulated depreciation.

Depreciation on plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful life of machinery and equipment is 3 to 10 years. Leasehold improvements are amortized on the straight-line method over the shorter of the remaining lease term or estimated useful life of the asset. Maintenance and repairs are charged to operations as incurred, include normal services, and do not include items of a capital nature.

The Company receives Commonwealth of Australia grant monies under grant agreements to support its development activities (refer section on “Government Grants”), including in connection with the purchase of plant and equipment. Plant and equipment is presented net of the government grant. The grant monies are recognized against the acquisition costs of the related plant and equipment as and when the related assets are purchased.

Impairment of Long-Lived Assets

The Company reviews its capital assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. In performing the review, the Company estimates undiscounted cash flows from products under development that are covered by these patents and licenses. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition is less than the carrying amount of the asset. If the evaluation indicates that the carrying value of an asset is not recoverable from its undiscounted cash flows, an impairment loss is measured by comparing the carrying value of the asset to its fair value, based on discounted cash flows. Impairment of long-lived-assets as at September 30, 2018 was nil (December 31, 2017: nil).

Government grants

UBS was awarded a grant from the Commonwealth of Australia under the Next Generation Manufacturing Investment Programme up to a maximum grant amount of A$575,000 payable over a three year period commencing from January 1, 2017. The grants are paid upon achievement of pre-agreed milestones. The milestones generally relate to UBS placing purchase orders, commissioning upgrades and validating the equipment. Amongst other reasons, the Commonwealth of Australia may terminate the grant agreement for breach of the agreement by UBS or for failure to undertake the required programme. Under these circumstances, the Commonwealth of Australia may require UBS to repay some or the entire grant. The Company continues to undertake the project funded by the Commonwealth of Australia.

An amount of A$271,318 and A$89,500 were received under this grant in November 2017 and June 2018, respectively. In the event UBS had achieved milestones and received grant payments, it believes that the likelihood of being required to repay grant funding is remote because the Company continues to comply with the grant agreement.

 

10


Table of Contents

Universal Biosensors, Inc.

Notes to Consolidated Condensed Financial Statements (Unaudited)

 

Other Liabilities

Other liabilities are broken down as follows:

 

     Nine Months Ended
September 30,
     Year Ended
December 31,
 
     2018      2017  
     A$      A$  

Current liabilites

     

Marketing support payment

     2,836,614        2,626,413  
  

 

 

    

 

 

 
     2,836,614        2,626,413  
  

 

 

    

 

 

 

Marketing Support Payment

During 2009, LifeScan chose not to proceed with the registration of the then current product but to proceed with an enhanced product, called OneTouch Verio®, and acknowledged that there would be a delay as a result. As a result of this change, LifeScan agreed to pay additional amounts per strip manufactured by the Company in 2010 and 2011 up to a specified volume limit (“manufacturing initiation payments”). At the same time, the Company agreed to pay LifeScan a marketing support payment in each of the two years following the first calendar year in which 1 billion strips are sold by LifeScan equal to 40% of the total manufacturing initiation payments made. The first calendar year in which 1 billion strips were sold by LifeScan was during the 2016 financial year. These amounts will be paid to LifeScan once supporting documentation has been provided to us. The total amount of marketing support payments to be paid to LifeScan in US$ once all the documentation is received is US$2,048,602 (equivalent to A$2,836,614).

Research and Development

Research and development expenses consist of costs incurred to further the Group’s research and product development activities and include salaries and related employee benefits, costs associated with clinical trial and preclinical development, regulatory activities, research-related overhead expenses, costs associated with the manufacture of clinical trial material, costs associated with developing a commercial manufacturing process, costs for consultants and related contract research, facility costs and depreciation. Research and development costs are expensed as incurred.

Research and development expenses for the respective periods are as follows:

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2018      2017      2018      2017  
     A$      A$      A$      A$  

Research and development expenses

     2,759,664        3,197,146        9,452,609        7,626,210  
  

 

 

    

 

 

    

 

 

    

 

 

 

Income Taxes

The Company applies ASC 740—Income Taxes which establishes financial accounting and reporting standards for the effects of income taxes that result from a company’s activities during the current and preceding years. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Where it is more likely than not that some portion or all of the deferred tax assets will not be realized, the deferred tax assets are reduced by a valuation allowance. The valuation allowance is sufficient to reduce the deferred tax assets to the amount that is more likely than not to be realized.

 

11


Table of Contents

Universal Biosensors, Inc.

Notes to Consolidated Condensed Financial Statements (Unaudited)

 

The recent U.S. Federal Tax Reform has established a mandatory repatriation of foreign accumulated undistributed earnings and profits (the “E&Ps”) for U.S. companies’ subsidiaries. In the past, none of these E&Ps’ were repatriated since such E&Ps’ were considered to be reinvested indefinitely in the foreign location. The E&Ps’ provisions are applicable to our Company commencing with our fiscal year 2018, however the E&Ps’ mandatory repatriation provisions establishes measurement dates for various computations. In our Company’s case this date is December 31, 2017. The Company’s estimated tax for the mandatory repatriation is estimated to be nil. However, the final tax due must be assessed with our December 31, 2018 closing figures. Any such tax liability may be paid over a period of eight years starting on February 28, 2019. As of the issuance date of this report, the U.S. Securities and Exchange Commission and the Financial Accounting Standards Board have issued some preliminary guidance, but have not issued final rules on how the effects of the U.S. Federal Tax Reform will be required to be reported for financial statements purposes.

At December 31, 2017 the Company has A$10,993,737 (A$22,616,230 at December 31, 2016) of accumulated tax losses available for carry forward against future earnings, which under Australian tax laws do not expire but may not be available under certain circumstances. The Company also has A$11,048,336 (A$5,800,672 at December 31, 2016) of non-refundable R&D tax offset as at December 31, 2017. The R&D Tax offset is a non-refundable tax offset, which assists to reduce a company’s tax liability. Once the liability has been reduced to zero, any excess offset may be carried forward into future income years. UBI has U.S. tax losses available for carry forward against future earnings of US$1,011,321 as of December 31, 2017 and 2016. Pursuant to the U.S. Federal Tax Reform, the effective tax rate of UBI has been reduced from 34% to 21%. The deferred tax benefit based on this new rate for UBI is US$212,377. HRL has Canadian tax losses available for carry forward against future earnings of CAD$668,043 and CAD$95,096 as at December 31, 2017 and 2016, respectively.

We are subject to income taxes in the United States, Canada and Australia. Tax returns up to and including the 2017 financial year have been filed in all these jurisdictions.

Asset Retirement Obligations

Asset retirement obligations (“ARO”) are legal obligations associated with the retirement and removal of long-lived assets. ASC 410 – Asset Retirement and Environmental Obligations requires entities to record the fair value of a liability for an asset retirement obligation when it is incurred. When the liability is initially recorded, the Company capitalizes the cost by increasing the carrying amounts of the related property, plant and equipment. Over time, the liability increases for the change in its present value, while the capitalized cost depreciates over the useful life of the asset. The Company derecognizes ARO liabilities when the related obligations are settled.

The ARO is in relation to our premises where in accordance with the terms of the lease, the lessee has to restore part of the building upon vacating the premises.

ARO for the years ended September 30, 2018 and December 31, 2017 was A$2,600,000.

Australian Goods and Services Tax (GST) and Canadian Harmonized Sales Tax (HST)

Revenues, expenses and assets are recognized net of the amount of associated GST and HST, unless the GST and HST incurred is not recoverable from the taxation authority. In this case it is recognized as part of the cost of acquisition of the asset or as part of the expense. Receivables and payables are stated inclusive of the amount of GST and HST receivable or payable. The net amount of GST and HST recoverable from, or payable to, the taxation authority is included with other receivables or payables in the consolidated condensed balance sheets.

Revenue Recognition

We recognize revenue from all sources based on the provisions of the U.S. SEC’s Staff Accounting Bulletin No. 104 and ASC 605 Revenue Recognition.

The Company’s revenue represents revenue from sales of products, provision of services and collaborative research and development agreements.

We recognize revenue from sales of products at the time title of goods passes to the buyer and the buyer assumes the risks and rewards of ownership, assuming all other revenue recognition criteria have been met. Generally, this is at the time products are shipped to the customer.

 

12


Table of Contents

Universal Biosensors, Inc.

Notes to Consolidated Condensed Financial Statements (Unaudited)

 

Revenue from services is recognized when a persuasive evidence of an arrangement exists, services have been rendered, the price is fixed or determinable, and collectability is reasonably assured. Revenue recognition principles are assessed for each new contractual arrangement and the appropriate accounting is determined for each service.

On September 21, 2018 LifeScan exercised its right to convert its obligation to pay quarterly service fees to us. We expect the lump sum service fees to be paid to Universal Biosensors on or before February 15, 2019. We estimate the lump sum service fee using the most expected value approach based on (i) actual quarterly service fees received this financial year, (ii) estimating the quarterly service fees for the remainder of the year based on the trend seen in prior years, and (iii) multiplying the total quarterly service fees expected to be received this financial year by two and converting the same into AUD using the period end exchange rate. We assessed if any amount of the lump sum service fees were attributable to the remaining obligation under the Master Services and Supply Agreement that states that LifeScan could require us to provide manufacturing services at our Rowville facility to recommence production of glucose strips. We conclude that this obligation has no fair value attributable to it due to (i) high set-up costs to recommence manufacturing, (ii) the required lead time to gain regulatory compliance, and (iii) the fact there is deemed to be no commercial rationale for LifeScan to request us to recommence glucose-strip manufacturing on the basis of current information. As such, the lump sum service fee revenue has been fully recognized this quarter and no revenue has been deferred.

Where our agreements contain multiple elements, or deliverables, such as the manufacture and sale of products, provision of services or research and development activities, they are assessed to determine whether separate delivery of the individual elements of such arrangements comprises more than one unit of accounting. Where an arrangement can be divided into separate units of accounting (each unit constituting a separate earnings process), the arrangement consideration is allocated amongst those varying units based on the relative selling price of the separate units of accounting and the applicable revenue recognition criteria applied to the separate units. Selling prices are determined using fair value as determined by either vendor specific objective evidence or third party evidence of the selling price, when available, or the Company’s best estimate of selling price when fair value is not available for a given unit of accounting.

Under ASC 605-25, the delivered item(s) are separate units of accounting, provided (i) the delivered item(s) have value to a customer on a stand-alone basis, and (ii) if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item(s) is considered probable and substantially in our control. Where the arrangement cannot be divided into separate units, the individual deliverables are combined as a single unit of accounting and the total arrangement consideration is recognized across other deliverables in the arrangement or over the estimated collaboration period. Payments under these arrangements typically include one or more of the following: non-refundable, upfront payments; funding of research and/or development efforts; and milestone payments.

We typically generate milestone payments from our customers pursuant to the various agreements we have with them. Non-refundable milestone payments which represent the achievement of a significant technical/regulatory hurdle in the research and development process pursuant to collaborative agreements, and are deemed to be substantive, are recognized as revenue upon the achievement of the specified milestone. If the non-refundable milestone payment is not substantive or stand-alone value, the non-refundable milestone payment is deferred and recognized as revenue either over the estimated performance period stipulated in the agreement or across other deliverables in the arrangement.

Management has concluded that the core operations of the Company are expected to be research and development activities, commercial manufacture of approved medical or testing devices and the provision of services. The Company’s ultimate goal is to utilize the underlying technology and skill base for the development of marketable products that the Company will manufacture. The Company considers revenue from the sales of products, revenue from services and the income received from milestone payments indicative of its core operating activities or revenue producing goals of the Company, and as such have accounted for this income as “revenues”.

Master Services and Supply Agreement

In October 2007, the Company and LifeScan entered into a Master Services and Supply Agreement, under which the Company would provide certain services to LifeScan in the field of blood glucose monitoring and act as a non-exclusive manufacturer of blood glucose test strips. The Master Services and Supply Agreement was subsequently amended and restated in May 2009. The Company has concluded the Master Services and Supply Agreement should be accounted for as three separate units of accounting: 1) research and development to assist LifeScan in receiving regulatory clearance to sell the blood glucose product (milestone payment), 2) contract manufacturing of the blood glucose test strips (contract manufacturing) which ceased in December 2013, and 3) ongoing services and efforts to enhance the product (product enhancement).

 

13


Table of Contents

Universal Biosensors, Inc.

Notes to Consolidated Condensed Financial Statements (Unaudited)

 

All consideration within the Master Services and Supply Agreement is contingent. The Company concluded the undelivered items were not priced at a significant incremental discount to the delivered items and revenue for each deliverable will be recognized as each contingency is met and the consideration becomes fixed and determinable. The milestone payment was considered to be a substantive payment and the entire amount has been recognized as revenue when the regulatory approval was received. Revenues for contract manufacturing and ongoing efforts to enhance the product are recognized as revenue from products or revenue from services, respectively, when the four basic criteria for revenue recognition are met.

Collaboration Agreement

On September 9, 2011 the Company entered into a Collaboration Agreement with Siemens to develop coagulation related products for hospital point-of-care and ambulatory care coagulation markets. In addition to an up-front, non-refundable payment of A$2,961,245 (equivalent to US$3 million), the Collaboration Agreement (as amended) contains a further seven payments from Siemens upon the achievement of certain defined milestones. These seven milestones, to a large extent, relate to feasibility, regulatory submissions and the launch of the products to be developed. The Company has concluded that the up-front payment is not a separate unit of accounting and recorded the amount as deferred revenue to be recognized as revenue across other deliverables in the arrangement with Siemens based upon the Company’s best estimate of selling price. The deliverables related to each of the seven milestones are considered substantive and are not priced at a significant incremental discount to the other deliverables. As the achievement of the seven milestones is contingent upon a future event, the revenue for each deliverable will be recognized as the contingencies are met and the consideration becomes fixed and determinable.

Of the seven milestones, the Company has delivered on four as of September 30, 2018. The last milestone delivered was in July 2015.

Interest income

Interest income is recognized as it accrues, taking into account the effective yield on the cash and cash equivalents.

Research and development tax incentive income

Research and development tax incentive income is recognized when there is reasonable assurance that the income will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured.

The research and development tax incentive is one of the key elements of the Australian Government’s support for Australia’s innovation system and is supported by legislative law primarily in the form of the Australian Income Tax Assessment Act 1997 as long as eligibility criteria are met. Generally speaking, entities which are an R&D entity involved in eligible R&D activities may claim research and development tax incentive income as follows:

 

  (1)

as a 43.5% refundable tax offset if aggregate turnover (which generally means an entity’s total income that it derives in the ordinary course of carrying on a business, subject to certain exclusions) of the entity is less than A$20 million, or

 

  (2)

as a 38.5% non-refundable tax offset if aggregate turnover of the entity is more than A$20 million.

In accordance with SEC Regulation S-X Article 5-03, the Company’s research and development tax incentive income has been recognized as non-operating income as it is not indicative of the core operating activities or revenue producing goals of the Company.

 

14


Table of Contents

Universal Biosensors, Inc.

Notes to Consolidated Condensed Financial Statements (Unaudited)

 

Management has assessed the Company’s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the tax incentive regime described above. At each period end management estimates the refundable tax offset available to the Company based on available information at the time. This estimate is also reviewed by external tax advisors on an annual basis.

In the nine months ended September 30, 2018 and 2017, the aggregate turnover of the Company had exceeded A$20 million and accordingly it was not eligible for a refundable tax offset. The Company was however eligible for the non-refundable tax offset. The eligible R&D activities and expenditures are able to be claimed as part of the current year income tax computation and any amounts included as a tax asset will be subject to recognition rules under ASC 740 “Income Taxes”.

Foreign Currency

Functional and reporting currency

Items included in the financial statements of each of the Group’s entities are measured using the currency of the primary economic environment in which the entity operates (“the functional currency”). The functional currency of UBI and UBS is AUD or A$ for all years presented. The functional currency of HRL is CAD$.

The consolidated condensed financial statements are presented using a reporting currency of Australian dollars.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in the consolidated condensed statements of comprehensive income.

The Company has recorded foreign currency transaction gains of A$183,395 and A$61,873 for the three months ended September 30, 2018 and 2017, respectively and A$412,768 and A$703,420 for the nine months ended September 30, 2018 and 2017, respectively.

The results and financial position of all the Group entities that have a functional currency different from the reporting currency are translated into the reporting currency as follows:

 

   

assets and liabilities for each balance sheet item reported are translated at the closing rate at the date of that balance sheet;

 

   

income and expenses for each income statement item reported are translated at average exchange rates (unless this is not a reasonable approximation of the effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions); and

 

   

all resulting exchange differences are recognized as a separate component of equity.

On consolidation, exchange differences arising from the translation of any net investment in foreign entities are taken to the Accumulated Other Comprehensive Income.

Commitments and Contingencies

Liabilities for loss contingencies, arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. These were nil as at September 30, 2018. Purchase commitments contracted for as at September 30, 2018 is A$1,538,429 (December 31, 2017 : A$2,359,443).

 

15


Table of Contents

Universal Biosensors, Inc.

Notes to Consolidated Condensed Financial Statements (Unaudited)

 

Patent and License Costs

Legal and maintenance fees incurred for patent application costs have been charged to expense and reported in general and administrative expense.

Clinical Trial Expenses

Clinical trial costs are a component of research and development expenses. These expenses include fees paid to participating hospitals and other service providers, which conduct certain testing activities on behalf of the Company. Depending on the timing of payments to the service providers and the level of service provided, the Company records prepaid or accrued expenses relating to these costs.

These prepaid or accrued expenses are based on estimates of the work performed under service agreements.

Leased Assets

All of the Company’s leases for the periods ending September 30, 2018 and December 31, 2017 are considered operating leases. The costs of operating leases are charged to the consolidated condensed statements of comprehensive income on a straight-line basis over the lease term.

Stock-based Compensation

We measure stock-based compensation at grant date, based on the estimated fair value of the award, and recognize the cost as an expense on a straight-line basis over the vesting period of the award. We estimate the fair value of stock options using the Trinomial Lattice model. We also grant our employees Restricted Stock Units (“RSUs”) and Zero Priced Employee Options (“ZEPOs”). RSUs are stock awards granted to employees that entitle the holder to shares of common stock as the award vests. ZEPOs are stock options granted to employees that entitle the holder to shares of common stock as the award vests. The value of RSUs are determined and fixed on the grant date based on the Company’s stock price. The exercise price of ZEPOs is nil.

We record deferred tax assets for awards that will result in deductions on our income tax returns, based on the amount of compensation cost recognized and our statutory tax rate in the jurisdiction in which we will receive a deduction. Differences between the deferred tax assets recognized for financial reporting purposes and the actual tax deduction reported in our income tax return are recorded in expense or in capital in excess of par value if the tax deduction exceeds the deferred tax assets or to the extent that previously recognized credits to paid-in-capital are still available if the tax deduction is less than the deferred tax asset.

(a) Stock Option Plan

In 2004, the Company adopted an employee option plan (“Plan”). Options may be granted pursuant to the Plan to any person considered by the board to be employed by the Group on a permanent basis (whether full time, part time or on a long term casual basis). Each option gives the holder the right to subscribe for one share of common stock. The total number of options that may be issued under the Plan is such maximum amount permitted by law and the Listing Rules of the ASX. The exercise price and any exercise conditions are determined by the board at the time of grant of the options. Any exercise conditions must be satisfied before the options vest and become capable of exercise. The options lapse on such date determined by the board at the time of grant or earlier in accordance with the Plan. Options granted to date have had a term up to 10 years and generally vest in equal tranches over three years.

An option holder is not permitted to participate in a bonus issue or new issue of securities in respect of an option held prior to the issue of shares to the option holder pursuant to the exercise of an option. If the Company changes the number of issued shares through, or as a result of, any consolidation, subdivision, or similar reconstruction of the issued capital of the Company, the total number of options and the exercise price of the options (as applicable) will likewise be adjusted.

 

16


Table of Contents

Universal Biosensors, Inc.

Notes to Consolidated Condensed Financial Statements (Unaudited)

 

In accordance with ASC 718, the fair value of the option grants was estimated on the date of each grant using the Trinomial Lattice model. The assumptions for these grants were:

 

     Grant Date  
     Oct-17     Oct-17     Oct-17     Feb-17  

Exercise Price (A$)

     0.50       0.60       0.80       0.50  

Share Price at Grant Date (A$)

     0.38       0.38       0.38       0.39  

Volatility

     68     68     68     69

Expected Life (years)

     5       5       5       6  

Risk Free Interest Rate

     2.36     2.36     2.36     2.47

Fair Value of Option (A$)

     0.15       0.13       0.11       0.13  

Stock option activity during the current period is as follows:

 

     Number of shares      Weighted average
exercise price

A$
 

Balance at December 31, 2017

     22,003,215        0.63  

Granted

     0        0.00  

Exercised

     (503,334      0.00  

Lapsed

     (5,124,431      0.70  
  

 

 

    

 

 

 

Balance at September 30, 2018

     16,375,450        0.63  
  

 

 

    

 

 

 

The number of options exercisable as at September 30, 2018 and 2017 was 7,208,775 and 10,963,629, respectively. The total stock compensation expense recognized in the consolidated condensed statements of comprehensive income was A$51,182 and A$154,218 for the three months ended September 30, 2018 and 2017, respectively and A$228,224 and A$354,243 for the nine months ended September 30, 2018 and 2017, respectively.

As of September 30, 2018, there was A$674,671 of unrecognized compensation expense related to unvested share-based compensation arrangements under the Employee Option Plan. This expense is expected to be recognized over the vesting years as follows:

 

Fiscal Year    A$  

2018

     94,357  

2019

     321,558  

2020

     258,756  
  

 

 

 
     674,671  
  

 

 

 

The aggregate intrinsic value for all options outstanding as at September 30, 2018 and 2017 was zero.

(b) Restricted Share Plan

Our Employee Share Plan was adopted by the Board of Directors in 2009. The Employee Share Plan permits our Board to grant shares of our common stock to our employees and directors (although our Board has determined not to issue equity to non-executive directors). The number of shares able to be granted is limited to the amount permitted to be granted at law, the ASX Listing Rules and by the limits on our authorized share capital in our certificate of incorporation. All our employees are eligible for shares under the Employee Share Plan. The Company has in the past issued A$1,000 worth of restricted shares of common stock to employees of the Company but no more frequently than annually. The restricted shares have the same terms of issue as our existing shares of common stock but are not able to be traded until the earlier of three years from the date on which the shares are issued or the date the relevant employee ceases to be an employee of the Company or any of its associated group of companies.

 

17


Table of Contents

Universal Biosensors, Inc.

Notes to Consolidated Condensed Financial Statements (Unaudited)

 

No restricted shares have been issued by the Company since January 1, 2017.

Restricted stock awards activity during the current period is as follows:

 

     Number of shares      Weighted average
issue price

A$
 

Balance at December 31, 2017

     492,749        0.31  

Granted

     0        0.00  

Release of restricted shares

     (287,087      0.27  
  

 

 

    

 

 

 

Balance at September 30, 2018

     205,662        0.31  
  

 

 

    

 

 

 

Employee Benefit Costs

The Company contributes 9.5% of each employee’s salary to standard defined contribution superannuation funds on behalf of all UBS employees. Superannuation is a compulsory savings program whereby employers are required to pay a portion of an employee’s remuneration to an approved superannuation fund that the employee is typically not able to access until they have reached the statutory retirement age. Whilst the Company has a third party default superannuation fund, it permits UBS employees to choose an approved and registered superannuation fund into which the contributions are paid. Contributions are charged to the consolidated condensed statements of comprehensive income as they become payable.

Registered Retirement Savings Plan and Deferred Sharing Profit Plan

The Company provides eligible HRL employees a retirement plan. The retirement plan includes a Registered Retirement Savings Plan (“RRSP”) and Deferred Profit Sharing Plan (“DPSP”). The RRSP is voluntary and the employee contributions are matched by the Company up to a maximum of 5% based on their continuous years of service and placed into the DPSP. The Company contributes 1% to 2% of the employee’s base earnings towards the DPSP. The DPSP contributions are vested immediately.

Benefit Plan

The Company provides eligible HRL employees a Benefit Plan to its employees. In general, the Benefit Plan includes extended health care, dental care, basic life insurance, basic accidental death and dismemberment, and disability insurance.

Net Income/(Loss) per Share and Anti-dilutive Securities

Basic and diluted net income/(loss) per share is presented in conformity with ASC 260 – Earnings per Share. Basic and diluted net income/(loss) per share has been computed using the weighted-average number of common shares outstanding during the period. Diluted net income/(loss) per share is calculated by adjusting the basic net income/(loss) per share by assuming all dilutive potential ordinary shares are converted.

Total Comprehensive Income/(Loss)

The Company follows ASC 220 – Comprehensive Income. Comprehensive income/(loss) is defined as the total change in shareholders’ equity during the period other than from transactions with shareholders, and for the Company, includes net income/(loss).

 

18


Table of Contents

Universal Biosensors, Inc.

Notes to Consolidated Condensed Financial Statements (Unaudited)

 

The tax effect allocated to each component of other comprehensive loss is as follows:

 

     Before-Tax Amount     

Tax (Expense)/

Benefit

     Net-of-Tax
Amount
 
     A$      A$      A$  

Nine Months Ended September 30, 2018

        

Foreign currency translation reserve

     36,525        0        36,525  

Reclassification for gains realised in net income

     0        0        0  
  

 

 

    

 

 

    

 

 

 

Other comprehensive loss

     36,525        0        36,525  
  

 

 

    

 

 

    

 

 

 

Nine Months Ended September 30, 2017

        

Foreign currency translation reserve

     5,497        0        5,497  

Reclassification for gains realised in net income

     0        0        0  
  

 

 

    

 

 

    

 

 

 

Other comprehensive loss

     5,497        0        5,497  
  

 

 

    

 

 

    

 

 

 

Business combinations

Business combinations are accounted for using the acquisition method of accounting. Acquisition cost is measured as the aggregate of the fair value at the date of acquisition of the assets given, equity instruments issued or liabilities incurred or assumed. Acquisition related costs are expensed as incurred (except for those costs arising on the issue of equity instruments which are recognized directly in equity). Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured at fair value on the acquisition date. Goodwill is measured as the excess of the acquisition cost, the amount of any non-controlling interest and the fair value of any previous UBI equity interest in the acquiree, over the fair value of the identifiable net assets acquired.

Reclassification

Certain prior year amounts have been reclassified to conform to the current year presentation.

Recent Accounting Pronouncements

(a) Recent issued accounting standards not yet adopted

ASU No.2016-02, “Leases’

On February 25, 2016, the FASB issued ASU 2016-02, its new standard on accounting for leases. ASU 2016-02 introduces a lessee model that brings most leases on the balance sheet and eliminates the requirement in current U.S. GAAP for an entity to use bright-line tests in determining lease classification. The standard also requires lessors to increase the transparency of their exposure to changes in value of their residual assets and how they manage that exposure.

The new guidance will be effective for public business entities for annual periods beginning after December 15, 2018, and interim periods therein. Early adoption is permitted. The Company is currently evaluating the impact the adoption of ASU 2016-02 will have on the Company’s consolidated financial statements.

ASU No.2014-09, “Revenue from Contracts with Customers’

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (Topic 606), which provides companies with a single revenue recognition model for recognizing revenue from contracts with customers. The core principle of the new standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. There are two permitted transition methods under the new standard, the full retrospective method or the modified retrospective method. The new standard is effective for annual reporting periods beginning after December 15, 2017. The Company has deferred the adoption of this standard as is allowable for an Emerging Growth Company.

 

19


Table of Contents

Universal Biosensors, Inc.

Notes to Consolidated Condensed Financial Statements (Unaudited)

 

UBI has selected the modified retrospective method where the effect of applying the standard will be recognized at the date of initial application, without restating previous years. The Company is currently evaluating the impact the adoption of ASU 2014-09 will have on the Company’s consolidated financial statements.

ASU No. 2017-12, “Targeted Improvements to Accounting for Hedging Activities”

On August 28, 2017, the FASB issued ASU 2017-12, which amends the hedge accounting recognition and presentation requirements in ASC 815.2. The FASB’s objectives in issuing the ASU are to (1) improve the transparency and understandability of information conveyed to financial statement users about an entity’s risk management activities by better aligning the entity’s financial reporting for hedging relationships with those risk management activities and (2) reduce the complexity of and simplify the application of hedge accounting by preparers.

For public business entities, the ASU is effective for fiscal years beginning after December 15, 2018, and interim periods therein; however, early adoption by all entities is permitted upon its issuance. The Company is currently evaluating the impact the adoption of ASU 2014-09 will have on the Company’s consolidated financial statements.

(b) Recently adopted accounting pronouncements

ASU No.2016-18, “Restricted Cash’

On November 17, 2016, the FASB issued ASU 2016-18, which amends ASC 230 to add or clarify guidance on the classification and presentation of restricted cash in the statement of cash flows. For public business entities, the guidance is effective for fiscal years beginning after December 15, 2017, including interim periods therein. For all other entities, it is effective for fiscal years beginning after December 15, 2018, and interim periods thereafter. Early adoption is permitted for all entities. The Company has adopted this guidance from January 1, 2018 and it has not had a material impact on the Company’s consolidated financial statements.

ASU No.2016-15, “Classification of Certain Cash Receipts and Cash Payments”

On August 26, 2016, the FASB issued ASU 2016-15, which amends the guidance in ASC 230 to eliminate diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The guidance in the ASU is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted for all entities. The Company has adopted this guidance and it has not had a material impact on the Company’s consolidated financial statements.

ASU No.2016-16, “Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory’

On October 24, 2016, the FASB issued ASU 2016-16, which removes the prohibition in ASC 740 against the immediate recognition of the current and deferred income tax effects of intra-entity transfers of assets other than inventory. This ASU is effective for annual periods beginning after December 15, 2017, and interim periods within those annual periods. Early adoption is permitted for all entities as of the beginning of a fiscal year for which neither the annual or interim financial statements have been issued. Entities should apply the ASU’s amendments on a modified retrospective basis, recognizing the effects in retained earnings as of the beginning of the year of adoption. The Company has adopted this guidance and it has not had a material impact on the Company’s consolidated financial statements.

ASU No.2017-01, “Business Combination: Clarifying the Definition of a Business’

On January 5, 2017, the FASB issued ASU 2017-01 to clarify the definition of a business in ASC 805. The amendments in the ASU are intended to make application of the guidance more consistent and cost-efficient. The ASU is effective for annual periods beginning after December 15, 2017, including interim periods therein. The ASU must be applied prospectively on or after the effective date, and no disclosures for a change in accounting principle are required at transition. Early adoption is permitted for transactions (i.e., acquisitions or dispositions) that occurred before the issuance date or effective date of the standard. The Company has adopted this guidance and it has not had a material impact on the Company’s consolidated financial statements.

 

20


Table of Contents

Universal Biosensors, Inc.

Notes to Consolidated Condensed Financial Statements (Unaudited)

 

ASU No.2017-09, “Compensation – Stock Compensation: Scope of Modification Accounting’

On May 10, 2017, the FASB issued ASU 2017-09, which amends the scope of modification accounting for share-based payment arrangements. The ASU provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting under ASC 718. This ASU is effective for annual reporting periods, including interim periods within those annual reporting periods, beginning after December 15, 2017. Early adoption is permitted. The Company has adopted this guidance and it has not had a material impact on the Company’s consolidated financial statements.

ASU No. 2018-05, “Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118.”

On March 13, 2018, the FASB issued ASU 2018-05. This Financial Reporting Alert contains responses to frequently asked questions about how an entity should account for the tax effects of the new tax reform legislation in accordance with ASC 740, Income Taxes. This ASU is effective upon issuance and the adoption of this guidance has not had a material impact on the Company’s consolidated financial statements.

ASU No. 2018-09, “Codification Improvements”

The FASB issued ASU 2018-09 on July 16, 2018. The ASU’s amendments “clarify, correct errors in, or make minor improvements to the Codification.” This ASU is effective upon issuance and the adoption of this guidance has not had a material impact on the Company’s consolidated financial statements.

Related Party Transactions

Details of related party transactions material to the operations of the Group other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business, are set out below:

In September 2011, we entered into a non-exclusive license agreement with SpeeDx Pty Ltd (“SpeeDx”) pursuant to which SpeeDx granted us a license to use its proprietary MNAzyme technology in the field of molecular diagnostics. Under the agreement we make milestone payments totaling A$500,000 to SpeeDx if certain specified targets are achieved, and royalty payments ranging from 5% to 15% of that portion of our sales and licensing revenues arising from SpeeDx technology or products incorporating SpeeDx technology.

The license agreement and the obligation to pay royalties continues until SpeeDx’s patent rights have expired, lapsed, are found to be invalid or are rejected. The agreement will terminate by mutual agreement or by one party for breach or insolvency of the other. SpeeDx may also terminate the license agreement if the research and development on a first licensed product is not completed by UBS within 7 years (subject to certain exceptions), and UBS may terminate if it determines that it does not wish to proceed with further commercialization of SpeeDx’s technology.

Mr. Denver is a director of SpeeDx and up until August 7, 2017 was a director of the Company. Mr. Denver continued to provide services to the Company in an advisory capacity between October 1, 2017 and June 30, 2018.

Mr. Coleman is a Non-Executive Chairman of the Company and Executive Chairman of Viburnum Funds Pty Ltd. Viburnum Funds Pty Ltd, as an investment manager for its associated funds holds a beneficial interest and voting power over approximately 18% of our shares.

An employee of Viburnum Funds Pty Ltd has on occasions been seconded to Universal Biosensors to assist the Company on strategic matters. During this period Viburnum Funds Pty Ltd continue to pay all the salary entitlements of the seconded person. Universal Biosensors is solely responsible for the reimbursement of certain expenditure such as travel and rental whilst the employee is on secondment. The total expenditure reimbursed by the Company to Viburnum Funds Pty Ltd as at September 30, 2018 was A$21,716.

 

21


Table of Contents

Universal Biosensors, Inc.

Notes to Consolidated Condensed Financial Statements (Unaudited)

 

Borrowings

Future maturities, interest and other payments under the Company’s long term secured loan pursuant to the credit agreement (described below) as of September 30, 2018 and December 31, 2017 are as follows:

 

     September 30, 2018      December 31, 2017  
     US$      A$      US$      A$  

2018

     442,750           1,956,563     

2019

     15,221,375           15,875,875     
  

 

 

       

 

 

    

Total minimum payments

     15,664,125           17,832,438     

Less amount representing interest and other fees

     (664,125         (2,832,438   
  

 

 

       

 

 

    

Gross balance of long term debt

     15,000,000           15,000,000     

Less fair value of warrants recorded within loan (a)

     (815,655         (815,655   

Plus interest accretion

     736,851           658,334     
  

 

 

       

 

 

    

Total carrying value

     14,921,196        20,660,753        14,842,679        19,029,076  
  

 

 

    

 

 

    

 

 

    

 

 

 

Less current portion

     14,921,196        20,660,753        0        0  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total carrying value, non-current portion

     0        0        14,842,679        19,029,076  
  

 

 

    

 

 

    

 

 

    

 

 

 

The above assumes, as provided under the Athyrium Credit Agreement, the loan will be repaid immediately out of the proceeds from the lump sum service fees which is expected to be received on or about February 15, 2019.

The carrying value of the borrowings approximates its fair value. The fair value is estimated by discounting future cash flows at the currently offered rates for borrowings of similar remaining maturities.

 

  (a)

The warrants issued in December 2013 had a fair value of US$815,655 as of September 30, 2018 and December 31, 2017, and are included in equity.

Athyrium Credit Agreement

On December 19, 2013 (“Closing Date”), UBI and its wholly owned subsidiary, UBS (together UBI and UBS, the “Transaction Parties”) entered into a credit agreement with Athyrium Opportunities Fund (A) LP (“Athyrium A”), as administrative agent (the “Administrative Agent”) and as a lender, and Athyrium Opportunities Fund (B) LP (“Athyrium B”) as a lender (Athyrium A and Athyrium B together with any other lenders party thereto from time to time, the “Lenders”) for a secured term loan of up to US$25 million, which was amended on January 30, 2015 (“Credit Agreement”). Of this amount, US$15 million had been drawn at December 31, 2013 with a further US$10 million available to be drawn down on or before July 31, 2015, if UBS satisfied certain conditions precedent relating to product revenues.

The credit agreement was amended again on December 29, 2017 (“Amendment”). Subject to the terms of the Amendment, the Amendment modifies the Credit Agreement to (i) extend the maturity date to July 1, 2019 (“Maturity Date”), (ii) add the Borrower’s wholly owned subsidiary, Hemostasis Reference Laboratory, Inc. (“HRL”), as a guarantor of the Borrower’s obligations under the Credit Agreement and (iii) subject to the prior written consent of the Lenders in their sole discretion, permit UBI to repurchase shares in an aggregate amount up to US$2,000,000 within 12 months after the date Lenders provide any such consent.

The term loan bears interest at 10.5% per annum payable in cash quarterly in arrears over the term, and as otherwise described in the Credit Agreement. A default interest rate of 13% per annum shall apply during the existence of a default under the Credit Agreement. Other than as summarized below, UBS is not required to make payments of principal for amounts outstanding under the term loan until maturity, July 1, 2019. The term loan under the Credit Agreement is secured by substantially all of UBI, UBS’ and HRL’s assets. UBI and HRL (together with any future subsidiaries) guarantees all of UBS’s obligations under the term loan.

 

22


Table of Contents

Universal Biosensors, Inc.

Notes to Consolidated Condensed Financial Statements (Unaudited)

 

Voluntary prepayments of the term loans were not permitted prior to the second anniversary of the Closing Date, except in the event of a change of control of a Transaction Party. After the second anniversary, UBS can make voluntary repayments in minimum principal amounts of US$2,500,000 together with interest, plus the premium described below. UBS must make mandatory prepayments in certain prescribed circumstances, including in the event of raising additional debt financing, a sale or transfer of assets other than in certain circumstances and in the event of other specified extraordinary receipts. Extraordinary receipts include cash received or paid other than in the ordinary course of business, such as tax refunds (other than GST and R&D tax rebates), LifeScan lump sum fee payments and Siemens termination fees. In such events, UBS must prepay to the Lenders 100% of the net cash proceeds received up to the outstanding principal amount of the loans drawn down, together with all accrued and unpaid interest thereon and all other obligations. In the event of any prepayment after the second anniversary of the Closing Date with respect to any obligations under the Credit Agreement, UBS must pay a prepayment premium commencing at 15% of the principal of such prepayment due and payable on the applicable date and reducing pro-rata on a monthly basis until the Maturity Date.

Unless the facility is otherwise terminated earlier pursuant to the terms of the Credit Agreement, UBS (as the borrower) is required to repay the outstanding principal amount of the loans drawn down, together with all accrued and unpaid interest thereon and all other obligations on Maturity Date.

UBS paid a non-refundable fee of US$625,000 to the Lenders on the Closing Date (being 2.5% of the aggregate credit facility) and non-refundable fees of US$200,000 to the Lenders in connection with each of the January 2015 and December 2017 amendments to the Credit Agreement. A 2% commitment fee based on any available unused borrowing commitment was paid by UBS under the Credit Agreement until July 31, 2015. The Lenders are also entitled to receive 30% of the net proceeds of milestone payments paid under the Collaboration Agreement by and among UBS, UBI and Siemens, up to a maximum of US$600,000 in the aggregate of which US$300,000 was paid in February 2015 and the balance of US$300,000 was paid in August 2015 (upon receipt of two further milestone payments). UBS has also agreed to pay certain taxes arising in connection with the Credit Agreement and other Loan Documents, including withholding taxes. UBS has also agreed to pay certain reasonable out-of-pocket expenses incurred by the Lenders in connection with the loan documents including the January 2015 and December 2017 amendments, or as may be incurred in connection with the enforcement or protection of their rights.

The Credit Agreement also contains certain covenants, including among other things, covenants: (i) relating to the delivery of financial and other information and certificates, notices of defaults, litigation and other material events; payment of taxes and other obligations; maintenance of insurance; (ii) which limit or restrict the incurrence of liens; the making of investments; the incurrence of certain indebtedness; mergers, dispositions, liquidations, or consolidations and significant asset sales; restricted payments; transactions with affiliates other than on normal and arms-length terms; burdensome agreements; prepayment of other indebtedness; ownership of subsidiaries; and (iii) which require UBS to maintain restricted cash of not less than US$2,000,000 in a specified bank account at any time.

As further described below, pursuant to the Credit Agreement, UBI issued to the Lenders warrants entitling the holder to purchase up to an aggregate total of 4.5 million shares of UBI’s common stock in the form of CDIs at a price of A$1.00 per share (the “Exercise Price”), which represents a 117% premium over the closing price of UBI’s common stock on December 19, 2013. The warrants are immediately exercisable and have a term of seven years.

Other

In December 2016, UBS entered into an arrangement with Elantis Premium Funding Ltd to fund the Group’s 2017 insurance premium. The total amount financed was A$369,630 at inception and the short-term borrowing was fully repaid in September 2017. Interest was charged at a fixed rate of 2.60% per annum. The short-term borrowing was secured by the insurance premium refund. The Group’s 2018 insurance premium was funded from its operating cash flows.

 

23


Table of Contents

Universal Biosensors, Inc.

Notes to Consolidated Condensed Financial Statements (Unaudited)

 

Warrants

Pursuant to the Credit Agreement, UBI issued to the Lenders warrants entitling the holder to purchase up to an aggregate total of 4.5 million shares of UBI’s common stock in the form of CDIs at a price of A$1.00 per share (the “Exercise Price”), which represents a 117% premium over the closing price of UBI’s common stock on December 19, 2013. The warrants are immediately exercisable and have a term of seven years.

The warrants may be exercised at any time until December 19, 2020, in whole or in part in minimum multiples of 500,000 shares of common stock. The holder of the warrants can pay the Exercise Price in cash or it has the right to pay all or a portion of the Exercise Price by making a cashless exercise, therefore reducing the number of shares of common stock the holder would otherwise be issued.

The warrant is subject to adjustments in the event of certain issuances by UBI, such as bonus issues, pro rata (rights) issues and reorganizations (e.g., consolidation, subdivision).

The Company assessed that the warrants are not liabilities within scope of ASC 480-10-25. The warrants are legally detachable from the loan and separately exercisable and as such meet the definition of a freestanding derivative instrument pursuant to ASC 815.

However, the scope exception in accordance with ASC 815-10-15-74 applies to warrants and it meets the requirements of ASC 815 that would be classified in stockholders’ equity. Therefore, the warrants were initially accounted for within stockholders’ equity, and subsequent changes in fair value will not be recorded. The fair value of the warrant was estimated using the Trinomial Lattice model.

The debt issuance costs were recorded as deferred issuance costs and are amortized as interest expense, using the effective interest method, over the term of the loan pursuant to ASC 835-30-35-2.

Restricted Cash

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated condensed balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows.

 

     Nine Months Ended
September 30,
     Year Ended
December 31,
 
     2018      2017  
     A$      A$  

Cash and cash equivalents

     28,531,432        26,259,918  

Restricted cash - current assets

     2,915,949        15,309  

Restricted cash - non-current assets

     320,000        3,220,000  
  

 

 

    

 

 

 
     31,767,381        29,495,227  
  

 

 

    

 

 

 

 

24


Table of Contents

Universal Biosensors, Inc.

Notes to Consolidated Condensed Financial Statements (Unaudited)

 

Restricted cash maintained by the Company in the form of term deposits is as follows:

 

     Nine Months Ended
September 30,
     Year Ended
December 31,
 
     2018      2017  
     A$      A$  

Collateral for facilities (a) - current assets

     15,949        15,309  

Collateral for facilities (b) - non-current assets

     320,000        320,000  

Financial covenant pursuant to the credit agreement (c) - current assets

     2,900,000        0  

Financial covenant pursuant to the credit agreement (c) - non-current assets

     0        2,900,000  
  

 

 

    

 

 

 
     3,235,949        3,235,309  
  

 

 

    

 

 

 

 

(a)

Represents bank guarantee of CDN$15,000 as security deposit on HRL’s credit card

(b)

Represents bank guarantee of A$250,000 for commercial lease of UBS’ premises and security deposit on Company’s credit cards of A$70,000

(c)

Represents amounts pledged as collateral for financing arrangements as contractually required by the Lenders. The restriction will lapse when the related debt is paid off in July 2019 or earlier as provided pursuant to the Credit Agreement

Interest earned on the restricted cash for the three months ended September 30, 2018 and 2017 were A$18,500 and A$12,394, respectively and for the nine months ended September 30, 2018 and 2017 were A$53,420 and A$50,423, respectively.

 

25


Table of Contents

Item 2 Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis provides information that we believe is relevant to an assessment and understanding of our results of operations and financial condition. You should read this analysis in conjunction with our audited consolidated financial statements and related footnotes and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our most recent Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (“SEC”). This Form 10-Q contains, including this discussion and analysis, certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) which are intended to be covered by the safe harbors created by such acts. For this purpose, any statements that are not statements of historical fact may be deemed to be forward-looking statements, including statements relating to future events and our future financial performance. Those statements in this Form 10-Q containing the words “believes”, “anticipates”, “plans”, “expects”, “intends”, “may”, “assumes”, “illustration”, and similar expressions constitute forward-looking statements, although not all forward-looking statements contain such identifying words.

The forward-looking statements contained in this Form 10-Q are based on our current expectations, assumptions, estimates and projections about the Company and its businesses. All such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from those results expressed or implied by these forward-looking statements, including those set forth in this Quarterly Report on Form 10-Q.

Results of Operations

Analysis of Consolidated Revenue

We recognized one-off revenue of A$42,164,868 being the lump sum service fees during the current quarter which has increased our total revenue for the current period by just over A$40 million compared to the prior comparable period. Excluding this one-off revenue and despite sales of the OneTouch Verio® strips increasing, our total revenue decreased by 20% and 10% to A$5,070,157 and $18,560,406, respectively during the three and nine months ended September 30, 2018 compared to the same period in the previous financial year as a result of a slow-down in sales of the Xprecia StrideTM strips.

Revenue from Products

The financial results of the PT-INR test strips for the Xprecia StrideTM Coagulation Analyzer we manufactured and sold to Siemens during the respective periods are as follows:

 

     Three Months Ended September 30,      Nine Months Ended September 30,  
     2018      2017      2018      2017  
     A$      A$      A$      A$  

Revenue from products

     227,649        1,764,855        1,131,319        4,062,470  

Cost of goods sold

     (186,515      (998,674      (1,055,534      (2,913,808
  

 

 

    

 

 

    

 

 

    

 

 

 

Production margin

     41,134        766,181        75,785        1,148,662  
  

 

 

    

 

 

    

 

 

    

 

 

 

The movement in revenues is primarily volume driven. Management is of the view that revenues increased in 2017 as a result of the full commercial launch by Siemens of the Xprecia StrideTM Coagulation Analyzer after successful completion of its limited release and inventory buildup for future sales. Due to the latter and as foreshadowed, the revenues during the current period are low. Management believes that the revenues will remain low until Siemens gains meaningful market share. The volatile and low production margin from the sale of our PT-INR strips is reflective of lower throughput.

 

26


Table of Contents

Revenue from Services

We provide various services to our customers and partners. The revenue is grouped into the following categories:

 

   

Product enhancement – a quarterly service fee based on the number of strips sold by LifeScan which falls within a valid claim of certain LifeScan patents is payable to us as an ongoing reward for our services and efforts to enhance the product;

 

   

Contract research and development – we undertake contract research and development on behalf of our customers and partners;

 

   

Lump sum service fees – this one-off fee is calculated by multiplying the quarterly service fees for the 2018 financial year by two;

 

   

Other services – calibration services provided by HRL and other ad-hoc services provided on an agreed basis according to our customers and partners requirements.

There are different arrangements for each service being provided. The net margin during the respective periods in relation to the provision of services is as follows:

 

     Three Months Ended September 30,      Nine Months Ended September 30,  
     2018      2017      2018      2017  
     A$      A$      A$      A$  

Revenue from services:

           

Lump sum service fees

     42,164,868        0        42,164,868        0  

Quarterly service fee

     4,420,358        4,278,165        16,445,552        15,733,157  

Other services

     422,150        302,586        983,535        877,330  
  

 

 

    

 

 

    

 

 

    

 

 

 
     47,007,376        4,580,751        59,593,955        16,610,487  

Cost of services

     (217,313      (254,330      (644,508      (737,135
  

 

 

    

 

 

    

 

 

    

 

 

 

Net margin

     46,790,063        4,326,421        58,949,447        15,873,352  
  

 

 

    

 

 

    

 

 

    

 

 

 

Lump sum service fees – During the current quarter, LifeScan gave notice and exercised its right to “convert” its obligation to pay quarterly service fees to Universal Biosensors. Following delivery of the conversion notice, LifeScan is obliged to continue to pay quarterly service fees to Universal Biosensors for the balance of the 2018 LifeScan financial year (as defined in Johnson & Johnson’s internal accounting policies and procedures, which ends on the last Sunday of the calendar year). Promptly after the end of the 2018 LifeScan financial year, LifeScan will calculate and within forty-five days pay to Universal Biosensors a one time lump sum service fee to convert or “buy out” its obligation to pay future quarterly service fees. The 2018 quarterly service fees has been calculated based on (i) actual quarterly service fees received this financial year, and (ii) estimating the quarterly service fees for the remainder of the year based on prior years trend. The lump sum service fees has been calculated by multiplying the total quarterly service fees expected for this financial year by two and converting the same into AUD using the period end exchange rate. We assessed if any amount of the lump sum service fees were attributable to the remaining obligation under the Master Services and Supply Agreement that states that LifeScan could require us to provide manufacturing services at our Rowville facility to recommence production of glucose strips. We conclude that this obligation has no fair value attributable to it due to (i) high set-up costs to recommence manufacturing, (ii) the required lead time to gain regulatory compliance, and (iii) the fact there is deemed to be no commercial rationale for LifeScan to request us to recommence glucose-strip manufacturing on the basis of current information. As such, the lump sum service fee revenue has been fully recognized this quarter and no revenue has been deferred.

Quarterly service fee—The quarterly service fee from LifeScan, as reflected below, increased by 3% and 5%, respectively during the three and nine months ended September 30, 2018 when compared to the same period in the previous financial year. Whilst the volume for the current quarter declined when compared to the prior comparable period, the quarterly service fees increased reflecting the impact of the weakening AUD against the USD. Year to date volumes increased together with a corresponding increase in quarterly service fees when compared to the prior comparable period reflecting ongoing market penetration and growth and the impact of the weakening AUD against USD.

 

     Three Months Ended September 30,      Nine Months Ended September 30,  
     2018      2017      2018      2017  
     Millions      Millions      Millions      Millions  

No. of strips sold

     426        447        1,303        1,284  

Quarterly service fees - USD

     3.19        3.35        12.27        12.13  

Quarterly service fees - AUD

     4.42        4.28        16.45        15.73  

 

27


Table of Contents

The quarterly service fee for each quarter in a LifeScan financial year is calculated based on the number of OneTouch Verio® blood glucose test strips sold in such LifeScan financial year as follows: US$0.0125 per strip for the first 500 million strips sold in a financial year and US$0.0075 per strip for sales in excess of 500 million strips in such financial year. Quarterly service fees are reported and paid by LifeScan in USD. Accordingly, revenues recognized by us from quarterly services fees paid by LifeScan were impacted by the movement of the AUD against the USD over the periods covered above. For the three months and nine months ended September 30, 2018, revenue from quarterly service fees were up 8% and 3%, respectively, due to depreciation of AUD against USD.

Other services - We generated revenues principally from calibration services performed by HRL and from Siemens based on work undertaken for them. Increase in “Other services” is as a result of increase in revenues by HRL during the current period.

Contribution from Products & Services

The net contribution from our products and services is as follows:

 

     Three Months Ended September 30,      Nine Months Ended September 30,  
     2018      2017      2018      2017  
     A$      A$      A$      A$  

Lump sum service fees

     42,164,868        0        42,164,868        0  

Quarterly service fees

     4,420,358        4,278,165        16,445,552        15,733,157  

Manufacturing contribution

     41,134        766,181        75,785        1,148,662  

Other services

     204,837        48,256        339,027        140,195  
  

 

 

    

 

 

    

 

 

    

 

 

 

Contribution from products & services

     46,831,197        5,092,602        59,025,232        17,022,014  
  

 

 

    

 

 

    

 

 

    

 

 

 

The increase in period to period total contributions from products and services reflected in the table above is primarily represented by the lump sum service fee and quarterly service fees which has a 100% margin.

The manufacturing operation is currently running on one shift with all costs being expensed. The Company is investing in scale up projects which will improve efficiency and yields and lead to a profitable manufacturing operation. We are targeting a margin of 40% which we believe is typical of device manufacturers with shared investment and research and development risk. The manufacturing operation has the flexibility to expand in order to support volume increases on the Siemens contract.

Contribution from other services increased over the period primarily as a result of increase in revenue generated by HRL

EBITDA

EBITDA is essentially earnings before interest, taxes, depreciation and amortization. EBITDA is a non-GAAP measurement. Management uses EBITDA because it believes that such measurements are widely accepted financial indicators used by investors and analysts to analyze and compare companies on the basis of operating performance and that these measurements may be used by investors to make informed investment decisions, including our ability to generate earnings sufficient to service our debt, and enhances our understanding of our financial performance and highlights operational trends. These measures are not in accordance with, or an alternative for, generally accepted accounting principles in the United States (GAAP). The most comparable GAAP measure is net earnings from continuing operations. Consolidated EBITDA should not be considered in isolation or as a substitution for analysis of our results as reported under GAAP.

EBITDA for the respective periods and a reconciliation of net income to EBITDA is as follows:

 

28


Table of Contents
     Three Months Ended September 30,      Nine Months Ended September 30,  
     2018      2017      2018      2017  
     A$      A$      A$      A$  

Net income/(loss)

     41,865,596        (1,180,725      41,391,958        1,318,644  

Interest income

     (175,643      (15,772      (365,542      (74,625

Interest expense

     606,166        510,882        1,741,825        1,561,871  

Depreciation - cost of goods sold & services

     7,007        34,562        160,948        444,437  

Depreciation - other operating costs & expenses

     451,481        636,000        1,519,375        1,485,014  
  

 

 

    

 

 

    

 

 

    

 

 

 

EBITDA

     42,754,607        (15,053      44,448,564        4,735,341  
  

 

 

    

 

 

    

 

 

    

 

 

 

Increase in EBITDA primarily as a result of the recognition of the lump sum service fees during the current quarter.

Product Support

Product support relates to work undertaken by us to further enhance the product in the market.

Product support for the respective periods are as follows:

 

     Three Months Ended September 30,      Nine Months Ended September 30,  
     2018      2017      2018      2017  
     A$      A$                

Product support

     8,750        205,317        202,899        537,010  
  

 

 

    

 

 

    

 

 

    

 

 

 

Product support expenditure varies and is dependent upon the improvements we undertake. Management expects product support expenditure to decline over time.

Depreciation

Depreciation of fixed assets is based on a straight line basis over the useful life of property, plant and equipment. Depreciation is allocated to cost of goods sold and research and development expenditure based on output. With lower commercial production volume and increased production in research and development, more depreciation is allocated towards research and development during the current period.

Depreciation for the respective periods have been charged as follows:

 

     Three Months Ended September 30,      Nine Months Ended September 30,  
     2018      2017      2018      2017  
     A$      A$                

Research and development expenses

     410,326        584,515        1,391,294        1,341,700  

General and administrative expenses

     41,096        41,745        126,901        130,151  

Product support depreciation

     59        9,740        1,180        13,163  
  

 

 

    

 

 

    

 

 

    

 

 

 

Depreciation

     451,481        636,000        1,519,375        1,485,014  
  

 

 

    

 

 

    

 

 

    

 

 

 

Research and Development Expenses

Total research and development expenditure for the respective periods are as follows:

 

29


Table of Contents
     Three Months Ended September 30,      Nine Months Ended September 30,  
     2018      2017      2018      2017  
     A$      A$      A$      A$  

Research and development expenses

     2,759,664        3,197,146        9,452,609        7,626,210  
  

 

 

    

 

 

    

 

 

    

 

 

 

Research and development expenditure principally reflects the effort required in product development of the tests we are developing. Research and development expenditure decreased by 14% for the three months ended September 30, 2018 compared to the same period in the previous financial year and increased by 24% for the nine months ended September 30, 2018 compared to the same period in the previous financial year.

The increase in year-to-date research and development expenses is primarily represented by the ramp up of the further tests in development for Siemens as we head towards regulatory clinical trials.

This financial year we also re-commenced work on our home PT-INR self testing device which has contributed to the increase in expenditure as well.

Research and development expenditure also include separation payments made to certain staff during the second quarter as part of management initiative to reduce expenditures. Whilst this represented a cost during the second quarter, the overall research and development expenditure has decreased during the current quarter as a result of the decline in headcount.

While we have a degree of control as to how much we spend on research and development activities in the future, we cannot predict with certainty what it will cost to complete our individual research and development programs successfully or when or if they will be commercialized. The timing and cost of any program is dependent upon a number of factors including achieving technical objectives, which are inherently uncertain, and subsequent regulatory approvals. We do however have project plans in place for all our development programs which we use to plan, manage and assess our projects. As part of this procedure, we also undertake commercial assessments of such projects to optimize outcomes and make go no-go decisions.

In addition, our business strategy contemplates that we may enter into collaborative arrangements with third parties for one or more of our non-blood glucose programs. In the event that we are successful in securing such third party collaborative arrangements, the third party may direct the research and development activities and may contribute towards all or part of the cost of these activities, both of which will influence our research and development expenditure. Research and development activities undertaken on behalf of our customers and partners for the three months ended September 30, 2018 and 2017 were A$2,157,841 and A$2,223,905, respectively and A$6,761,280 and A$4,965,247 for the nine months ended September 30, 2018 and 2017, respectively.

Research and development expenses are related to the development of new technologies and products based on the electrochemical cell platform.

The Company conducts research and development activities to build an expanding portfolio of product-based revenues and cash flows and increase the value of UBI’s core technology assets. Research is focused on demonstrating technical feasibility of new technology applications. Development activity is focused on turning these technology platforms into commercial-ready product and represents the majority of the Company’s research and development expenses.

Research and development expenses consist of costs associated with research activities, as well as costs associated with our product development efforts, including pilot manufacturing costs. Research and development expenses include:

 

   

consultant and employee related expenses, which include consulting fees, salaries and benefits;

 

   

materials and consumables acquired for the research and development activities;

 

   

external research and development expenses incurred under agreements with third party organizations and universities; and

 

   

facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, depreciation of leasehold improvements and equipment and laboratory and other supplies.

Our principal research and development activity is in blood coagulation testing.

 

30


Table of Contents

In September 2011 we entered into a Collaboration Agreement with Siemens which was amended in September 2012 and March 2016, pursuant to which we will develop a range of test strips and reader products for the hospital point-of-care and alternative site coagulation testing markets. The first such product developed with Siemens, the Xprecia Stride™ Coagulation Analyzer, received CE mark approval on December 9, 2014 and FDA approval on October 4, 2016. The Xprecia Stride™ Coagulation Analyzer is now available for sale in North America, Latin America, Europe, the Middle East, Africa and Asia Pacific. In 2012, we entered into a Supply Agreement with Siemens under which we manufacture and supply the test strips for this product and will manufacture and supply the test strips for further tests still in development with Siemens. In addition, UBS is engaged in point-of-care coagulation product development for the consumer, home testing market which could be distributed globally.

General and Administrative Expenses

General and administrative expenses currently consist principally of salaries and related costs, including stock option expense, for personnel in executive, business development, finance, accounting, information technology and human resources functions. Other general and administrative expenses include depreciation, repairs and maintenance, insurance, facility costs not otherwise included in research and development expenses, consultancy fees and professional fees for legal including legal and maintenance fees incurred for patent applications, audit and accounting services. General and administrative expenses decreased by 16% for the three months ended September 30, 2018 compared to the same period in the previous financial year and increased by 5% for the nine months ended September 30, 2018 compared to the same period in the previous financial year.

The year-to-date increase in part is based upon separation payments made to certain staff during the second quarter as part of management initiative to reduce expenditures. The resultant impact is cost savings during the current quarter.

General and administrative expenses for the respective periods are as follows:

 

     Three Months Ended September 30,      Nine Months Ended September 30,  
     2018      2017      2018      2017  
     A$      A$      A$      A$  

General and administrative expenses

     1,360,040        1,624,974        5,110,134        4,855,136  
  

 

 

    

 

 

    

 

 

    

 

 

 

Interest Income

Interest income increased by 1,014% and 390%, respectively during the three and nine months ended September 30, 2018 and 2017 when compared to the same period in the previous financial year. The increase in interest income is generally attributable to the higher amount of funds available for investment noting that in addition to Australian currency, from this financial year, our U.S. denominated currency have been placed in term deposit accounts which generate interest income.

 

     Three Months Ended September 30,      Nine Months Ended September 30,  
     2018      2017      2018      2017  
     A$      A$      A$      A$  

Interest income

     175,643        15,772        365,542        74,625  
  

 

 

    

 

 

    

 

 

    

 

 

 

Interest Expense

Interest expense relates to interest being charged on a short-term borrowing initiated by the Company in prior years. These short-term loans were taken out to fund our insurance premiums and are repaid during the financial year. The insurance premium at inception was A$369,630 for the 2017 financial year. The interest rate was 2.60%. No short-term borrowings were initiated in 2018 and as a result there is no interest expense.

 

31


Table of Contents
     Three Months Ended September 30,      Nine Months Ended September 30,  
     2018      2017      2018      2017  
     A$      A$      A$      A$  

Interest expense

     0        1,922        0        8,649  
  

 

 

    

 

 

    

 

 

    

 

 

 

Financing Costs

In December 2013, UBS accessed new capital via a US$25,000,000 loan facility of which US$15,000,000 was drawn in December 2013. The breakdown of the financing costs is as follows:

 

     Three Months Ended September 30,      Nine Months Ended September 30,  
     2018      2017      2018      2017  
     A$      A$      A$      A$  

Interest expense

     606,166        508,960        1,741,825        1,553,222  

Warrants expense

     36,226        51,994        104,096        158,672  

Other debt issuance costs

     92,554        124,659        272,148        377,434  
  

 

 

    

 

 

    

 

 

    

 

 

 
     734,946        685,613        2,118,069        2,089,328  
  

 

 

    

 

 

    

 

 

    

 

 

 

Interest expense relates to applicable interest of 10.5% levied on the loan. The debt issuance costs were recorded as deferred issuance costs and are amortized as interest expense, using the effective interest method, over the term of the loan.

Increase in financing costs is primarily a result of weakening of the AUD against the USD, noting that our loan is denominated in USD. For the three and nine month period ending September 30, 2018, the period-over-period foreign currency movements relative to the AUD dollar would have had a favorable impact (exclusive of hedging impact) of A$46,310 and A$33,281, respectively on our reported results.

Exchange gain

Exchange gain for the respective periods are as follows:

 

     Three Months Ended September 30,      Nine Months Ended September 30,  
     2018      2017      2018      2017  
     A$      A$                

Exchange gain

     183,395        61,873        412,768        703,420  
  

 

 

    

 

 

    

 

 

    

 

 

 

Foreign exchange gains and losses arise from the settlement of foreign currency transactions that are translated into the functional currency using the exchange rates prevailing at the dates of the transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies.

Critical Accounting Estimates and Judgments

Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, income, costs and expenses, and related disclosures. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates.

We believe that of our significant accounting policies, which are described in the notes to our consolidated financial statements, the following accounting policies involve a greater degree of judgment and complexity. Accordingly, we believe that the following accounting policies are the most critical to aid in fully understanding and evaluating our consolidated financial condition and results of operations.

 

32


Table of Contents

(a) Revenue Recognition

Revenue is measured based on a consideration specified in a contract with a customer. The Company recognizes revenue when it satisfies a performance obligation by transferring control over a product or service to a customer. In relation to the lump sum service fees, there are no further performance obligations of value affecting revenue being recognized.

(b) Stock-Based Compensation

We account for stock-based employee compensation arrangements using the modified prospective method as prescribed in accordance with the provisions of ASC 718 – Compensation – Stock Compensation.

Each of the inputs to the Trinomial Lattice model is discussed below.

Share Price and Exercise Price at Valuation Date

With the exception of ZEPOs, the exercise price of the options granted has been determined using the closing price of our common stock trading in the form of CDIs on ASX at the time of grant of the options. The exercise price of ZEPOs is nil. The ASX is the only exchange upon which our securities are quoted.

Volatility

We applied volatility having regard to the historical price change of our shares in the form of CDIs available from the ASX.

Time to Expiry

All options granted under our share option plan have a maximum 10 year term and are non-transferable.

Risk Free Rate

The risk free rate which we applied is equivalent to the yield on an Australian government bond with a time to expiry approximately equal to the expected time to expiry on the options being valued.

(c) Income Taxes

We apply ASC 740 – Income Taxes which establishes financial accounting and reporting standards for the effects of income taxes that result from a company’s activities during the current and preceding years. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Where it is more likely than not that some portion or all of the deferred tax assets will not be realized, the deferred tax assets are reduced by a valuation allowance. The valuation allowance is sufficient to reduce the deferred tax assets to the amount that is more likely than not to be realized.

(d) Impairment of Long-Lived Assets

We review our capital assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. In performing the review, we estimate undiscounted cash flows from products under development that are covered by these patents and licenses. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition is less than the carrying amount of the asset. If the evaluation indicates that the carrying value of an asset is not recoverable from its undiscounted cash flows, an impairment loss is measured by comparing the carrying value of the asset to its fair value, based on discounted cash flows.

 

33


Table of Contents

(e) Warrants

In connection with our US$15 million loan facility, we issued to the Lenders warrants entitling the holder to purchase up to an aggregate total of 4.5 million shares of UBI’s common stock in the form of CDIs at a price of A$1.00 per share. The fair value of the warrants to purchase common stock is estimated using the Trinomial Lattice model. Each of the inputs to the Trinomial Lattice model is discussed below.

Exercise Price at Valuation Date

The exercise price of the warrants has been determined as stated in the Credit Agreement. For further details, see Notes to Consolidated Condensed Financial Statements—Summary of Significant Accounting Policies – Borrowings – Athyrium Credit Agreement.

Volatility

We applied volatility having regard to the historical price change of our shares in the form of CDIs available from the ASX.

Time to Expiry

The warrants have a term of seven years.

Risk Free Rate

The risk free rate which we applied is equivalent to the yield on an Australian government bond with a time to expiry approximately equal to the expected time to expiry on the warrants to purchase common stock being valued.

(f) Research and development tax incentive income

Research and development tax incentive income is recognized when there is reasonable assurance that the income will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured. The research and development tax incentive is one of the key elements of the Australian Government’s support for Australia’s innovation system and is supported by legislative law primarily in the form of the Australian Income Tax Assessment Act 1997 as long as eligibility criteria are met.

Management has assessed the Company’s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the tax incentive regime described above. At each period end management reviews the aggregate turnover of the Company to determine if the research and development tax incentive income should be recorded and based on this information and other available information at the time estimates the refundable tax offset available to the Company. This estimate is also reviewed by external tax advisors on an annual basis.

 

34


Table of Contents

Financial Condition, Liquidity and Capital Resources

Net Financial Assets

Our net financial assets position is shown below:

 

     Nine Months Ended
September 30,
     Year Ended
December 31,
 
     2018      2017  
     A$      A$  

Financial assets:

     

Cash and cash equivalents

     28,531,432        26,259,918  

Accounts receivables

     4,902,417        4,397,268  
  

 

 

    

 

 

 

Total financial assets

     33,433,849        30,657,186  
  

 

 

    

 

 

 

Debt:

     

Short term secured loan

     20,660,753        0  

Long term secured loan

     0        19,029,076  
  

 

 

    

 

 

 

Total debt

     20,660,753        19,029,076  
  

 

 

    

 

 

 

Net financial assets

     12,773,096        11,628,110  
  

 

 

    

 

 

 

Since inception, we have financed our business primarily through the issuance of equity securities, funding from strategic partners, government grants and rebates (including the research and development tax incentive income), cash flows generated from operations, and the loan discussed below.

On December 19, 2013 we entered into the Credit Agreement which was subsequently amended in January 2015 and on December 2017 with Lenders for a US$25 million secured term loan. A first tranche loan of US$15,000,000 was drawn on December 2013 and we elected not to draw down the additional US$10,000,000. The term loan has a maturity date of July 1, 2019 and bears interest at 10.5% per annum. Interest payments are due quarterly over the term of the term loan and, other than as described elsewhere herein, we are not required to make payments of principal for amounts outstanding under the term loan until the Maturity Date. Subject to certain exceptions, the term loan is secured by substantially all of our assets, including our intellectual property. For further details, see Notes to Consolidated Financial Statements—Summary of Significant Accounting Policies – Borrowings – Athyrium Credit Agreement.

To a large extent, the increase in our USD denominated currency and the weakening of the AUD against the USD has resulted in an improvement to our net financial asset position. Note a major portion of our net financial assets/(liabilities) is denominated in USD, including our operating account and the long term secured loan hence is subject to variation with movements in exchange rates.

We believe we have sufficient cash and cash equivalents to fund our operations for at least the next twelve months. Liquidity risk is the risk that the Company may encounter difficulty meeting obligations associated with financial liabilities. The Company manages liquidity risk through the management of its capital structure. The purpose of liquidity management is to ensure that there is sufficient cash to meet all the financial commitments and obligations of the Company as they come due. In managing the Company’s capital, management estimates future cash requirements by preparing a budget and a multi-year plan for review and approval by the Board. The budget is reviewed and updated periodically and establishes the approved activities for the next twelve months and estimates the costs associated with those activities. The multi-year plan estimates future activity along with the potential cash requirements and is based upon management’s assessment of current progress along with the expected results from the coming years’ activity. Budget to actual variances are prepared and reviewed by management and are presented on a regular basis to the Board of Directors.

The carrying value of the cash and cash equivalents and the accounts receivables approximates fair value because of their short-term nature.

We regularly review all our financial assets for impairment. There were no impairments recognized as at September 30, 2018 or for the year ended December 31, 2017.

Derivative Instruments and Hedging Activities

In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as consider our own and counterparty credit risk. At September 30, 2018 and December 31, 2017, we did not have any assets or liabilities that utilize Level 3 inputs. The valuation of our foreign exchange derivatives is based on the market approach using observable

 

35


Table of Contents

market inputs, such as forward rates, and incorporates non-performance risk (the credit standing of the counterparty when the derivative is in a net asset position, and the credit standing of the Company when the derivative is in a net liability position). Our derivative assets are categorized as Level 2.

We had no outstanding contracts as at September 30,, 2018 and December 31, 2017. We recognized gains of nil for the periods ended September 30, 2018 and December 31, 2017. No amount of ineffectiveness was recorded in earnings for these designated cash flow hedges for the periods ended September 30, 2018 and December 31, 2017. For further details, see Notes to Consolidated Financial Statements – Summary of Significant Accounting Policies.

Measures of Liquidity and Capital Resources

The following table provides certain relevant measures of liquidity and capital resources:

 

     Nine Months Ended
September 30,
     Year Ended
December 31,
 
     2018      2017  
     A$      A$  

Cash and cash equivalents

     28,531,432        26,259,918  

Working capital

     51,578,449        24,746,728  

Ratio of current assets to current liabilities

     2.76 : 1        3.97 : 1  

Shareholders’ equity per common share

     0.31        0.07  

The movement in cash and cash equivalents and working capital during the above periods was primarily due to cash flows generated from/used in operations including outflows arising from the effort required to complete the products in development, servicing of the secured loan and the timing of payments and accruals in the ordinary course of business.

With the weakening of the AUD against the USD, our cash and cash equivalents position has improved as a large portion of our funds is held in USD denominated currency. There has been a significant improvement to our working capital position as a result of the recording of the lump sum service fee during the current quarter. A portion of this increase has been offset by the re-classification of the loan. This loan has been re-classed from non-current liabilities to current liabilities as at June 30, 2018 as it will be repaid within the next 12 months to the Lenders pursuant to the Credit Agreement.

We have not identified any collection issues with respect to receivables.

Summary of Cash Flows

 

     Nine Months Ended September 30,  
     2018      2017  
     A$      A$  

Cash provided by/(used in):

     

Operating activities

     864,431      2,186,039

Investing activities

     (306,087      (997,503

Financing activities

     (256,410      (334,044
  

 

 

    

 

 

 

Net increase in cash and cash equivalents

     301,934      854,492
  

 

 

    

 

 

 

Our net cash provided by operating activities for all periods represents receipts offset by payments for our research and development projects including efforts involved in establishing and maintaining our manufacturing operations, interest on our long term secured loan and general and administrative expenditure. A decline in our operating cash flow position is reflective of the decline in our total revenues (excluding lump sum service fees) and an increase in our operating costs and expenses.

 

36


Table of Contents

Our net cash used in investing activities for all periods is primarily for the purchase of various plant and equipment and for the various continuous improvement program we are undertaking.

Our net cash used in financing activities in 2018 represents US$200,000 fee paid to the Lenders for the December 2017 Amendment whilst for 2017, it represents repayment of the short-term borrowing.

Off-Balance Sheet Arrangement

The future minimum lease payments under non-cancellable operating leases (with initial or remaining lease terms in excess of one year) as of September 30, 2018 are:

 

     A$  

Less than 1 year

     410,281  

1 – 3 years

     52,942  

3 – 5 years

     14,112  

More than 5 years

     0  
  

 

 

 

Total minimum lease payments

     477,335  
  

 

 

 

The above relates to our operating lease obligations in relation to the lease of our premises and certain office equipment.

As of the date of this Quarterly Report, we do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

Contractual Obligations

Our future contractual obligations at September 30, 2018 were as follows:

 

     Payments Due By Period  
     Total      Less than 1
year
     1 – 3 years      3 – 5 years      More than 5
years
 
     A$      A$      A$      A$      A$  

Asset Retirement Obligations (1)

     2,600,000        0        0        0        2,600,000  

Operating Lease Obligations (2)

     477,335        410,281        52,942        14,112        0  

Purchase Obligations (3)

     1,538,429        1,538,429        0        0        0  

Short term secured loan (4)

     20,660,753        20,660,753        0        0        0  

Financing costs (5)

     919,586        919,586        0        0        0  

Other liability (6)

     2,836,614        2,836,614        0        0        0  

Other Long-Term Liabilities on Balance Sheet (7)

     50,538        0        41,909        6,412        2,217  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     29,083,255        26,365,663        94,851        20,524        2,602,217  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

(1)

Represents legal obligations associated with the retirement and removal of long-lived assets (making good of the premises the Company currently leases in Rowville). The current lease expires on March 31, 2019 and the Company has until December 31, 2018 to take up the option of extending the lease for another 5 years which is at its discretion. The Company is currently negotiating the lease extension of the Rowville facility.

(2)

Our operating lease obligations relate primarily to the lease of our premises.

(3)

Represents outstanding purchase orders.

(4)

US$15 million payable to the lenders on maturity date pursuant to the Credit Agreement.

(5)

Interest payable to the lenders pursuant to the Credit Agreement.

(6)

Represents marketing support fees payable to LifeScan.

(7)

Represents long service leave owing to the employees.

 

37


Table of Contents

Segments

We operate in one segment. Our principal activities are research and development, commercial manufacture of approved medical or testing devices and the provision of services including contract research work.

We operate predominantly in one geographical area, being Australia and continue to derive significant revenues from LifeScan.

The Company’s material long-lived assets are all based in Australia.

 

38


Table of Contents

Item 3 Quantitative and Qualitative Disclosures About Market Risk

As a “smaller reporting company”, we are not required to provide the information called for by this Item.

 

39


Table of Contents

Item 4. Controls and Procedures

Disclosure Controls and Procedures. At the end of the period covered by this report, the Company and management evaluated the effectiveness of the design and operation of its disclosure controls and procedures. The Company’s disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Rick Legleiter, Chief Executive Officer, and Salesh Balak, Chief Financial Officer, reviewed and participated in this evaluation. Based on this evaluation, Messrs. Legleiter and Balak concluded that, as of the end of the period covered by this report, the Company’s disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting. During the fiscal quarter ended September 30, 2018, there were no changes in the Company’s internal control over financial reporting identified in connection with the evaluation referred to above in this Item 9A that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

40


Table of Contents

PART II

Item 1 Legal Proceedings

None.

Item 1A Risk Factors

The following risk factors supplement and, to the extent inconsistent, supersede the risks discussed in Part I, Item 1A – “Risk Factors” in the Annual Report. Investing in our shares or CDIs involves a high degree of risk. Before you invest in our shares or CDIs, you should understand the high degree of risk involved. You should carefully consider the following risks and other information in this Form 10-Q and the risks discussed in Part I, Item 1A – “Risk Factors” in the Annual Report and the other information in the Annual Report, including our financial statements and related notes appearing in this Form 10-Q and in the Annual Report, before you decide to invest in our shares or CDIs. If any of the events described herein or therein actually occurs, our business, financial condition and operating results could be harmed. In such an event, the market price of our CDIs would likely decline and you could lose part or all of your investment.

If any of our key contracts are terminated our business would be severely harmed and development and commercialization opportunities restricted or eliminated.

The License Agreement with LifeScan imposes material obligations on us. LifeScan may terminate the License Agreement if we fail to use commercially reasonable efforts to commercialise and fail to provide evidence of our compliance within 90 days of written notice, are liquidated or wound up, or are in persistent and material breach of our obligations and fail to remedy the breach within 90 days of written notice requiring us to do so. If we were to breach the License Agreement and LifeScan were to validly terminate the agreement in response, it would severely and adversely affect our financial results, business and business prospects and the future of our research and development activities. Amongst other things, it would seriously restrict or eliminate our ability to develop and commercialize our own tests and our ability to grant further sublicenses, which would restrict or eliminate our commercialization opportunities. It would also trigger a cross default under our Credit Agreement (as defined below). If the License Agreement was terminated, any sublicense under the License Agreement previously granted by us to a third party that is in effect immediately prior to such termination (which would include licenses granted to Siemens under the Collaboration Agreement) would survive termination as a direct license from LifeScan to such sublicensee, provided certain conditions are met, including that the sublicensee is not in material breach of any provision of the License Agreement and agrees to be bound to the terms of the License Agreement with respect to the applicable sublicense field. If the sublicense under the Collaboration Agreement was terminated, the ability for Siemens to commercialize the products we have developed with them may be restricted or eliminated which would have a material adverse effect on us.

We have received notice from the LifeScan of LifeScan’s exercise of its right to convert, or “buy out,” its obligation to pay quarterly service fees to us under the Master Services and Supply Agreement. Accordingly, LifeScan is obliged to continue to pay quarterly service fees to us for the balance of the 2018 LifeScan financial year (as defined in Johnson & Johnson’s internal accounting policies and procedures, which ends on the last Sunday of the calendar year). Promptly after the end of the 2018 LifeScan financial year, LifeScan will calculate and within forty-five (45) days pay to us a one time lump sum service fee to convert or “buy out” its obligation to pay future quarterly service fees. After payment of the lump sum service fee, either of LifeScan or us may provide notice of termination of the Master Services and Supply Agreement after payment of the lump sum service fee. Unless we are engaged to provide additional services to LifeScan, following receipt of the lump sum service fee we will cease to receive cash flows under the Master Services and Supply Agreement irrespective of whether that agreement is terminated. We have not provided services under the Master Services and Supply Agreement to LifeScan for over three years. Platinum Equity announced that it had completed its acquisition of LifeScan from Johnson & Johnson on October 1, 2018. As a result, there is further uncertainty whether we will be engaged for further services in the future.

The Collaboration Agreement with Siemens expires on the end of all payment obligations under the Collaboration Agreement and the Supply Agreement. The Collaboration Agreement can be terminated by Siemens as set out in the agreement including for our insolvency, after 60 days’ notice for our uncured material breach, upon 30 days’ written notice to us for any reason (provided that if it does so prior to the milestones being achieved, it must pay a termination fee), or if a developed product infringes a third party patent and it is not commercially viable to work around or obtain a license for the infringed patent.

The Supply Agreement with Siemens expires after 10 years but Siemens may extend the term of the Supply Agreement for an additional five-years. Siemens may also extend the term of the Supply Agreement under other limited circumstances, but in no event beyond 18 years from the Effective Date. Siemens may terminate the Supply Agreement prior to its expiration upon 42 months’ prior written notice to us, or due to uncured material breach and persistent failures by us to supply products.

Any termination of the Collaboration Agreement or Supply Agreement may severely and adversely affect our financial results, business and business prospects and the future of our research and development activities. Amongst other things we would not receive remaining milestones under the Collaboration Agreement and would be required to reimburse Siemens for certain prepaid milestones. We would also not receive any fees from manufacturing product (except in certain circumstances where Siemens manufactures products or has products manufactured by a third party on its behalf where Siemens is obligated to pay us a fee for each product manufactured and the profit-sharing obligations under the Collaboration Agreement continue to apply).

 

41


Table of Contents

Quarterly service fees from LifeScan currently represent a significant proportion of our revenue.

The majority of our products and services revenue has historically been derived from LifeScan. Despite our relationship with Siemens and our plans to develop and commercialize own product, we do not currently have, and may never have, other contracts in place or products in the market, generating similar or material revenues. Although the Siemens Xprecia StrideTM Coagulation Analyzer was released in Europe in December 2014 and initial sales activities commenced in the United States in May 2017, sales of the product are currently comparatively low and are not sufficient to offset our current level of expenditure. We are in discussions with Siemens regarding product profitability (performance of the product currently in market) and R&D expenditure (majority of the costs continue to be borne by us). Our own product is still in development requiring significant additional development expenditure. We do not currently, and may never, generate revenue from our own product in development. As a result, following receipt of the lump sum service fee we will have increased reliance on revenues from Siemens and could in the future face substantial liquidity problems and may be forced to restructure our operations, dispose of material assets or operations, or seek to obtain equity capital, or indebtedness to fund our operations, or undertake a combination of the foregoing actions.

If Siemens withdraws the product or does not submit purchase orders for a certain amount of product, our manufacturing capacity may not be fully utilized and we will lose the revenue opportunity from the product. If this occurs, we will be faced with surplus capacity in our manufacturing operations and our revenues will decline. Further, Siemens may obtain the right to manufacture product or have a third party manufacture product on its behalf if certain events occur (for example, insolvency, failure to supply). The Supply Agreement with Siemens may also be terminated as a result of either party defaulting on its material obligations. If any of these circumstances arise, we would cease to have the potential to receive manufacturing revenues from the sale of product purchased by Siemens.

An important part of our strategy is to seek to enter into other collaborative arrangements or strategic alliances with respect to the development and commercialization of specific tests or in specific fields.

Our Credit Agreement has financial and non-financial covenants, and default of any covenant could materially adversely impact us.

On December 19, 2013 UBI and UBS entered into a credit agreement with Athyrium Opportunities Fund (A) LP, as administrative agent (the “Administrative Agent”) and as a lender, and Athyrium Opportunities Fund (B) LP as a lender (Athyrium A and Athyrium B together with any other lenders party thereto from time to time, the “Lenders”), which was amended on January 30, 2015 and on December 29, 2017, for a secured term loan of up to US$25,000,000 (the “Credit Agreement”). A first tranche loan of US$15,000,000 was drawn on December 2013 and UBI elected not to draw down the additional US$10,000,000. Unless the facility is otherwise terminated earlier pursuant to the terms of the Credit Agreement, UBS is required to repay the outstanding principal amount of the loans drawn down, together with all accrued and unpaid interest thereon and all other obligations on July 1, 2019 (the “Maturity Date”). Receipt of the lump sum service fee from LifeScan will constitute an “extraordinary receipt” under the Credit Agreement and as a result the loan will be repayable upon receipt of the LifeScan lump sum fee, which is expected to occur within 45 days following the end of LifeScan 2018 financial year. We expect to repay the loans upon receipt of the lump sum service fee from LifeScan. The Credit Agreement is secured by substantially all of the assets of UBS and UBI, including the stock in UBS and HRL. The obligations of UBS under the Credit Agreement are guaranteed by UBI and HRL.

UBS’ ability to maintain compliance with the covenants in our Credit Agreement is dependent upon, among other things, our ability to continue to execute our business plans and our ability to generate cash from operations. The debt facility is subject to certain specified events of default, defaults relating to non-payment, breach of covenants or inaccuracy of representations and warranties, cross-defaults to other indebtedness, bankruptcy and insolvency defaults, material judgment defaults, regulatory defaults, the occurrence of a material adverse effect, or un-remedied material breach by UBS, UBI or HRL or termination of a key contract. The occurrence of an event of default could result in the amounts owing under the Credit Agreement, including all unpaid principal and interest being due and payable, and could result in the administrative agent enforcing its security over the assets of UBS, UBI and HRL. If the loans are accelerated or commitments terminated, we could face substantial liquidity problems and may be forced to dispose of material assets or operations, seek to obtain equity capital, or restructure or refinance our indebtedness. Such alternative measures may not be available or successful. Also, our debt covenants may limit our ability to dispose of material assets or operations or to restructure or refinance our indebtedness. Even if we are able to restructure or refinance our indebtedness, the economic terms may not be favorable to us. In addition, an event of default under our key commercial contracts could result in a cross-default under our Credit Agreement. All of the foregoing could have serious consequences to our financial condition and results of operations and could cause us to become bankrupt or insolvent.

Item 2 Unregistered Sales of Equity Securities and Use of Proceeds

There has been no sale of equity securities by the Company or purchase of equity securities by the Company, or by an affiliated purchaser on behalf of the Company, since December  31, 2017.

Item 3 Defaults Upon Senior Securities

None.

 

42


Table of Contents

Item 4 Mine Safety Disclosures

Not applicable.

Item 5 Other Information

None.

Item 6 Exhibits

 

Exhibit No

  

Description

  

Location

31.1    Rule 13a-14(a)/15d-14(a) Certification (Principal Executive Officer)    Filed herewith
31.2    Rule 13a-14(a)/15d-14(a) Certification (Principal Financial Officer)    Filed herewith
32    Section 1350 Certificate    Furnished herewith
101    The following materials from the Universal Biosensors, Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 formatted in Extensible Business Reporting Language (XBRL): (i) the Consolidated Condensed Balance Sheets, (ii) the Consolidated Condensed Statements of Comprehensive Income/(Loss), (iii) the Consolidated Condensed Statements of Changes in Stockholder’s Equity and Comprehensive Income/(Loss), (iv) the Consolidated Condensed Statements of Cash Flows and (v) the Notes to Consolidated Condensed Financial Statements    Filed herewith

 

43


Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

     

UNIVERSAL BIOSENSORS, INC.

                (Registrant)

Date: October 30, 2018     By:  

/s/ Rick Legleiter

      Rick Legleiter
      Principal Executive Officer
    By:  

/s/ Salesh Balak

Date: October 30, 2018       Salesh Balak
      Principal Financial Officer

 

 

44

EX-31.1 2 d631294dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Rick Legleiter, certify that:

 

1.

I have reviewed this report on Form 10-Q of Universal Biosensors, Inc.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 30, 2018

 

/s/ Rick Legleiter

Rick Legleiter
Principal Executive Officer
Universal Biosensors, Inc.
EX-31.2 3 d631294dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Salesh Balak, certify that:

 

1.

I have reviewed this report on Form 10-Q of Universal Biosensors, Inc.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 30, 2018

 

/s/ Salesh Balak

Salesh Balak
Principal Financial Officer
Universal Biosensors, Inc.
EX-32 4 d631294dex32.htm EX-32 EX-32

Exhibit 32

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 *

In connection with the quarterly report of Universal Biosensors, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company does hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of such officer’s knowledge:

 

  (1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. The undersigned have executed this Certificate as of the 30th day of October, 2018.

 

/s/ Rick Legleiter

Rick Legleiter
Principal Executive Officer

/s/ Salesh Balak

Salesh Balak
Principal Financial Officer

 

*

This certification is being furnished as required by Rule 13a-14(b) under the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code, and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section. This certification shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent such certification is explicitly incorporated by reference in such filing.

EX-101.INS 5 ubi-20180930.xml XBRL INSTANCE DOCUMENT 2961245 3000000 1.00 4500000 1.17 1.00 4500000 25000000 1.17 15000000 23622322 22616230 13254275 5800672 95096 369630 1011321 93167465 -298203 176386884 17639 -79632626 0.50 0.39 0.60 0.38 0.80 0.38 0.50 0.38 1472692 2600000 33082184 0 4397268 27264680 93450721 13179762 329586 4397268 2626413 -301709 46261946 26259918 29495227 0 300000000 176498550 0.0001 176498550 17650 2356583 3463737 1550182 658334 253483 662132 28109 380540 8335456 15000000 33492627 46261946 25157171 19029076 14842679 0 0 15875875 1956563 19029076 14842679 860254 10993737 887303 2626413 9959762 0.01 1000000 3235309 37224442 15309 -79632626 3220000 0 12769319 815655 29495227 11048336 17832438 -764717 64358 2832438 22003215 0.63 0.31 492749 668043 1011321 15309 320000 0 2900000 93450721 -301709 176498550 17650 -80397343 177001884 23067767 10963629 14922431 0 93522470 -303700 176431883 17643 -78313982 1643828 2600000 80827871 0 4902417 28790321 93678895 8888802 472930 4902417 2836614 -338234 89716673 28531432 31767381 0 300000000 177001884 0.0001 177001884 17700 2356583 3463737 1278714 736851 158883 481282 0 322399 29249422 15000000 35363697 89716673 6114275 14921196 20660753 14921196 20660753 15221375 442750 0 0 43331479 665312 2836614 8568802 0.01 1000000 3235949 37359123 2915949 -80397343 320000 20660753 7208775 54352976 815655 31767381 15664125 1000 41391958 50538 664125 1000000000 0.40 674671 16375450 0.63 0 94357 258756 321558 0.31 205662 70000 15000 250000 575000 0.105 10000000 2 2000000 2000000 0.0260 0.18 15949 320000 2900000 0 4 93678895 -338234 177001884 17700 -39005385 0.02 625000 0.025 2019-07-01 500000 P7Y 0.15 0.05 158672 354243 2089328 854492 1313147 3650943 703420 1485014 1929451 0.01 -1409047 0.01 159889 703420 -2409 4855136 1318644 0 -90616 17022014 -546655 -314914 949175 8649 105655 -196982 74625 -1200000 -997503 -334044 2186039 1318644 5497 0 0 -5497 0 119932 -5497 5497 0 14503370 2518644 0 997503 0 767 1318644 7626210 334811 20672957 354243 766 177602842 176395711 537010 20000000 354243 50423 2913808 4062470 737135 16610487 354243 0 0 762 0 0 -5497 0 0 0 0 4 44999 0 1318644 0 0 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Asset Retirement Obligations</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Asset retirement obligations (&#x201C;ARO&#x201D;) are legal obligations associated with the retirement and removal of long-lived assets. ASC 410 &#x2013; Asset Retirement and Environmental Obligations requires entities to record the fair value of a liability for an asset retirement obligation when it is incurred. When the liability is initially recorded, the Company capitalizes the cost by increasing the carrying amounts of the related property, plant and equipment. Over time, the liability increases for the change in its present value, while the capitalized cost depreciates over the useful life of the asset. The Company derecognizes ARO liabilities when the related obligations are settled.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The ARO is in relation to our premises where in accordance with the terms of the lease, the lessee has to restore part of the building upon vacating the premises.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> ARO for the years ended September 30, 2018 and December&#xA0;31, 2017 was A$2,600,000.</p> </div> false 104096 228224 2118069 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Business combinations</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Business combinations are accounted for using the acquisition method of accounting. Acquisition cost is measured as the aggregate of the fair value at the date of acquisition of the assets given, equity instruments issued or liabilities incurred or assumed. Acquisition related costs are expensed as incurred (except for those costs arising on the issue of equity instruments which are recognized directly in equity). Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured at fair value on the acquisition date. Goodwill is measured as the excess of the acquisition cost, the amount of any <font style="WHITE-SPACE: nowrap">non-controlling</font> interest and the fair value of any previous UBI equity interest in the acquiree, over the fair value of the identifiable net assets acquired.</p> </div> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>Basis of Presentation</b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The Company&#x2019;s consolidated condensed financial statements have been prepared assuming the Company will continue as a going concern. We rely largely on our existing cash and cash equivalents balance and operating cash flow to provide for the working capital needs of our operations. We believe we have sufficient cash and cash equivalents to fund our operations for at least the next twelve months. However, in the event our financing needs for the foreseeable future are not able to be met by our existing cash and cash equivalents balance and operating cash flow, we would seek to raise funds through public or private equity offerings, debt financings, and through other means to meet the financing requirements. There is no assurance that funding would be available at acceptable terms, if at all.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Restricted Cash</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated condensed balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br /> September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Year Ended<br /> December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Cash and cash equivalents</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">28,531,432</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">26,259,918</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Restricted cash - current assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,915,949</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">15,309</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Restricted cash - <font style="WHITE-SPACE: nowrap">non-current</font> assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">320,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,220,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">31,767,381</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">29,495,227</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> Restricted cash maintained by the Company in the form of term deposits is as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br /> September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Year Ended<br /> December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Collateral for facilities (a) - current assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">15,949</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">15,309</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Collateral for facilities (b) - <font style="WHITE-SPACE: nowrap">non-current</font> assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">320,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">320,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Financial covenant pursuant to the credit agreement (c) - current assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,900,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Financial covenant pursuant to the credit agreement (c) - <font style="WHITE-SPACE: nowrap">non-current</font> assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,900,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,235,949</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,235,309</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td valign="top" width="4%" align="left">(a)</td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">Represents bank guarantee of CDN$15,000 as security deposit on HRL&#x2019;s credit card</p> </td> </tr> </table> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td valign="top" width="4%" align="left">(b)</td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">Represents bank guarantee of A$250,000 for commercial lease of UBS&#x2019; premises and security deposit on Company&#x2019;s credit cards of A$70,000</p> </td> </tr> </table> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td valign="top" width="4%" align="left">(c)</td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">Represents amounts pledged as collateral for financing arrangements as contractually required by the Lenders. The restriction will lapse when the related debt is paid off in July 2019 or earlier as provided pursuant to the Credit Agreement</p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Interest earned on the restricted cash for the three months ended September 30, 2018 and 2017 were A$18,500 and A$12,394, respectively and for the nine months ended September 30, 2018 and 2017 were A$53,420 and A$50,423, respectively.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Cash, Cash Equivalents and Restricted Cash</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company considers all highly liquid investments purchased with an initial maturity of three months or less to be cash equivalents. For cash and cash equivalents, the carrying amount approximates fair value due to the short maturity of those instruments. The Company maintains cash and restricted cash, which includes tenant security deposits, credit card security deposits and cash collateral for its borrowings. As of September 30, 2018, the Company has not realized any losses in such cash accounts and believes it is not exposed to any significant risk of loss.</p> </div> 301934 2020-12-19 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Commitments and Contingencies</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Liabilities for loss contingencies, arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. These were nil as at September 30, 2018. Purchase commitments contracted for as at September 30, 2018 is A$1,538,429 (December 31, 2017 : A$2,359,443).</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Employee Benefit Costs</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company contributes 9.5% of each employee&#x2019;s salary to standard defined contribution superannuation funds on behalf of all UBS employees. Superannuation is a compulsory savings program whereby employers are required to pay a portion of an employee&#x2019;s remuneration to an approved superannuation fund that the employee is typically not able to access until they have reached the statutory retirement age. Whilst the Company has a third party default superannuation fund, it permits UBS employees to choose an approved and registered superannuation fund into which the contributions are paid. Contributions are charged to the consolidated condensed statements of comprehensive income as they become payable.</p> </div> 41355433 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Total Comprehensive Income/(Loss)</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company follows ASC 220 &#x2013; Comprehensive Income. Comprehensive income/(loss) is defined as the total change in shareholders&#x2019; equity during the period other than from transactions with shareholders, and for the Company, includes net income/(loss).</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> The tax effect allocated to each component of other comprehensive loss is as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="59%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b><font style="WHITE-SPACE: nowrap">Before-Tax&#xA0;Amount</font></b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"><b>Tax&#xA0;(Expense)/</b></p> <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"><b>Benefit</b></p> </td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b><font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">Net-of-Tax</font></font><br /> Amount</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> <b><u>Nine Months Ended September&#xA0;30, 2018</u></b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Foreign currency translation reserve</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">36,525</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">36,525</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Reclassification for gains realised in net income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Other comprehensive loss</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">36,525</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">36,525</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> <b><u>Nine Months Ended September&#xA0;30, 2017</u></b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Foreign currency translation reserve</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,497</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,497</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Reclassification for gains realised in net income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Other comprehensive loss</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,497</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,497</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <b><i>Principles of Consolidation</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries, UBS and HRL. All intercompany balances and transactions have been eliminated on consolidation.</p> </div> 1700042 --12-31 412768 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b><i>Borrowings</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Future maturities, interest and other payments under the Company&#x2019;s long term secured loan pursuant to the credit agreement (described below) as of September 30, 2018 and December&#xA0;31, 2017 are as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="56%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>September&#xA0;30, 2018</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31, 2017</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">US$</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">A$</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">US$</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">A$</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">442,750</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,956,563</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2019</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">15,221,375</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">15,875,875</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total minimum payments</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">15,664,125</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">17,832,438</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Less amount representing interest and other fees</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(664,125</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(2,832,438</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Gross balance of long term debt</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">15,000,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">15,000,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Less fair value of warrants recorded within loan (a)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(815,655</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(815,655</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Plus interest accretion</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">736,851</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">658,334</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total carrying value</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">14,921,196</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">20,660,753</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">14,842,679</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">19,029,076</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Less current portion</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">14,921,196</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">20,660,753</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total carrying value, <font style="WHITE-SPACE: nowrap">non-current</font> portion</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">14,842,679</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">19,029,076</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The above assumes, as provided under the Athyrium Credit Agreement, the loan will be repaid immediately out of the proceeds from the lump sum service fees which is expected to be received on or about February&#xA0;15, 2019.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The carrying value of the borrowings approximates its fair value. The fair value is estimated by discounting future cash flows at the currently offered rates for borrowings of similar remaining maturities.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="4%">&#xA0;</td> <td valign="top" width="4%" align="left">(a)</td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">The warrants issued in December 2013 had a fair value of US$815,655 as of September 30, 2018 and December&#xA0;31, 2017, and are included in equity.</p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Athyrium Credit Agreement</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> On December&#xA0;19, 2013 (&#x201C;Closing Date&#x201D;), UBI and its wholly owned subsidiary, UBS (together UBI and UBS, the &#x201C;Transaction Parties&#x201D;) entered into a credit agreement with Athyrium Opportunities Fund (A)&#xA0;LP (&#x201C;Athyrium A&#x201D;), as administrative agent (the &#x201C;Administrative Agent&#x201D;) and as a lender, and Athyrium Opportunities Fund (B)&#xA0;LP (&#x201C;Athyrium B&#x201D;) as a lender (Athyrium A and Athyrium B together with any other lenders party thereto from time to time, the &#x201C;Lenders&#x201D;) for a secured term loan of up to US$25&#xA0;million, which was amended on January&#xA0;30, 2015 (&#x201C;Credit Agreement&#x201D;). Of this amount, US$15&#xA0;million had been drawn at December&#xA0;31, 2013 with a further US$10&#xA0;million available to be drawn down on or before July&#xA0;31, 2015, if UBS satisfied certain conditions precedent relating to product revenues.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The credit agreement was amended again on December&#xA0;29, 2017 (&#x201C;Amendment&#x201D;). Subject to the terms of the Amendment, the Amendment modifies the Credit Agreement to (i)&#xA0;extend the maturity date to July&#xA0;1, 2019 (&#x201C;Maturity Date&#x201D;), (ii) add the Borrower&#x2019;s wholly owned subsidiary, Hemostasis Reference Laboratory, Inc. (&#x201C;HRL&#x201D;), as a guarantor of the Borrower&#x2019;s obligations under the Credit Agreement and (iii)&#xA0;subject to the prior written consent of the Lenders in their sole discretion, permit UBI to repurchase shares in an aggregate amount up to US$2,000,000 within 12 months after the date Lenders provide any such consent.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The term loan bears interest at 10.5% per annum payable in cash quarterly in arrears over the term, and as otherwise described in the Credit Agreement. A default interest rate of 13% per annum shall apply during the existence of a default under the Credit Agreement. Other than as summarized below, UBS is not required to make payments of principal for amounts outstanding under the term loan until maturity, July&#xA0;1, 2019. The term loan under the Credit Agreement is secured by substantially all of UBI, UBS&#x2019; and HRL&#x2019;s assets. UBI and HRL (together with any future subsidiaries) guarantees all of UBS&#x2019;s obligations under the term loan.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> Voluntary prepayments of the term loans were not permitted prior to the second anniversary of the Closing Date, except in the event of a change of control of a Transaction Party. After the second anniversary, UBS can make voluntary repayments in minimum principal amounts of US$2,500,000 together with interest, plus the premium described below. UBS must make mandatory prepayments in certain prescribed circumstances, including in the event of raising additional debt financing, a sale or transfer of assets other than in certain circumstances and in the event of other specified extraordinary receipts. Extraordinary receipts include cash received or paid other than in the ordinary course of business, such as tax refunds (other than GST and R&amp;D tax rebates), LifeScan lump sum fee payments and Siemens termination fees. In such events, UBS must prepay to the Lenders 100% of the net cash proceeds received up to the outstanding principal amount of the loans drawn down, together with all accrued and unpaid interest thereon and all other obligations. In the event of any prepayment after the second anniversary of the Closing Date with respect to any obligations under the Credit Agreement, UBS must pay a prepayment premium commencing at 15% of the principal of such prepayment due and payable on the applicable date and reducing <font style="WHITE-SPACE: nowrap">pro-rata</font> on a monthly basis until the Maturity Date.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Unless the facility is otherwise terminated earlier pursuant to the terms of the Credit Agreement, UBS (as the borrower) is required to repay the outstanding principal amount of the loans drawn down, together with all accrued and unpaid interest thereon and all other obligations on Maturity Date.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> UBS paid a <font style="WHITE-SPACE: nowrap">non-refundable</font> fee of US$625,000 to the Lenders on the Closing Date (being 2.5% of the aggregate credit facility) and <font style="WHITE-SPACE: nowrap">non-refundable</font> fees of US$200,000 to the Lenders in connection with each of the January 2015 and December 2017 amendments to the Credit Agreement. A 2% commitment fee based on any available unused borrowing commitment was paid by UBS under the Credit Agreement until July&#xA0;31, 2015. The Lenders are also entitled to receive 30% of the net proceeds of milestone payments paid under the Collaboration Agreement by and among UBS, UBI and Siemens, up to a maximum of US$600,000 in the aggregate of which US$300,000 was paid in February 2015 and the balance of US$300,000 was paid in August 2015 (upon receipt of two further milestone payments). UBS has also agreed to pay certain taxes arising in connection with the Credit Agreement and other Loan Documents, including withholding taxes. UBS has also agreed to pay certain reasonable <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">out-of-pocket</font></font> expenses incurred by the Lenders in connection with the loan documents including the January 2015 and December 2017 amendments, or as may be incurred in connection with the enforcement or protection of their rights.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Credit Agreement also contains certain covenants, including among other things, covenants: (i)&#xA0;relating to the delivery of financial and other information and certificates, notices of defaults, litigation and other material events; payment of taxes and other obligations; maintenance of insurance; (ii)&#xA0;which limit or restrict the incurrence of liens; the making of investments; the incurrence of certain indebtedness; mergers, dispositions, liquidations, or consolidations and significant asset sales; restricted payments; transactions with affiliates other than on normal and arms-length terms; burdensome agreements; prepayment of other indebtedness; ownership of subsidiaries; and (iii)&#xA0;which require UBS to maintain restricted cash of not less than US$2,000,000 in a specified bank account at any time.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> As further described below, pursuant to the Credit Agreement, UBI issued to the Lenders warrants entitling the holder to purchase up to an aggregate total of 4.5&#xA0;million shares of UBI&#x2019;s common stock in the form of CDIs at a price of A$1.00 per share (the &#x201C;Exercise Price&#x201D;), which represents a 117% premium over the closing price of UBI&#x2019;s common stock on December&#xA0;19, 2013. The warrants are immediately exercisable and have a term of seven years.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Other</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> In December 2016, UBS entered into an arrangement with Elantis Premium Funding Ltd to fund the Group&#x2019;s 2017 insurance premium. The total amount financed was A$369,630 at inception and the short-term borrowing was fully repaid in September 2017. Interest was charged at a fixed rate of 2.60% per annum. The short-term borrowing was secured by the insurance premium refund. The Group&#x2019;s 2018 insurance premium was funded from its operating cash flows.</p> </div> 1519375 Q3 2018 10-Q 0.095 1680323 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b><i>Derivative Instruments and Hedging Activities</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <i>Derivative financial instruments</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company may use derivative financial instruments to hedge its exposure to foreign exchange arising from operating, investing and financing activities. The Company does not hold or issue derivative financial instruments for trading purposes. However, derivatives that do not qualify for hedge accounting are accounted for as trading instruments.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Derivative financial instruments are recognized initially at fair value. Subsequent to initial recognition, derivative financial instruments are stated at fair value. The gain or loss on remeasurement to fair value is recognized immediately in the income statement. However, where derivatives qualify for hedge accounting, recognition of any resultant gain or loss depends on the nature of the item being hedged.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Cash flow hedges</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Exposure to foreign exchange risks arises in the normal course of the Company&#x2019;s business and it is the Company&#x2019;s policy to use forward exchange contracts to hedge anticipated sales and purchases in foreign currencies. The amount of forward cover taken is in accordance with approved policy and internal forecasts.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Where a derivative financial instrument is designated as a hedge of the variability in cash flows of a recognized asset or liability, or a highly probable forecast transaction, the effective part of any unrealized gain or loss on the derivative financial instrument is recognized directly in equity. When the forecast transaction subsequently results in the recognition of a <font style="WHITE-SPACE: nowrap">non-financial</font> asset or <font style="WHITE-SPACE: nowrap">non-financial</font> liability, the associated cumulative gain or loss is removed from equity and included in the initial cost or other carrying amount of the <font style="WHITE-SPACE: nowrap">non-financial</font> asset or liability.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> For cash flow hedges, other than those covered by the preceding statement, the associated cumulative gain or loss is removed from equity and recognized in the consolidated condensed statements of comprehensive income in the same period or periods during which the hedged forecast transaction affects the consolidated condensed statements of comprehensive income and on the same line item as that hedged forecast transaction. The ineffective part of any gain or loss is recognized immediately in the consolidated condensed statements of comprehensive income.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> When a hedging instrument expires or is sold, terminated or exercised, or the Company revokes designation of the hedge relationship but the hedged forecast transaction is still probable to occur, the cumulative gain or loss at that point remains in equity and is recognized in accordance with the above policy when the transaction occurs. If the hedged transaction is no longer expected to take place, then the cumulative unrealized gain or loss recognized in equity is recognized immediately in the consolidated condensed statements of comprehensive income.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Derivative Instruments and Hedging Activities</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as consider our own and counterparty credit risk. For periods ended September 30, 2018 and December&#xA0;31, 2017, we did not have any assets or liabilities that utilize Level&#xA0;3 inputs. The valuation of our foreign exchange derivatives are based on the market approach using observable market inputs, such as forward rates and incorporate <font style="WHITE-SPACE: nowrap">non-performance</font> risk (the credit standing of the counterparty when the derivative is in a net asset position, and the credit standing of the Company when the derivative is in a net liability position). Our derivative assets are categorized as Level&#xA0;2. The fair value methodologies described as Level&#xA0;2 and 3 inputs are defined elsewhere in these notes to the consolidated condensed financial statements.</p> </div> 0.23 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Net Income/(Loss) per Share and Anti-dilutive Securities</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Basic and diluted net income/(loss) per share is presented in conformity with ASC 260 &#x2013; Earnings per Share. Basic and diluted net income/(loss) per share has been computed using the weighted-average number of common shares outstanding during the period. Diluted net income/(loss) per share is calculated by adjusting the basic net income/(loss) per share by assuming all dilutive potential ordinary shares are converted.</p> </div> 1970220 0001279695 UNIVERSAL BIOSENSORS INC true 2018-09-30 0.23 true false Non-accelerated Filer <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <i>Fair Value of Financial Instruments</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The carrying value of all current assets and current liabilities approximates fair value because of their short-term nature. The estimated fair value of all other amounts has been determined, depending on the nature and complexity of the assets or the liability, by using one or all of the following approaches:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">Market approach &#x2013; based on market prices and other information from market transactions involving identical or comparable assets or liabilities.</p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">Cost approach &#x2013; based on the cost to acquire or construct comparable assets less an allowance for functional and/or economic obsolescence.</p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">Income approach &#x2013; based on the present value of a future stream of net cash flows.</p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> These fair value methodologies depend on the following types of inputs:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).</p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">Quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in markets that are not active or are directly or indirectly observable (Level 2 inputs).</p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).</p> </td> </tr> </table> </div> 442639 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Foreign Currency</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <i>Functional and reporting currency</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Items included in the financial statements of each of the Group&#x2019;s entities are measured using the currency of the primary economic environment in which the entity operates (&#x201C;the functional currency&#x201D;). The functional currency of UBI and UBS is AUD or A$ for all years presented. The functional currency of HRL is CAD$.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The consolidated condensed financial statements are presented using a reporting currency of Australian dollars.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Transactions and balances</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at <font style="WHITE-SPACE: nowrap">year-end</font> exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in the consolidated condensed statements of comprehensive income.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company has recorded foreign currency transaction gains of A$183,395 and A$61,873 for the three months ended September 30, 2018 and 2017, respectively and A$412,768 and A$703,420 for the nine months ended September 30, 2018 and 2017, respectively.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The results and financial position of all the Group entities that have a functional currency different from the reporting currency are translated into the reporting currency as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="1%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">assets and liabilities for each balance sheet item reported are translated at the closing rate at the date of that balance sheet;</p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="1%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">income and expenses for each income statement item reported are translated at average exchange rates (unless this is not a reasonable approximation of the effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions); and</p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="1%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">all resulting exchange differences are recognized as a separate component of equity.</p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> On consolidation, exchange differences arising from the translation of any net investment in foreign entities are taken to the Accumulated Other Comprehensive Income.</p> </div> 412768 -8498 5110134 0 41391958 0 42249234 59025232 0 <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b><i>Income Taxes</i></b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The Company applies ASC 740&#x2014;Income Taxes which establishes financial accounting and reporting standards for the effects of income taxes that result from a company&#x2019;s activities during the current and preceding years. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Where it is more likely than not that some portion or all of the deferred tax assets will not be realized, the deferred tax assets are reduced by a valuation allowance. The valuation allowance is sufficient to reduce the deferred tax assets to the amount that is more likely than not to be realized.</p> <p style="font-size:1px;margin-top:12px;margin-bottom:0px"> &#xA0;</p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The recent U.S. Federal Tax Reform has established a mandatory repatriation of foreign accumulated undistributed earnings and profits (the &#x201C;E&amp;Ps&#x201D;) for U.S. companies&#x2019; subsidiaries. In the past, none of these E&amp;Ps&#x2019; were repatriated since such E&amp;Ps&#x2019; were considered to be reinvested indefinitely in the foreign location. The E&amp;Ps&#x2019; provisions are applicable to our Company commencing with our fiscal year 2018, however the E&amp;Ps&#x2019; mandatory repatriation provisions establishes measurement dates for various computations. In our Company&#x2019;s case this date is December&#xA0;31, 2017. The Company&#x2019;s estimated tax for the mandatory repatriation is estimated to be nil. However, the final tax due must be assessed with our December&#xA0;31, 2018 closing figures. Any such tax liability may be paid over a period of eight years starting on February&#xA0;28, 2019. As of the issuance date of this report, the U.S. Securities and Exchange Commission and the Financial Accounting Standards Board have issued some preliminary guidance, but have not issued final rules on how the effects of the U.S. Federal Tax Reform will be required to be reported for financial statements purposes.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> At December&#xA0;31, 2017 the Company has A$10,993,737 (A$22,616,230 at December&#xA0;31, 2016) of accumulated tax losses available for carry forward against future earnings, which under Australian tax laws do not expire but may not be available under certain circumstances. The Company also has A$11,048,336 (A$5,800,672 at December&#xA0;31, 2016) of <font style="white-space:nowrap">non-refundable</font> R&amp;D tax offset as at December&#xA0;31, 2017. The R&amp;D Tax offset is a <font style="white-space:nowrap">non-refundable</font> tax offset, which assists to reduce a company&#x2019;s tax liability. Once the liability has been reduced to zero, any excess offset may be carried forward into future income years. UBI has U.S. tax losses available for carry forward against future earnings of US$1,011,321 as of December&#xA0;31, 2017 and 2016. Pursuant to the U.S. Federal Tax Reform, the effective tax rate of UBI has been reduced from 34% to 21%. The deferred tax benefit based on this new rate for UBI is US$212,377. HRL has Canadian tax losses available for carry forward against future earnings of CAD$668,043 and CAD$95,096 as at December&#xA0;31, 2017 and 2016, respectively.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> We are subject to income taxes in the United States, Canada and Australia. Tax returns up to and including the 2017 financial year have been filed in all these jurisdictions.</p> </div> 789318 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Impairment of Long-Lived Assets</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company reviews its capital assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. In performing the review, the Company estimates undiscounted cash flows from products under development that are covered by these patents and licenses. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition is less than the carrying amount of the asset. If the evaluation indicates that the carrying value of an asset is not recoverable from its undiscounted cash flows, an impairment loss is measured by comparing the carrying value of the asset to its fair value, based on discounted cash flows. Impairment of long-lived-assets as at September&#xA0;30, 2018 was nil (December 31, 2017: nil).</p> </div> 505149 0 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Inventory</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Inventories are stated at the lower of cost or net realizable value. Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and estimated costs necessary to dispose. Inventories are principally determined under the average cost method which approximates cost. Cost comprises direct materials, direct labour and an appropriate portion of variable and fixed overhead expenditure, the latter being allocated on the basis of normal operating capacity. Cost also includes the transfer from equity of any gains/losses on qualifying cash flow hedges relating to purchases of raw material. Costs of purchased inventory are determined after deducting rebates and discounts.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br /> September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Year Ended<br /> December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Raw materials</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">322,399</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">380,540</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Work in progress</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">158,883</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">253,483</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Finished goods</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">28,109</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">481,282</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">662,132</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> -321814 -180850 365542 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Leased Assets</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> All of the Company&#x2019;s leases for the periods ending September 30, 2018 and December&#xA0;31, 2017 are considered operating leases. The costs of operating leases are charged to the consolidated condensed statements of comprehensive income on a straight-line basis over the lease term.</p> </div> 1538429 <div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>Organization of the Company</b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> We are a specialist medical diagnostics company focused primarily on the research, development and manufacture of in vitro diagnostic test devices for consumer and professional <font style="white-space:nowrap"><font style="white-space:nowrap">point-of-care</font></font> use. In addition, we own, manage and operate a hemostasis laboratory.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Key aspects of our strategy for increasing shareholder value include:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr style="page-break-inside:avoid"> <td width="5%">&#xA0;</td> <td width="2%" valign="top" align="left">&#x2022;</td> <td width="1%" valign="top">&#xA0;</td> <td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"> executing on our existing business activities, including undertaking research and development activities for our customers and partners, manufacturing products (test strips and analyzers) and providing development and support services including providing laboratory services, to our customers and partners;</p> </td> </tr> </table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr style="page-break-inside:avoid"> <td width="5%">&#xA0;</td> <td width="2%" valign="top" align="left">&#x2022;</td> <td width="1%" valign="top">&#xA0;</td> <td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"> extending and demonstrating the broader application of our technology and seeking to enter into collaborative, strategic or distribution arrangements with other life sciences companies or other industry participants with respect to specific tests or specific fields;</p> </td> </tr> </table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr style="page-break-inside:avoid"> <td width="5%">&#xA0;</td> <td width="2%" valign="top" align="left">&#x2022;</td> <td width="1%" valign="top">&#xA0;</td> <td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"> participating in healthcare markets across the globe; and</p> </td> </tr> </table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr style="page-break-inside:avoid"> <td width="5%">&#xA0;</td> <td width="2%" valign="top" align="left">&#x2022;</td> <td width="1%" valign="top">&#xA0;</td> <td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"> identifying and pursuing related opportunities for growth.</p> </td> </tr> </table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Our plan of operations over the remainder of the fiscal year ending December 2018 is to:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr style="page-break-inside:avoid"> <td width="5%">&#xA0;</td> <td width="2%" valign="top" align="left">&#x2022;</td> <td width="1%" valign="top">&#xA0;</td> <td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"> manufacture products;</p> </td> </tr> </table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr style="page-break-inside:avoid"> <td width="5%">&#xA0;</td> <td width="2%" valign="top" align="left">&#x2022;</td> <td width="1%" valign="top">&#xA0;</td> <td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"> undertake research and development work;</p> </td> </tr> </table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr style="page-break-inside:avoid"> <td width="5%">&#xA0;</td> <td width="2%" valign="top" align="left">&#x2022;</td> <td width="1%" valign="top">&#xA0;</td> <td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"> provide the necessary post-market support for our customers and partners;</p> </td> </tr> </table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr style="page-break-inside:avoid"> <td width="5%">&#xA0;</td> <td width="2%" valign="top" align="left">&#x2022;</td> <td width="1%" valign="top">&#xA0;</td> <td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"> provide laboratory services for our customers and partners;</p> </td> </tr> </table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr style="page-break-inside:avoid"> <td width="5%">&#xA0;</td> <td width="2%" valign="top" align="left">&#x2022;</td> <td width="1%" valign="top">&#xA0;</td> <td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"> demonstrate the broader application of our technology platform for markets with significant commercial potential; and</p> </td> </tr> </table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr style="page-break-inside:avoid"> <td width="5%">&#xA0;</td> <td width="2%" valign="top" align="left">&#x2022;</td> <td width="1%" valign="top">&#xA0;</td> <td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"> seek to enter into collaborative, strategic or distribution arrangements with other life sciences companies or other industry participants with respect to the development and commercialization of specific tests or specific fields.</p> </td> </tr> </table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The Company&#x2019;s first global strategic partnership was established with LifeScan, Inc. (&#x201C;LifeScan&#x201D;) in diabetes care. We have developed a blood glucose product with LifeScan (&#x201C;OneTouch Verio<sup style="font-size:85%; vertical-align:top">&#xAE;</sup>&#x201D;) which is now available in countries that represent over 90% of the world self-monitoring blood glucose market. Unless otherwise noted, references to &#x201C;LifeScan&#x201D; in this document are references collectively or individually to LifeScan, Inc., and/or LifeScan Europe, a division of Cilag GmbH International, both affiliates of Johnson and Johnson. During the current quarter, LifeScan gave notice and exercised its right to &#x201C;convert&#x201D; its obligation to pay quarterly service fees to Universal Biosensors.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> We are working with Siemens Healthcare Diagnostics, Inc. (&#x201C;Siemens&#x201D;) in relation to a range of products for the <font style="white-space:nowrap"><font style="white-space:nowrap">point-of-care</font></font> coagulation testing market, pursuant to a Collaboration Agreement with Siemens (&#x201C;Collaboration Agreement&#x201D;). The first such product developed with Siemens, the Xprecia Stride&#x2122; Coagulation Analyzer, is now available in the United States, Europe, the Middle East, Africa, Asia Pacific, Latin America and Canada. Under the terms of a supply agreement with Siemens (&#x201C;Supply Agreement&#x201D;), UBS is the manufacturer of test strips for this product and further tests still in development for Siemens.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> In addition, UBS is engaged in <font style="white-space:nowrap"><font style="white-space:nowrap">point-of-care</font></font> coagulation product development for the consumer, home testing market which could be distributed globally on its own account.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Recent Accounting Pronouncements</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> (a) Recent issued accounting standards not yet adopted</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <u>ASU <font style="WHITE-SPACE: nowrap">No.2016-02,</font> &#x201C;Leases&#x2019;</u></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> On February&#xA0;25, 2016, the FASB issued ASU <font style="WHITE-SPACE: nowrap">2016-02,</font> its new standard on accounting for leases. ASU <font style="WHITE-SPACE: nowrap">2016-02</font> introduces a lessee model that brings most leases on the balance sheet and eliminates the requirement in current U.S. GAAP for an entity to use bright-line tests in determining lease classification. The standard also requires lessors to increase the transparency of their exposure to changes in value of their residual assets and how they manage that exposure.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The new guidance will be effective for public business entities for annual periods beginning after December&#xA0;15, 2018, and interim periods therein. Early adoption is permitted. The Company is currently evaluating the impact the adoption of ASU <font style="WHITE-SPACE: nowrap">2016-02</font> will have on the Company&#x2019;s consolidated financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <u>ASU <font style="WHITE-SPACE: nowrap">No.2014-09,</font> &#x201C;Revenue from Contracts with Customers&#x2019;</u></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) <font style="WHITE-SPACE: nowrap">2014-09,</font> Revenue from Contracts with Customers (Topic 606), which provides companies with a single revenue recognition model for recognizing revenue from contracts with customers. The core principle of the new standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. There are two permitted transition methods under the new standard, the full retrospective method or the modified retrospective method. The new standard is effective for annual reporting periods beginning after December&#xA0;15, 2017. The Company has deferred the adoption of this standard as is allowable for an Emerging Growth Company.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> UBI has selected the modified retrospective method where the effect of applying the standard will be recognized at the date of initial application, without restating previous years. The Company is currently evaluating the impact the adoption of ASU <font style="WHITE-SPACE: nowrap">2014-09</font> will have on the Company&#x2019;s consolidated financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i><u>ASU <font style="WHITE-SPACE: nowrap">No.&#xA0;2017-12,</font> &#x201C;Targeted Improvements to Accounting for Hedging Activities&#x201D;</u></i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> On August&#xA0;28, 2017, the FASB issued ASU <font style="WHITE-SPACE: nowrap">2017-12,</font> which amends the hedge accounting recognition and presentation requirements in ASC 815.2. The FASB&#x2019;s objectives in issuing the ASU are to (1)&#xA0;improve the transparency and understandability of information conveyed to financial statement users about an entity&#x2019;s risk management activities by better aligning the entity&#x2019;s financial reporting for hedging relationships with those risk management activities and (2)&#xA0;reduce the complexity of and simplify the application of hedge accounting by preparers.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> For public business entities, the ASU is effective for fiscal years beginning after December&#xA0;15, 2018, and interim periods therein; however, early adoption by all entities is permitted upon its issuance. The Company is currently evaluating the impact the adoption of ASU <font style="WHITE-SPACE: nowrap">2014-09</font> will have on the Company&#x2019;s consolidated financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> (b) Recently adopted accounting pronouncements</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i><u>ASU <font style="WHITE-SPACE: nowrap">No.2016-18,</font> &#x201C;Restricted Cash&#x2019;</u></i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> On November&#xA0;17, 2016, the FASB issued ASU <font style="WHITE-SPACE: nowrap">2016-18,</font> which amends ASC 230 to add or clarify guidance on the classification and presentation of restricted cash in the statement of cash flows. For public business entities, the guidance is effective for fiscal years beginning after December&#xA0;15, 2017, including interim periods therein. For all other entities, it is effective for fiscal years beginning after December&#xA0;15, 2018, and interim periods thereafter. Early adoption is permitted for all entities. The Company has adopted this guidance from January&#xA0;1, 2018 and it has not had a material impact on the Company&#x2019;s consolidated financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i><u>ASU <font style="WHITE-SPACE: nowrap">No.2016-15,</font> &#x201C;Classification of Certain Cash Receipts and Cash Payments&#x201D;</u></i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> On August&#xA0;26, 2016, the FASB issued ASU <font style="WHITE-SPACE: nowrap">2016-15,</font> which amends the guidance in ASC 230 to eliminate diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The guidance in the ASU is effective for fiscal years beginning after December&#xA0;15, 2017, including interim periods within those fiscal years. Early adoption is permitted for all entities. The Company has adopted this guidance and it has not had a material impact on the Company&#x2019;s consolidated financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i><u>ASU <font style="WHITE-SPACE: nowrap">No.2016-16,</font> &#x201C;Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory&#x2019;</u></i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> On October&#xA0;24, 2016, the FASB issued ASU <font style="WHITE-SPACE: nowrap">2016-16,</font> which removes the prohibition in ASC 740 against the immediate recognition of the current and deferred income tax effects of intra-entity transfers of assets other than inventory. This ASU is effective for annual periods beginning after December&#xA0;15, 2017, and interim periods within those annual periods. Early adoption is permitted for all entities as of the beginning of a fiscal year for which neither the annual or interim financial statements have been issued. Entities should apply the ASU&#x2019;s amendments on a modified retrospective basis, recognizing the effects in retained earnings as of the beginning of the year of adoption. The Company has adopted this guidance and it has not had a material impact on the Company&#x2019;s consolidated financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i><u>ASU <font style="WHITE-SPACE: nowrap">No.2017-01,</font> &#x201C;Business Combination: Clarifying the Definition of a Business&#x2019;</u></i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> On January&#xA0;5, 2017, the FASB issued ASU <font style="WHITE-SPACE: nowrap">2017-01</font> to clarify the definition of a business in ASC 805. The amendments in the ASU are intended to make application of the guidance more consistent and <font style="WHITE-SPACE: nowrap">cost-efficient.</font> The ASU is effective for annual periods beginning after December&#xA0;15, 2017, including interim periods therein. The ASU must be applied prospectively on or after the effective date, and no disclosures for a change in accounting principle are required at transition. Early adoption is permitted for transactions (i.e., acquisitions or dispositions) that occurred before the issuance date or effective date of the standard. The Company has adopted this guidance and it has not had a material impact on the Company&#x2019;s consolidated financial statements.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <i><u>ASU <font style="WHITE-SPACE: nowrap">No.2017-09,</font> &#x201C;Compensation &#x2013; Stock Compensation: Scope of Modification Accounting&#x2019;</u></i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> On May&#xA0;10, 2017, the FASB issued ASU <font style="WHITE-SPACE: nowrap">2017-09,</font> which amends the scope of modification accounting for share-based payment arrangements. The ASU provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting under ASC 718. This ASU is effective for annual reporting periods, including interim periods within those annual reporting periods, beginning after December&#xA0;15, 2017. Early adoption is permitted. The Company has adopted this guidance and it has not had a material impact on the Company&#x2019;s consolidated financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i><u>ASU <font style="WHITE-SPACE: nowrap">No.&#xA0;2018-05,</font> &#x201C;Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No.&#xA0;118.&#x201D;</u></i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> On March&#xA0;13, 2018, the FASB issued ASU <font style="WHITE-SPACE: nowrap">2018-05.</font> This Financial Reporting Alert contains responses to frequently asked questions about how an entity should account for the tax effects of the new tax reform legislation in accordance with ASC 740, Income Taxes. This ASU is effective upon issuance and the adoption of this guidance has not had a material impact on the Company&#x2019;s consolidated financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i><u>ASU <font style="WHITE-SPACE: nowrap">No.&#xA0;2018-09,</font> &#x201C;Codification Improvements&#x201D;</u></i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The FASB issued ASU <font style="WHITE-SPACE: nowrap">2018-09</font> on July&#xA0;16, 2018. The ASU&#x2019;s amendments &#x201C;clarify, correct errors in, or make minor improvements to the Codification.&#x201D; This ASU is effective upon issuance and the adoption of this guidance has not had a material impact on the Company&#x2019;s consolidated financial statements.</p> </div> -1348257 -306087 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Short-Term Investments <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">(Held-to-maturity)</font></font></i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Short-term investments constitute all highly liquid investments with term to maturity from three months to twelve months. The carrying amount of short-term investments is equivalent to their fair value.</p> </div> -256410 864431 41391958 36525 0 0 -36525 0 -8498 -36525 36525 0 16285017 42740215 0 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Reclassification</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Certain prior year amounts have been reclassified to conform to the current year presentation.</p> </div> 308669 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Registered Retirement Savings Plan and Deferred Sharing Profit Plan</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company provides eligible HRL employees a retirement plan. The retirement plan includes a Registered Retirement Savings Plan (&#x201C;RRSP&#x201D;) and Deferred Profit Sharing Plan (&#x201C;DPSP&#x201D;). The RRSP is voluntary and the employee contributions are matched by the Company up to a maximum of 5% based on their continuous years of service and placed into the DPSP. The Company contributes 1% to 2% of the employee&#x2019;s base earnings towards the DPSP. The DPSP contributions are vested immediately.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Other liabilities are broken down as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br /> September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Year Ended<br /> December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> <b>Current liabilites</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Marketing support payment</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,836,614</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,626,413</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,836,614</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,626,413</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 2582 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Benefit Plan</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company provides eligible HRL employees a Benefit Plan to its employees. In general, the Benefit Plan includes extended health care, dental care, basic life insurance, basic accidental death and dismemberment, and disability insurance.</p> </div> 0 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Interest income</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Interest income is recognized as it accrues, taking into account the effective yield on the cash and cash equivalents.</p> </div> 41391958 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Property, Plant, and Equipment&#x2014;net</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Property, plant, and equipment are recorded at acquisition cost, less accumulated depreciation.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Depreciation on plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful life of machinery and equipment is 3 to 10 years. Leasehold improvements are amortized on the straight-line method over the shorter of the remaining lease term or estimated useful life of the asset. Maintenance and repairs are charged to operations as incurred, include normal services, and do not include items of a capital nature.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company receives Commonwealth of Australia grant monies under grant agreements to support its development activities (refer section on &#x201C;Government Grants&#x201D;), including in connection with the purchase of plant and equipment. Plant and equipment is presented net of the government grant. The grant monies are recognized against the acquisition costs of the related plant and equipment as and when the related assets are purchased.</p> </div> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>Interim Financial Statements</b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The accompanying unaudited consolidated condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201C;U.S. GAAP&#x201D;) and with the instructions to Form <font style="white-space:nowrap">10-Q</font> and Article 10 of Regulation <font style="white-space:nowrap">S-X</font> for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the nine months ended September 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December&#xA0;31, 2018. The accompanying unaudited consolidated condensed financial statements should be read in conjunction with the financial statements and footnotes thereto as of and for the year ended December&#xA0;31, 2017, included in the Annual Report on Form <font style="white-space:nowrap">10-K</font> of Universal Biosensors, Inc. filed with the U.S. Securities and Exchange Commission (the &#x201C;SEC&#x201D;) on February&#xA0;23, 2018 (the &#x201C;Annual Report&#x201D;).</p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt"> &#xA0;</p> <p style="font-size:1px;margin-top:6px;margin-bottom:0px"> &#xA0;</p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The <font style="white-space:nowrap">year-end</font> consolidated condensed balance sheets data as at December&#xA0;31, 2017 was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain prior year amounts in the consolidated condensed financial statements have been reclassified to conform to the current presentation.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Related Party Transactions</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Details of related party transactions material to the operations of the Group other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business, are set out below:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> In September 2011, we entered into a&#xA0;<font style="WHITE-SPACE: nowrap">non-exclusive</font>&#xA0;license agreement with SpeeDx Pty Ltd (&#x201C;SpeeDx&#x201D;) pursuant to which SpeeDx granted us a license to use its proprietary MNAzyme technology in the field of molecular diagnostics. Under the agreement we make milestone payments totaling A$500,000 to SpeeDx if certain specified targets are achieved, and royalty payments ranging from 5% to 15% of that portion of our sales and licensing revenues arising from SpeeDx technology or products incorporating SpeeDx technology.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The license agreement and the obligation to pay royalties continues until SpeeDx&#x2019;s patent rights have expired, lapsed, are found to be invalid or are rejected.&#xA0;The agreement will terminate by mutual agreement or by one party for breach or insolvency of the other. SpeeDx may also terminate the license agreement if the research and development on a first licensed product is not completed by UBS within 7 years (subject to certain exceptions), and UBS may terminate if it determines that it does not wish to proceed with further commercialization of SpeeDx&#x2019;s technology.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Mr.&#xA0;Denver is a director of SpeeDx and up until August&#xA0;7, 2017 was a director of the Company. Mr.&#xA0;Denver continued to provide services to the Company in an advisory capacity between October&#xA0;1, 2017 and June&#xA0;30, 2018.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Mr.&#xA0;Coleman is a&#xA0;<font style="WHITE-SPACE: nowrap">Non-Executive</font>&#xA0;Chairman of the Company and Executive Chairman of Viburnum Funds Pty Ltd. Viburnum Funds Pty Ltd, as an investment manager for its associated funds holds a beneficial interest and voting power over approximately 18% of our shares.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> An employee of Viburnum Funds Pty Ltd has on occasions been seconded to Universal Biosensors to assist the Company on strategic matters. During this period Viburnum Funds Pty Ltd continue to pay all the salary entitlements of the seconded person. Universal Biosensors is solely responsible for the reimbursement of certain expenditure such as travel and rental whilst the employee is on secondment. The total expenditure reimbursed by the Company to Viburnum Funds Pty Ltd as at September 30, 2018 was A$21,716.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Receivables</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the best estimate of the amount of probable credit losses in the existing accounts receivable. The allowance is determined based on a review of individual accounts for collectability, generally focusing on those accounts that are past due. The expense to adjust the allowance for doubtful accounts, if any, is recorded within general and administrative expenses in the consolidated condensed statements of comprehensive income. Account balances are charged against the allowance when it is probable the receivable will not be recovered.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br /> September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Year Ended<br /> December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Accounts receivable</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,902,417</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,397,268</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Allowance for doubtful debts</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,902,417</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,397,268</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 9452609 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Research and Development</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Research and development expenses consist of costs incurred to further the Group&#x2019;s research and product development activities and include salaries and related employee benefits, costs associated with clinical trial and preclinical development, regulatory activities, research-related overhead expenses, costs associated with the manufacture of clinical trial material, costs associated with developing a commercial manufacturing process, costs for consultants and related contract research, facility costs and depreciation. Research and development costs are expensed as incurred.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Research and development expenses for the respective periods are as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="60%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Three Months Ended<br /> September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine Months Ended<br /> September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Research and development expenses</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,759,664</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,197,146</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">9,452,609</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7,626,210</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> Restricted cash maintained by the Company in the form of term deposits is as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br /> September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Year Ended<br /> December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Collateral for facilities (a) - current assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">15,949</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">15,309</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Collateral for facilities (b) - <font style="WHITE-SPACE: nowrap">non-current</font> assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">320,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">320,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Financial covenant pursuant to the credit agreement (c) - current assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,900,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Financial covenant pursuant to the credit agreement (c) - <font style="WHITE-SPACE: nowrap">non-current</font> assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,900,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,235,949</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,235,309</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td valign="top" width="4%" align="left">(a)</td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">Represents bank guarantee of CDN$15,000 as security deposit on HRL&#x2019;s credit card</p> </td> </tr> </table> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td valign="top" width="4%" align="left">(b)</td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">Represents bank guarantee of A$250,000 for commercial lease of UBS&#x2019; premises and security deposit on Company&#x2019;s credit cards of A$70,000</p> </td> </tr> </table> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td valign="top" width="4%" align="left">(c)</td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">Represents amounts pledged as collateral for financing arrangements as contractually required by the Lenders. The restriction will lapse when the related debt is paid off in July 2019 or earlier as provided pursuant to the Credit Agreement</p> </td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Restricted stock awards activity during the current period is as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number&#xA0;of&#xA0;shares</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted&#xA0;average<br /> issue price</b><br /> <b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Balance at December&#xA0;31, 2017</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">492,749</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.31</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Granted</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.00</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Release of restricted shares</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(287,087</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.27</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Balance at September&#xA0;30, 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">205,662</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.31</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> This expense is expected to be recognized over the vesting years as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"><b>Fiscal Year</b></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">94,357</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2019</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">321,558</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2020</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">258,756</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">674,671</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 256410 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Revenue Recognition</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> We recognize revenue from all sources based on the provisions of the U.S. SEC&#x2019;s Staff Accounting Bulletin No.&#xA0;104 and ASC 605 Revenue Recognition.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company&#x2019;s revenue represents revenue from sales of products, provision of services and collaborative research and development agreements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> We recognize revenue from sales of products at the time title of goods passes to the buyer and the buyer assumes the risks and rewards of ownership, assuming all other revenue recognition criteria have been met. Generally, this is at the time products are shipped to the customer.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Revenue from services is recognized when a persuasive evidence of an arrangement exists, services have been rendered, the price is fixed or determinable, and collectability is reasonably assured. Revenue recognition principles are assessed for each new contractual arrangement and the appropriate accounting is determined for each service.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> On September&#xA0;21, 2018 LifeScan exercised its right to convert its obligation to pay quarterly service fees to us. We expect the lump sum service fees to be paid to Universal Biosensors on or before February 15, 2019. We estimate the lump sum service fee using the most expected value approach based on (i)&#xA0;actual quarterly service fees received this financial year, (ii)&#xA0;estimating the quarterly service fees for the remainder of the year based on the trend seen in prior years, and (iii)&#xA0;multiplying the total quarterly service fees expected to be received this financial year by two and converting the same into AUD using the period end exchange rate. We assessed if any amount of the lump sum service fees were attributable to the remaining obligation under the Master Services and Supply Agreement that states that LifeScan could require us to provide manufacturing services at our Rowville facility to recommence production of glucose strips. We conclude that this obligation has no fair value attributable to it due to (i) high set-up costs to recommence manufacturing, (ii) the required lead time to gain regulatory compliance, and (iii) the fact there is deemed to be no commercial rationale for LifeScan to request us to recommence glucose-strip manufacturing on the basis of current information. As such, the lump sum service fee revenue has been fully recognized this quarter and no revenue has been deferred.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Where our agreements contain multiple elements, or deliverables, such as the manufacture and sale of products, provision of services or research and development activities, they are assessed to determine whether separate delivery of the individual elements of such arrangements comprises more than one unit of accounting. Where an arrangement can be divided into separate units of accounting (each unit constituting a separate earnings process), the arrangement consideration is allocated amongst those varying units based on the relative selling price of the separate units of accounting and the applicable revenue recognition criteria applied to the separate units. Selling prices are determined using fair value as determined by either vendor specific objective evidence or third party evidence of the selling price, when available, or the Company&#x2019;s best estimate of selling price when fair value is not available for a given unit of accounting.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Under ASC&#xA0;<font style="WHITE-SPACE: nowrap">605-25,</font>&#xA0;the delivered item(s) are separate units of accounting, provided (i)&#xA0;the delivered item(s) have value to a customer on a stand-alone basis, and (ii)&#xA0;if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item(s) is considered probable and substantially in our control. Where the arrangement cannot be divided into separate units, the individual deliverables are combined as a single unit of accounting and the total arrangement consideration is recognized across other deliverables in the arrangement or over the estimated collaboration period. Payments under these arrangements typically include one or more of the following:&#xA0;<font style="WHITE-SPACE: nowrap">non-refundable,</font>&#xA0;upfront payments; funding of research and/or development efforts; and milestone payments.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> We typically generate milestone payments from our customers pursuant to the various agreements we have with them.&#xA0;<font style="WHITE-SPACE: nowrap">Non-refundable</font>&#xA0;milestone payments which represent the achievement of a significant technical/regulatory hurdle in the research and development process pursuant to collaborative agreements, and are deemed to be substantive, are recognized as revenue upon the achievement of the specified milestone. If the&#xA0;<font style="WHITE-SPACE: nowrap">non-refundable</font>&#xA0;milestone payment is not substantive or stand-alone value, the&#xA0;<font style="WHITE-SPACE: nowrap">non-refundable</font>&#xA0;milestone payment is deferred and recognized as revenue either over the estimated performance period stipulated in the agreement or across other deliverables in the arrangement.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Management has concluded that the core operations of the Company are expected to be research and development activities, commercial manufacture of approved medical or testing devices and the provision of services. The Company&#x2019;s ultimate goal is to utilize the underlying technology and skill base for the development of marketable products that the Company will manufacture. The Company considers revenue from the sales of products, revenue from services and the income received from milestone payments indicative of its core operating activities or revenue producing goals of the Company, and as such have accounted for this income as &#x201C;revenues&#x201D;.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <i>Master Services and Supply Agreement</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> In October 2007, the Company and LifeScan entered into a Master Services and Supply Agreement, under which the Company would provide certain services to LifeScan in the field of blood glucose monitoring and act as a&#xA0;<font style="WHITE-SPACE: nowrap">non-exclusive</font>&#xA0;manufacturer of blood glucose test strips. The Master Services and Supply Agreement was subsequently amended and restated in May 2009. The Company has concluded the Master Services and Supply Agreement should be accounted for as three separate units of accounting: 1) research and development to assist LifeScan in receiving regulatory clearance to sell the blood glucose product (milestone payment), 2) contract manufacturing of the blood glucose test strips (contract manufacturing) which ceased in December 2013, and 3) ongoing services and efforts to enhance the product (product enhancement).</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> All consideration within the Master Services and Supply Agreement is contingent. The Company concluded the undelivered items were not priced at a significant incremental discount to the delivered items and revenue for each deliverable will be recognized as each contingency is met and the consideration becomes fixed and determinable. The milestone payment was considered to be a substantive payment and the entire amount has been recognized as revenue when the regulatory approval was received. Revenues for contract manufacturing and ongoing efforts to enhance the product are recognized as revenue from products or revenue from services, respectively, when the four basic criteria for revenue recognition are met.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <i>Collaboration Agreement</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> On September&#xA0;9, 2011 the Company entered into a Collaboration Agreement with Siemens to develop coagulation related products for hospital&#xA0;<font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">point-of-care</font></font>&#xA0;and ambulatory care coagulation markets. In addition to an&#xA0;<font style="WHITE-SPACE: nowrap">up-front,</font>&#xA0;<font style="WHITE-SPACE: nowrap">non-refundable</font>&#xA0;payment of A$2,961,245 (equivalent to US$3 million), the Collaboration Agreement (as amended) contains a further seven payments from Siemens upon the achievement of certain defined milestones. These seven milestones, to a large extent, relate to feasibility, regulatory submissions and the launch of the products to be developed. The Company has concluded that the&#xA0;<font style="WHITE-SPACE: nowrap">up-front</font>&#xA0;payment is not a separate unit of accounting and recorded the amount as deferred revenue to be recognized as revenue across other deliverables in the arrangement with Siemens based upon the Company&#x2019;s best estimate of selling price. The deliverables related to each of the seven milestones are considered substantive and are not priced at a significant incremental discount to the other deliverables. As the achievement of the seven milestones is contingent upon a future event, the revenue for each deliverable will be recognized as the contingencies are met and the consideration becomes fixed and determinable.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Of the seven milestones, the Company has delivered on four as of September 30, 2018. The last milestone delivered was in July 2015.</p> </div> 60725274 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Account balances are charged against the allowance when it is probable the receivable will not be recovered.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br /> September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Year Ended<br /> December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Accounts receivable</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,902,417</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,397,268</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Allowance for doubtful debts</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,902,417</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,397,268</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 228224 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b>Summary of Significant Accounting Policies</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Principles of Consolidation</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries, UBS and HRL. All intercompany balances and transactions have been eliminated on consolidation.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The preparation of the consolidated financial statements requires management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Significant items subject to such estimates and assumptions include the recognition of revenue, carrying amount of property, plant and equipment, deferred income taxes, asset retirement obligations, liabilities related to employee benefits, warrants and research and development tax incentive income. Actual results could differ from those estimates.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Cash, Cash Equivalents and Restricted Cash</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company considers all highly liquid investments purchased with an initial maturity of three months or less to be cash equivalents. For cash and cash equivalents, the carrying amount approximates fair value due to the short maturity of those instruments. The Company maintains cash and restricted cash, which includes tenant security deposits, credit card security deposits and cash collateral for its borrowings. As of September 30, 2018, the Company has not realized any losses in such cash accounts and believes it is not exposed to any significant risk of loss.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Short-Term Investments&#xA0;<font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">(Held-to-maturity)</font></font></i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Short-term investments constitute all highly liquid investments with term to maturity from three months to twelve months. The carrying amount of short-term investments is equivalent to their fair value.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Concentration of Credit Risk and Other Risks and Uncertainties</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Cash and cash equivalents and accounts receivable consist of financial instruments that potentially subject the Company to concentration of credit risk to the extent of the amount recorded on the consolidated condensed balance sheets. The Company&#x2019;s cash and cash equivalents are primarily invested with one of Australia&#x2019;s largest banks. The Company is exposed to credit risk in the event of default by the banks holding the cash or cash equivalents to the extent of the amount recorded on the consolidated condensed balance sheets. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company has not identified any collectability issues with respect to receivables.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Derivative Instruments and Hedging Activities</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <i>Derivative financial instruments</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company may use derivative financial instruments to hedge its exposure to foreign exchange arising from operating, investing and financing activities. The Company does not hold or issue derivative financial instruments for trading purposes. However, derivatives that do not qualify for hedge accounting are accounted for as trading instruments.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Derivative financial instruments are recognized initially at fair value. Subsequent to initial recognition, derivative financial instruments are stated at fair value. The gain or loss on remeasurement to fair value is recognized immediately in the income statement. However, where derivatives qualify for hedge accounting, recognition of any resultant gain or loss depends on the nature of the item being hedged.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <i>Cash flow hedges</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Exposure to foreign exchange risks arises in the normal course of the Company&#x2019;s business and it is the Company&#x2019;s policy to use forward exchange contracts to hedge anticipated sales and purchases in foreign currencies. The amount of forward cover taken is in accordance with approved policy and internal forecasts.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Where a derivative financial instrument is designated as a hedge of the variability in cash flows of a recognized asset or liability, or a highly probable forecast transaction, the effective part of any unrealized gain or loss on the derivative financial instrument is recognized directly in equity. When the forecast transaction subsequently results in the recognition of a&#xA0;<font style="WHITE-SPACE: nowrap">non-financial</font>&#xA0;asset or&#xA0;<font style="WHITE-SPACE: nowrap">non-financial</font>&#xA0;liability, the associated cumulative gain or loss is removed from equity and included in the initial cost or other carrying amount of the&#xA0;<font style="WHITE-SPACE: nowrap">non-financial</font>&#xA0;asset or liability.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> For cash flow hedges, other than those covered by the preceding statement, the associated cumulative gain or loss is removed from equity and recognized in the consolidated condensed statements of comprehensive income in the same period or periods during which the hedged forecast transaction affects the consolidated condensed statements of comprehensive income and on the same line item as that hedged forecast transaction. The ineffective part of any gain or loss is recognized immediately in the consolidated condensed statements of comprehensive income.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> When a hedging instrument expires or is sold, terminated or exercised, or the Company revokes designation of the hedge relationship but the hedged forecast transaction is still probable to occur, the cumulative gain or loss at that point remains in equity and is recognized in accordance with the above policy when the transaction occurs. If the hedged transaction is no longer expected to take place, then the cumulative unrealized gain or loss recognized in equity is recognized immediately in the consolidated condensed statements of comprehensive income.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <i>Derivative Instruments and Hedging Activities</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as consider our own and counterparty credit risk. For periods ended September 30, 2018 and December&#xA0;31, 2017, we did not have any assets or liabilities that utilize Level&#xA0;3 inputs. The valuation of our foreign exchange derivatives are based on the market approach using observable market inputs, such as forward rates and incorporate&#xA0;<font style="WHITE-SPACE: nowrap">non-performance</font>&#xA0;risk (the credit standing of the counterparty when the derivative is in a net asset position, and the credit standing of the Company when the derivative is in a net liability position). Our derivative assets are categorized as Level&#xA0;2. The fair value methodologies described as Level&#xA0;2 and 3 inputs are defined elsewhere in these notes to the consolidated condensed financial statements.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <i>Fair Value of Financial Instruments</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The carrying value of all current assets and current liabilities approximates fair value because of their short-term nature. The estimated fair value of all other amounts has been determined, depending on the nature and complexity of the assets or the liability, by using one or all of the following approaches:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="left">Market approach &#x2013; based on market prices and other information from market transactions involving identical or comparable assets or liabilities.</p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="left">Cost approach &#x2013; based on the cost to acquire or construct comparable assets less an allowance for functional and/or economic obsolescence.</p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="left">Income approach &#x2013; based on the present value of a future stream of net cash flows.</p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> These fair value methodologies depend on the following types of inputs:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="left">Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).</p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="left">Quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in markets that are not active or are directly or indirectly observable (Level 2 inputs).</p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="left">Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).</p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Inventory</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Inventories are stated at the lower of cost or net realizable value. Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and estimated costs necessary to dispose. Inventories are principally determined under the average cost method which approximates cost. Cost comprises direct materials, direct labour and an appropriate portion of variable and fixed overhead expenditure, the latter being allocated on the basis of normal operating capacity. Cost also includes the transfer from equity of any gains/losses on qualifying cash flow hedges relating to purchases of raw material. Costs of purchased inventory are determined after deducting rebates and discounts.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br /> September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Year Ended<br /> December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Raw materials</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">322,399</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">380,540</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Work in progress</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">158,883</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">253,483</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Finished goods</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">28,109</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">481,282</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">662,132</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Receivables</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the best estimate of the amount of probable credit losses in the existing accounts receivable. The allowance is determined based on a review of individual accounts for collectability, generally focusing on those accounts that are past due. The expense to adjust the allowance for doubtful accounts, if any, is recorded within general and administrative expenses in the consolidated condensed statements of comprehensive income. Account balances are charged against the allowance when it is probable the receivable will not be recovered.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <table style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br /> September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Year Ended<br /> December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Accounts receivable</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,902,417</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,397,268</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Allowance for doubtful debts</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,902,417</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,397,268</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Property, Plant, and Equipment&#x2014;net</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Property, plant, and equipment are recorded at acquisition cost, less accumulated depreciation.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Depreciation on plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful life of machinery and equipment is 3 to 10 years. Leasehold improvements are amortized on the straight-line method over the shorter of the remaining lease term or estimated useful life of the asset. Maintenance and repairs are charged to operations as incurred, include normal services, and do not include items of a capital nature.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company receives Commonwealth of Australia grant monies under grant agreements to support its development activities (refer section on &#x201C;Government Grants&#x201D;), including in connection with the purchase of plant and equipment. Plant and equipment is presented net of the government grant. The grant monies are recognized against the acquisition costs of the related plant and equipment as and when the related assets are purchased.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Impairment of Long-Lived Assets</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company reviews its capital assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. In performing the review, the Company estimates undiscounted cash flows from products under development that are covered by these patents and licenses. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition is less than the carrying amount of the asset. If the evaluation indicates that the carrying value of an asset is not recoverable from its undiscounted cash flows, an impairment loss is measured by comparing the carrying value of the asset to its fair value, based on discounted cash flows. Impairment of long-lived-assets as at September&#xA0;30, 2018 was nil (December 31, 2017: nil).</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Government grants</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> UBS was awarded a grant from the Commonwealth of Australia under the Next Generation Manufacturing Investment Programme up to a maximum grant amount of A$575,000 payable over a three year period commencing from January&#xA0;1, 2017. The grants are paid upon achievement of&#xA0;<font style="WHITE-SPACE: nowrap">pre-agreed</font>&#xA0;milestones. The milestones generally relate to UBS placing purchase orders, commissioning upgrades and validating the equipment. Amongst other reasons, the Commonwealth of Australia may terminate the grant agreement for breach of the agreement by UBS or for failure to undertake the required programme. Under these circumstances, the Commonwealth of Australia may require UBS to repay some or the entire grant. The Company continues to undertake the project funded by the Commonwealth of Australia.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> An amount of A$271,318 and A$89,500 were received under this grant in November 2017 and June 2018, respectively. In the event UBS had achieved milestones and received grant payments, it believes that the likelihood of being required to repay grant funding is remote because the Company continues to comply with the grant agreement.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Other Liabilities</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Other liabilities are broken down as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <table style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br /> September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Year Ended<br /> December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> <b>Current liabilites</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Marketing support payment</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,836,614</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,626,413</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,836,614</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,626,413</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <i>Marketing Support Payment</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> During 2009, LifeScan chose not to proceed with the registration of the then current product but to proceed with an enhanced product, called OneTouch Verio<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>, and acknowledged that there would be a delay as a result. As a result of this change, LifeScan agreed to pay additional amounts per strip manufactured by the Company in 2010 and 2011 up to a specified volume limit (&#x201C;manufacturing initiation payments&#x201D;). At the same time, the Company agreed to pay LifeScan a marketing support payment in each of the two years following the first calendar year in which 1&#xA0;billion strips are sold by LifeScan equal to 40% of the total manufacturing initiation payments made. The first calendar year in which 1&#xA0;billion strips were sold by LifeScan was during the 2016 financial year. These amounts will be paid to LifeScan once supporting documentation has been provided to us. The total amount of marketing support payments to be paid to LifeScan in US$ once all the documentation is received is US$2,048,602 (equivalent to A$2,836,614).</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Research and Development</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Research and development expenses consist of costs incurred to further the Group&#x2019;s research and product development activities and include salaries and related employee benefits, costs associated with clinical trial and preclinical development, regulatory activities, research-related overhead expenses, costs associated with the manufacture of clinical trial material, costs associated with developing a commercial manufacturing process, costs for consultants and related contract research, facility costs and depreciation. Research and development costs are expensed as incurred.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Research and development expenses for the respective periods are as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <table style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="60%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Three Months Ended<br /> September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine Months Ended<br /> September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Research and development expenses</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,759,664</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,197,146</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">9,452,609</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7,626,210</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Income Taxes</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company applies ASC 740&#x2014;Income Taxes which establishes financial accounting and reporting standards for the effects of income taxes that result from a company&#x2019;s activities during the current and preceding years. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Where it is more likely than not that some portion or all of the deferred tax assets will not be realized, the deferred tax assets are reduced by a valuation allowance. The valuation allowance is sufficient to reduce the deferred tax assets to the amount that is more likely than not to be realized.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The recent U.S. Federal Tax Reform has established a mandatory repatriation of foreign accumulated undistributed earnings and profits (the &#x201C;E&amp;Ps&#x201D;) for U.S. companies&#x2019; subsidiaries. In the past, none of these E&amp;Ps&#x2019; were repatriated since such E&amp;Ps&#x2019; were considered to be reinvested indefinitely in the foreign location. The E&amp;Ps&#x2019; provisions are applicable to our Company commencing with our fiscal year 2018, however the E&amp;Ps&#x2019; mandatory repatriation provisions establishes measurement dates for various computations. In our Company&#x2019;s case this date is December&#xA0;31, 2017. The Company&#x2019;s estimated tax for the mandatory repatriation is estimated to be nil. However, the final tax due must be assessed with our December&#xA0;31, 2018 closing figures. Any such tax liability may be paid over a period of eight years starting on February&#xA0;28, 2019. As of the issuance date of this report, the U.S. Securities and Exchange Commission and the Financial Accounting Standards Board have issued some preliminary guidance, but have not issued final rules on how the effects of the U.S. Federal Tax Reform will be required to be reported for financial statements purposes.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> At December&#xA0;31, 2017 the Company has A$10,993,737 (A$22,616,230 at December&#xA0;31, 2016) of accumulated tax losses available for carry forward against future earnings, which under Australian tax laws do not expire but may not be available under certain circumstances. The Company also has A$11,048,336 (A$5,800,672 at December&#xA0;31, 2016) of&#xA0;<font style="WHITE-SPACE: nowrap">non-refundable</font>&#xA0;R&amp;D tax offset as at December&#xA0;31, 2017. The R&amp;D Tax offset is a&#xA0;<font style="WHITE-SPACE: nowrap">non-refundable</font>&#xA0;tax offset, which assists to reduce a company&#x2019;s tax liability. Once the liability has been reduced to zero, any excess offset may be carried forward into future income years. UBI has U.S. tax losses available for carry forward against future earnings of US$1,011,321 as of December&#xA0;31, 2017 and 2016. Pursuant to the U.S. Federal Tax Reform, the effective tax rate of UBI has been reduced from 34% to 21%. The deferred tax benefit based on this new rate for UBI is US$212,377. HRL has Canadian tax losses available for carry forward against future earnings of CAD$668,043 and CAD$95,096 as at December&#xA0;31, 2017 and 2016, respectively.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> We are subject to income taxes in the United States, Canada and Australia. Tax returns up to and including the 2017 financial year have been filed in all these jurisdictions.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Asset Retirement Obligations</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Asset retirement obligations (&#x201C;ARO&#x201D;) are legal obligations associated with the retirement and removal of long-lived assets. ASC 410 &#x2013; Asset Retirement and Environmental Obligations requires entities to record the fair value of a liability for an asset retirement obligation when it is incurred. When the liability is initially recorded, the Company capitalizes the cost by increasing the carrying amounts of the related property, plant and equipment. Over time, the liability increases for the change in its present value, while the capitalized cost depreciates over the useful life of the asset. The Company derecognizes ARO liabilities when the related obligations are settled.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The ARO is in relation to our premises where in accordance with the terms of the lease, the lessee has to restore part of the building upon vacating the premises.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> ARO for the years ended September 30, 2018 and December&#xA0;31, 2017 was A$2,600,000.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Australian Goods and Services Tax (GST) and Canadian Harmonized Sales Tax (HST)</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Revenues, expenses and assets are recognized net of the amount of associated GST and HST, unless the GST and HST incurred is not recoverable from the taxation authority. In this case it is recognized as part of the cost of acquisition of the asset or as part of the expense. Receivables and payables are stated inclusive of the amount of GST and HST receivable or payable. The net amount of GST and HST recoverable from, or payable to, the taxation authority is included with other receivables or payables in the consolidated condensed balance sheets.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Revenue Recognition</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> We recognize revenue from all sources based on the provisions of the U.S. SEC&#x2019;s Staff Accounting Bulletin No.&#xA0;104 and ASC 605 Revenue Recognition.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company&#x2019;s revenue represents revenue from sales of products, provision of services and collaborative research and development agreements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> We recognize revenue from sales of products at the time title of goods passes to the buyer and the buyer assumes the risks and rewards of ownership, assuming all other revenue recognition criteria have been met. Generally, this is at the time products are shipped to the customer.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Revenue from services is recognized when a persuasive evidence of an arrangement exists, services have been rendered, the price is fixed or determinable, and collectability is reasonably assured. Revenue recognition principles are assessed for each new contractual arrangement and the appropriate accounting is determined for each service.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> On September&#xA0;21, 2018 LifeScan exercised its right to convert its obligation to pay quarterly service fees to us. We expect the lump sum service fees to be paid to Universal Biosensors on or before February 15, 2019. We estimate the lump sum service fee using the most expected value approach based on (i)&#xA0;actual quarterly service fees received this financial year, (ii)&#xA0;estimating the quarterly service fees for the remainder of the year based on the trend seen in prior years, and (iii)&#xA0;multiplying the total quarterly service fees expected to be received this financial year by two and converting the same into AUD using the period end exchange rate. We assessed if any amount of the lump sum service fees were attributable to the remaining obligation under the Master Services and Supply Agreement that states that LifeScan could require us to provide manufacturing services at our Rowville facility to recommence production of glucose strips. We conclude that this obligation has no fair value attributable to it due to (i) high set-up costs to recommence manufacturing, (ii) the required lead time to gain regulatory compliance, and (iii) the fact there is deemed to be no commercial rationale for LifeScan to request us to recommence glucose-strip manufacturing on the basis of current information. As such, the lump sum service fee revenue has been fully recognized this quarter and no revenue has been deferred.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Where our agreements contain multiple elements, or deliverables, such as the manufacture and sale of products, provision of services or research and development activities, they are assessed to determine whether separate delivery of the individual elements of such arrangements comprises more than one unit of accounting. Where an arrangement can be divided into separate units of accounting (each unit constituting a separate earnings process), the arrangement consideration is allocated amongst those varying units based on the relative selling price of the separate units of accounting and the applicable revenue recognition criteria applied to the separate units. Selling prices are determined using fair value as determined by either vendor specific objective evidence or third party evidence of the selling price, when available, or the Company&#x2019;s best estimate of selling price when fair value is not available for a given unit of accounting.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Under ASC&#xA0;<font style="WHITE-SPACE: nowrap">605-25,</font>&#xA0;the delivered item(s) are separate units of accounting, provided (i)&#xA0;the delivered item(s) have value to a customer on a stand-alone basis, and (ii)&#xA0;if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item(s) is considered probable and substantially in our control. Where the arrangement cannot be divided into separate units, the individual deliverables are combined as a single unit of accounting and the total arrangement consideration is recognized across other deliverables in the arrangement or over the estimated collaboration period. Payments under these arrangements typically include one or more of the following:&#xA0;<font style="WHITE-SPACE: nowrap">non-refundable,</font>&#xA0;upfront payments; funding of research and/or development efforts; and milestone payments.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> We typically generate milestone payments from our customers pursuant to the various agreements we have with them.&#xA0;<font style="WHITE-SPACE: nowrap">Non-refundable</font>&#xA0;milestone payments which represent the achievement of a significant technical/regulatory hurdle in the research and development process pursuant to collaborative agreements, and are deemed to be substantive, are recognized as revenue upon the achievement of the specified milestone. If the&#xA0;<font style="WHITE-SPACE: nowrap">non-refundable</font>&#xA0;milestone payment is not substantive or stand-alone value, the&#xA0;<font style="WHITE-SPACE: nowrap">non-refundable</font>&#xA0;milestone payment is deferred and recognized as revenue either over the estimated performance period stipulated in the agreement or across other deliverables in the arrangement.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Management has concluded that the core operations of the Company are expected to be research and development activities, commercial manufacture of approved medical or testing devices and the provision of services. The Company&#x2019;s ultimate goal is to utilize the underlying technology and skill base for the development of marketable products that the Company will manufacture. The Company considers revenue from the sales of products, revenue from services and the income received from milestone payments indicative of its core operating activities or revenue producing goals of the Company, and as such have accounted for this income as &#x201C;revenues&#x201D;.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <i>Master Services and Supply Agreement</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> In October 2007, the Company and LifeScan entered into a Master Services and Supply Agreement, under which the Company would provide certain services to LifeScan in the field of blood glucose monitoring and act as a&#xA0;<font style="WHITE-SPACE: nowrap">non-exclusive</font>&#xA0;manufacturer of blood glucose test strips. The Master Services and Supply Agreement was subsequently amended and restated in May 2009. The Company has concluded the Master Services and Supply Agreement should be accounted for as three separate units of accounting: 1) research and development to assist LifeScan in receiving regulatory clearance to sell the blood glucose product (milestone payment), 2) contract manufacturing of the blood glucose test strips (contract manufacturing) which ceased in December 2013, and 3) ongoing services and efforts to enhance the product (product enhancement).</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> All consideration within the Master Services and Supply Agreement is contingent. The Company concluded the undelivered items were not priced at a significant incremental discount to the delivered items and revenue for each deliverable will be recognized as each contingency is met and the consideration becomes fixed and determinable. The milestone payment was considered to be a substantive payment and the entire amount has been recognized as revenue when the regulatory approval was received. Revenues for contract manufacturing and ongoing efforts to enhance the product are recognized as revenue from products or revenue from services, respectively, when the four basic criteria for revenue recognition are met.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <i>Collaboration Agreement</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> On September&#xA0;9, 2011 the Company entered into a Collaboration Agreement with Siemens to develop coagulation related products for hospital&#xA0;<font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">point-of-care</font></font>&#xA0;and ambulatory care coagulation markets. In addition to an&#xA0;<font style="WHITE-SPACE: nowrap">up-front,</font>&#xA0;<font style="WHITE-SPACE: nowrap">non-refundable</font>&#xA0;payment of A$2,961,245 (equivalent to US$3 million), the Collaboration Agreement (as amended) contains a further seven payments from Siemens upon the achievement of certain defined milestones. These seven milestones, to a large extent, relate to feasibility, regulatory submissions and the launch of the products to be developed. The Company has concluded that the&#xA0;<font style="WHITE-SPACE: nowrap">up-front</font>&#xA0;payment is not a separate unit of accounting and recorded the amount as deferred revenue to be recognized as revenue across other deliverables in the arrangement with Siemens based upon the Company&#x2019;s best estimate of selling price. The deliverables related to each of the seven milestones are considered substantive and are not priced at a significant incremental discount to the other deliverables. As the achievement of the seven milestones is contingent upon a future event, the revenue for each deliverable will be recognized as the contingencies are met and the consideration becomes fixed and determinable.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Of the seven milestones, the Company has delivered on four as of September 30, 2018. The last milestone delivered was in July 2015.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <i>Interest income</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Interest income is recognized as it accrues, taking into account the effective yield on the cash and cash equivalents.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <i>Research and development tax incentive income</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Research and development tax incentive income is recognized when there is reasonable assurance that the income will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The research and development tax incentive is one of the key elements of the Australian Government&#x2019;s support for Australia&#x2019;s innovation system and is supported by legislative law primarily in the form of the Australian Income Tax Assessment Act 1997 as long as eligibility criteria are met. Generally speaking, entities which are an R&amp;D entity involved in eligible R&amp;D activities may claim research and development tax incentive income as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td width="4%">&#xA0;</td> <td valign="top" width="4%" align="left">(1)</td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="left">as a 43.5% refundable tax offset if aggregate turnover (which generally means an entity&#x2019;s total income that it derives in the ordinary course of carrying on a business, subject to certain exclusions) of the entity is less than A$20&#xA0;million, or</p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td width="4%">&#xA0;</td> <td valign="top" width="4%" align="left">(2)</td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="left">as a 38.5%&#xA0;<font style="WHITE-SPACE: nowrap">non-refundable</font>&#xA0;tax offset if aggregate turnover of the entity is more than A$20&#xA0;million.</p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> In accordance with SEC Regulation&#xA0;<font style="WHITE-SPACE: nowrap">S-X</font>&#xA0;Article&#xA0;<font style="WHITE-SPACE: nowrap">5-03,</font>&#xA0;the Company&#x2019;s research and development tax incentive income has been recognized as&#xA0;<font style="WHITE-SPACE: nowrap">non-operating</font>&#xA0;income as it is not indicative of the core operating activities or revenue producing goals of the Company.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Management has assessed the Company&#x2019;s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the tax incentive regime described above. At each period end management estimates the refundable tax offset available to the Company based on available information at the time. This estimate is also reviewed by external tax advisors on an annual basis.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> In the nine months ended September 30, 2018 and 2017, the aggregate turnover of the Company had exceeded A$20&#xA0;million and accordingly it was not eligible for a refundable tax offset. The Company was however eligible for the&#xA0;<font style="WHITE-SPACE: nowrap">non-refundable</font>&#xA0;tax offset. The eligible R&amp;D activities and expenditures are able to be claimed as part of the current year income tax computation and any amounts included as a tax asset will be subject to recognition rules under ASC 740 &#x201C;Income Taxes&#x201D;.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Foreign Currency</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <i>Functional and reporting currency</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Items included in the financial statements of each of the Group&#x2019;s entities are measured using the currency of the primary economic environment in which the entity operates (&#x201C;the functional currency&#x201D;). The functional currency of UBI and UBS is AUD or A$ for all years presented. The functional currency of HRL is CAD$.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The consolidated condensed financial statements are presented using a reporting currency of Australian dollars.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <i>Transactions and balances</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at&#xA0;<font style="WHITE-SPACE: nowrap">year-end</font>&#xA0;exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in the consolidated condensed statements of comprehensive income.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company has recorded foreign currency transaction gains of A$183,395 and A$61,873 for the three months ended September 30, 2018 and 2017, respectively and A$412,768 and A$703,420 for the nine months ended September 30, 2018 and 2017, respectively.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The results and financial position of all the Group entities that have a functional currency different from the reporting currency are translated into the reporting currency as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td width="1%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="left">assets and liabilities for each balance sheet item reported are translated at the closing rate at the date of that balance sheet;</p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td width="1%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="left">income and expenses for each income statement item reported are translated at average exchange rates (unless this is not a reasonable approximation of the effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions); and</p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td width="1%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="left">all resulting exchange differences are recognized as a separate component of equity.</p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> On consolidation, exchange differences arising from the translation of any net investment in foreign entities are taken to the Accumulated Other Comprehensive Income.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Commitments and Contingencies</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Liabilities for loss contingencies, arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. These were nil as at September 30, 2018. Purchase commitments contracted for as at September 30, 2018 is A$1,538,429 (December 31, 2017 : A$2,359,443).</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Patent and License Costs</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Legal and maintenance fees incurred for patent application costs have been charged to expense and reported in general and administrative expense.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Clinical Trial Expenses</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Clinical trial costs are a component of research and development expenses. These expenses include fees paid to participating hospitals and other service providers, which conduct certain testing activities on behalf of the Company. Depending on the timing of payments to the service providers and the level of service provided, the Company records prepaid or accrued expenses relating to these costs.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> These prepaid or accrued expenses are based on estimates of the work performed under service agreements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Leased Assets</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> All of the Company&#x2019;s leases for the periods ending September 30, 2018 and December&#xA0;31, 2017 are considered operating leases. The costs of operating leases are charged to the consolidated condensed statements of comprehensive income on a straight-line basis over the lease term.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Stock-based Compensation</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> We measure stock-based compensation at grant date, based on the estimated fair value of the award, and recognize the cost as an expense on a straight-line basis over the vesting period of the award. We estimate the fair value of stock options using the Trinomial Lattice model. We also grant our employees Restricted Stock Units (&#x201C;RSUs&#x201D;) and Zero Priced Employee Options (&#x201C;ZEPOs&#x201D;). RSUs are stock awards granted to employees that entitle the holder to shares of common stock as the award vests. ZEPOs are stock options granted to employees that entitle the holder to shares of common stock as the award vests. The value of RSUs are determined and fixed on the grant date based on the Company&#x2019;s stock price. The exercise price of ZEPOs is nil.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> We record deferred tax assets for awards that will result in deductions on our income tax returns, based on the amount of compensation cost recognized and our statutory tax rate in the jurisdiction in which we will receive a deduction. Differences between the deferred tax assets recognized for financial reporting purposes and the actual tax deduction reported in our income tax return are recorded in expense or in capital in excess of par value if the tax deduction exceeds the deferred tax assets or to the extent that previously recognized credits to&#xA0;<font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">paid-in-capital</font></font>&#xA0;are still available if the tax deduction is less than the deferred tax asset.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <i>(a) Stock Option Plan</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> In 2004, the Company adopted an employee option plan (&#x201C;Plan&#x201D;). Options may be granted pursuant to the Plan to any person considered by the board to be employed by the Group on a permanent basis (whether full time, part time or on a long term casual basis). Each option gives the holder the right to subscribe for one share of common stock. The total number of options that may be issued under the Plan is such maximum amount permitted by law and the Listing Rules of the ASX. The exercise price and any exercise conditions are determined by the board at the time of grant of the options. Any exercise conditions must be satisfied before the options vest and become capable of exercise. The options lapse on such date determined by the board at the time of grant or earlier in accordance with the Plan. Options granted to date have had a term up to 10 years and generally vest in equal tranches over three years.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> An option holder is not permitted to participate in a bonus issue or new issue of securities in respect of an option held prior to the issue of shares to the option holder pursuant to the exercise of an option. If the Company changes the number of issued shares through, or as a result of, any consolidation, subdivision, or similar reconstruction of the issued capital of the Company, the total number of options and the exercise price of the options (as applicable) will likewise be adjusted.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> In accordance with ASC 718, the fair value of the option grants was estimated on the date of each grant using the Trinomial Lattice model. The assumptions for these grants were:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"><b>Grant Date</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b><font style="WHITE-SPACE: nowrap">Oct-17</font></b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b><font style="WHITE-SPACE: nowrap">Oct-17</font></b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b><font style="WHITE-SPACE: nowrap">Oct-17</font></b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b><font style="WHITE-SPACE: nowrap">Feb-17</font></b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Exercise Price (A$)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.50</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.60</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.80</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.50</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Share Price at Grant Date (A$)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.38</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.38</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.38</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.39</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Volatility</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">68</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">68</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">68</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">69</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Expected Life (years)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Risk Free Interest Rate</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.36</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.36</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.36</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.47</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Fair Value of Option (A$)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.15</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.13</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.11</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.13</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Stock option activity during the current period is as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Number&#xA0;of&#xA0;shares</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted&#xA0;average<br /> exercise price</b><br /> <b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Balance at December&#xA0;31, 2017</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">22,003,215</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.63</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Granted</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.00</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Exercised</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(503,334</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.00</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Lapsed</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(5,124,431</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.70</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Balance at September&#xA0;30, 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">16,375,450</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.63</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The number of options exercisable as at September 30, 2018 and 2017 was 7,208,775 and 10,963,629, respectively. The total stock compensation expense recognized in the consolidated condensed statements of comprehensive income was A$51,182 and A$154,218 for the three months ended September 30, 2018 and 2017, respectively and A$228,224 and A$354,243 for the nine months ended September 30, 2018 and 2017, respectively.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> As of September 30, 2018, there was A$674,671 of unrecognized compensation expense related to unvested share-based compensation arrangements under the Employee Option Plan. This expense is expected to be recognized over the vesting years as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="bottom"><b>Fiscal Year</b></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">94,357</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2019</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">321,558</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2020</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">258,756</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">674,671</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The aggregate intrinsic value for all options outstanding as at September 30, 2018 and 2017 was zero.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <i>(b) Restricted Share Plan</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Our Employee Share Plan was adopted by the Board of Directors in 2009. The Employee Share Plan permits our Board to grant shares of our common stock to our employees and directors (although our Board has determined not to issue equity to&#xA0;<font style="WHITE-SPACE: nowrap">non-executive</font>&#xA0;directors). The number of shares able to be granted is limited to the amount permitted to be granted at law, the ASX Listing Rules and by the limits on our authorized share capital in our certificate of incorporation. All our employees are eligible for shares under the Employee Share Plan. The Company has in the past issued A$1,000 worth of restricted shares of common stock to employees of the Company but no more frequently than annually. The restricted shares have the same terms of issue as our existing shares of common stock but are not able to be traded until the earlier of three years from the date on which the shares are issued or the date the relevant employee ceases to be an employee of the Company or any of its associated group of companies.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 75px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> No restricted shares have been issued by the Company since January&#xA0;1, 2017.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Restricted stock awards activity during the current period is as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Number&#xA0;of&#xA0;shares</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted&#xA0;average<br /> issue price</b><br /> <b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Balance at December&#xA0;31, 2017</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">492,749</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.31</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Granted</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.00</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Release of restricted shares</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(287,087</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.27</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Balance at September&#xA0;30, 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">205,662</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.31</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Employee Benefit Costs</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company contributes 9.5% of each employee&#x2019;s salary to standard defined contribution superannuation funds on behalf of all UBS employees. Superannuation is a compulsory savings program whereby employers are required to pay a portion of an employee&#x2019;s remuneration to an approved superannuation fund that the employee is typically not able to access until they have reached the statutory retirement age. Whilst the Company has a third party default superannuation fund, it permits UBS employees to choose an approved and registered superannuation fund into which the contributions are paid. Contributions are charged to the consolidated condensed statements of comprehensive income as they become payable.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Registered Retirement Savings Plan and Deferred Sharing Profit Plan</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company provides eligible HRL employees a retirement plan. The retirement plan includes a Registered Retirement Savings Plan (&#x201C;RRSP&#x201D;) and Deferred Profit Sharing Plan (&#x201C;DPSP&#x201D;). The RRSP is voluntary and the employee contributions are matched by the Company up to a maximum of 5% based on their continuous years of service and placed into the DPSP. The Company contributes 1% to 2% of the employee&#x2019;s base earnings towards the DPSP. The DPSP contributions are vested immediately.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Benefit Plan</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company provides eligible HRL employees a Benefit Plan to its employees. In general, the Benefit Plan includes extended health care, dental care, basic life insurance, basic accidental death and dismemberment, and disability insurance.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Net Income/(Loss) per Share and Anti-dilutive Securities</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Basic and diluted net income/(loss) per share is presented in conformity with ASC 260 &#x2013; Earnings per Share. Basic and diluted net income/(loss) per share has been computed using the weighted-average number of common shares outstanding during the period. Diluted net income/(loss) per share is calculated by adjusting the basic net income/(loss) per share by assuming all dilutive potential ordinary shares are converted.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Total Comprehensive Income/(Loss)</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company follows ASC 220 &#x2013; Comprehensive Income. Comprehensive income/(loss) is defined as the total change in shareholders&#x2019; equity during the period other than from transactions with shareholders, and for the Company, includes net income/(loss).</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The tax effect allocated to each component of other comprehensive loss is as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="59%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b><font style="WHITE-SPACE: nowrap">Before-Tax&#xA0;Amount</font></b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="center"><b>Tax&#xA0;(Expense)/</b></p> <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="center"><b>Benefit</b></p> </td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b><font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">Net-of-Tax</font></font><br /> Amount</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> <b><u>Nine Months Ended September&#xA0;30, 2018</u></b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Foreign currency translation reserve</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">36,525</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">36,525</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Reclassification for gains realised in net income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Other comprehensive loss</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">36,525</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">36,525</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> <b><u>Nine Months Ended September&#xA0;30, 2017</u></b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Foreign currency translation reserve</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,497</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,497</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Reclassification for gains realised in net income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Other comprehensive loss</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,497</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,497</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Business combinations</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Business combinations are accounted for using the acquisition method of accounting. Acquisition cost is measured as the aggregate of the fair value at the date of acquisition of the assets given, equity instruments issued or liabilities incurred or assumed. Acquisition related costs are expensed as incurred (except for those costs arising on the issue of equity instruments which are recognized directly in equity). Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured at fair value on the acquisition date. Goodwill is measured as the excess of the acquisition cost, the amount of any&#xA0;<font style="WHITE-SPACE: nowrap">non-controlling</font>&#xA0;interest and the fair value of any previous UBI equity interest in the acquiree, over the fair value of the identifiable net assets acquired.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Reclassification</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Certain prior year amounts have been reclassified to conform to the current year presentation.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Recent Accounting Pronouncements</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> (a) Recent issued accounting standards not yet adopted</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <u>ASU&#xA0;<font style="WHITE-SPACE: nowrap">No.2016-02,</font>&#xA0;&#x201C;Leases&#x2019;</u></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> On February&#xA0;25, 2016, the FASB issued ASU&#xA0;<font style="WHITE-SPACE: nowrap">2016-02,</font>&#xA0;its new standard on accounting for leases. ASU&#xA0;<font style="WHITE-SPACE: nowrap">2016-02</font>&#xA0;introduces a lessee model that brings most leases on the balance sheet and eliminates the requirement in current U.S. GAAP for an entity to use bright-line tests in determining lease classification. The standard also requires lessors to increase the transparency of their exposure to changes in value of their residual assets and how they manage that exposure.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The new guidance will be effective for public business entities for annual periods beginning after December&#xA0;15, 2018, and interim periods therein. Early adoption is permitted. The Company is currently evaluating the impact the adoption of ASU&#xA0;<font style="WHITE-SPACE: nowrap">2016-02</font>&#xA0;will have on the Company&#x2019;s consolidated financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <u>ASU&#xA0;<font style="WHITE-SPACE: nowrap">No.2014-09,</font>&#xA0;&#x201C;Revenue from Contracts with Customers&#x2019;</u></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU)&#xA0;<font style="WHITE-SPACE: nowrap">2014-09,</font>&#xA0;Revenue from Contracts with Customers (Topic 606), which provides companies with a single revenue recognition model for recognizing revenue from contracts with customers. The core principle of the new standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. There are two permitted transition methods under the new standard, the full retrospective method or the modified retrospective method. The new standard is effective for annual reporting periods beginning after December&#xA0;15, 2017. The Company has deferred the adoption of this standard as is allowable for an Emerging Growth Company.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> UBI has selected the modified retrospective method where the effect of applying the standard will be recognized at the date of initial application, without restating previous years. The Company is currently evaluating the impact the adoption of ASU&#xA0;<font style="WHITE-SPACE: nowrap">2014-09</font>&#xA0;will have on the Company&#x2019;s consolidated financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <i><u>ASU&#xA0;<font style="WHITE-SPACE: nowrap">No.&#xA0;2017-12,</font>&#xA0;&#x201C;Targeted Improvements to Accounting for Hedging Activities&#x201D;</u></i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> On August&#xA0;28, 2017, the FASB issued ASU&#xA0;<font style="WHITE-SPACE: nowrap">2017-12,</font>&#xA0;which amends the hedge accounting recognition and presentation requirements in ASC 815.2. The FASB&#x2019;s objectives in issuing the ASU are to (1)&#xA0;improve the transparency and understandability of information conveyed to financial statement users about an entity&#x2019;s risk management activities by better aligning the entity&#x2019;s financial reporting for hedging relationships with those risk management activities and (2)&#xA0;reduce the complexity of and simplify the application of hedge accounting by preparers.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> For public business entities, the ASU is effective for fiscal years beginning after December&#xA0;15, 2018, and interim periods therein; however, early adoption by all entities is permitted upon its issuance. The Company is currently evaluating the impact the adoption of ASU&#xA0;<font style="WHITE-SPACE: nowrap">2014-09</font>&#xA0;will have on the Company&#x2019;s consolidated financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> (b) Recently adopted accounting pronouncements</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <i><u>ASU&#xA0;<font style="WHITE-SPACE: nowrap">No.2016-18,</font>&#xA0;&#x201C;Restricted Cash&#x2019;</u></i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> On November&#xA0;17, 2016, the FASB issued ASU&#xA0;<font style="WHITE-SPACE: nowrap">2016-18,</font>&#xA0;which amends ASC 230 to add or clarify guidance on the classification and presentation of restricted cash in the statement of cash flows. For public business entities, the guidance is effective for fiscal years beginning after December&#xA0;15, 2017, including interim periods therein. For all other entities, it is effective for fiscal years beginning after December&#xA0;15, 2018, and interim periods thereafter. Early adoption is permitted for all entities. The Company has adopted this guidance from January&#xA0;1, 2018 and it has not had a material impact on the Company&#x2019;s consolidated financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <i><u>ASU&#xA0;<font style="WHITE-SPACE: nowrap">No.2016-15,</font>&#xA0;&#x201C;Classification of Certain Cash Receipts and Cash Payments&#x201D;</u></i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> On August&#xA0;26, 2016, the FASB issued ASU&#xA0;<font style="WHITE-SPACE: nowrap">2016-15,</font>&#xA0;which amends the guidance in ASC 230 to eliminate diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The guidance in the ASU is effective for fiscal years beginning after December&#xA0;15, 2017, including interim periods within those fiscal years. Early adoption is permitted for all entities. The Company has adopted this guidance and it has not had a material impact on the Company&#x2019;s consolidated financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <i><u>ASU&#xA0;<font style="WHITE-SPACE: nowrap">No.2016-16,</font>&#xA0;&#x201C;Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory&#x2019;</u></i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> On October&#xA0;24, 2016, the FASB issued ASU&#xA0;<font style="WHITE-SPACE: nowrap">2016-16,</font>&#xA0;which removes the prohibition in ASC 740 against the immediate recognition of the current and deferred income tax effects of intra-entity transfers of assets other than inventory. This ASU is effective for annual periods beginning after December&#xA0;15, 2017, and interim periods within those annual periods. Early adoption is permitted for all entities as of the beginning of a fiscal year for which neither the annual or interim financial statements have been issued. Entities should apply the ASU&#x2019;s amendments on a modified retrospective basis, recognizing the effects in retained earnings as of the beginning of the year of adoption. The Company has adopted this guidance and it has not had a material impact on the Company&#x2019;s consolidated financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <i><u>ASU&#xA0;<font style="WHITE-SPACE: nowrap">No.2017-01,</font>&#xA0;&#x201C;Business Combination: Clarifying the Definition of a Business&#x2019;</u></i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> On January&#xA0;5, 2017, the FASB issued ASU&#xA0;<font style="WHITE-SPACE: nowrap">2017-01</font>&#xA0;to clarify the definition of a business in ASC 805. The amendments in the ASU are intended to make application of the guidance more consistent and&#xA0;<font style="WHITE-SPACE: nowrap">cost-efficient.</font>&#xA0;The ASU is effective for annual periods beginning after December&#xA0;15, 2017, including interim periods therein. The ASU must be applied prospectively on or after the effective date, and no disclosures for a change in accounting principle are required at transition. Early adoption is permitted for transactions (i.e., acquisitions or dispositions) that occurred before the issuance date or effective date of the standard. The Company has adopted this guidance and it has not had a material impact on the Company&#x2019;s consolidated financial statements.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <i><u>ASU&#xA0;<font style="WHITE-SPACE: nowrap">No.2017-09,</font>&#xA0;&#x201C;Compensation &#x2013; Stock Compensation: Scope of Modification Accounting&#x2019;</u></i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> On May&#xA0;10, 2017, the FASB issued ASU&#xA0;<font style="WHITE-SPACE: nowrap">2017-09,</font>&#xA0;which amends the scope of modification accounting for share-based payment arrangements. The ASU provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting under ASC 718. This ASU is effective for annual reporting periods, including interim periods within those annual reporting periods, beginning after December&#xA0;15, 2017. Early adoption is permitted. The Company has adopted this guidance and it has not had a material impact on the Company&#x2019;s consolidated financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <i><u>ASU&#xA0;<font style="WHITE-SPACE: nowrap">No.&#xA0;2018-05,</font>&#xA0;&#x201C;Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No.&#xA0;118.&#x201D;</u></i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> On March&#xA0;13, 2018, the FASB issued ASU&#xA0;<font style="WHITE-SPACE: nowrap">2018-05.</font>&#xA0;This Financial Reporting Alert contains responses to frequently asked questions about how an entity should account for the tax effects of the new tax reform legislation in accordance with ASC 740, Income Taxes. This ASU is effective upon issuance and the adoption of this guidance has not had a material impact on the Company&#x2019;s consolidated financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <i><u>ASU&#xA0;<font style="WHITE-SPACE: nowrap">No.&#xA0;2018-09,</font>&#xA0;&#x201C;Codification Improvements&#x201D;</u></i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The FASB issued ASU&#xA0;<font style="WHITE-SPACE: nowrap">2018-09</font>&#xA0;on July&#xA0;16, 2018. The ASU&#x2019;s amendments &#x201C;clarify, correct errors in, or make minor improvements to the Codification.&#x201D; This ASU is effective upon issuance and the adoption of this guidance has not had a material impact on the Company&#x2019;s consolidated financial statements.</p> </div> 0 0 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Costs of purchased inventory are determined after deducting rebates and discounts.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br /> September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Year Ended<br /> December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Raw materials</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">322,399</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">380,540</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Work in progress</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">158,883</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">253,483</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Finished goods</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">28,109</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">481,282</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">662,132</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Future maturities, interest and other payments under the Company&#x2019;s long term secured loan pursuant to the credit agreement (described below) as of September 30, 2018 and December&#xA0;31, 2017 are as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="56%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>September&#xA0;30, 2018</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31, 2017</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">US$</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">A$</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">US$</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">A$</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">442,750</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,956,563</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2019</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">15,221,375</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">15,875,875</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total minimum payments</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">15,664,125</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">17,832,438</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Less amount representing interest and other fees</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(664,125</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(2,832,438</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Gross balance of long term debt</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">15,000,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">15,000,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Less fair value of warrants recorded within loan (a)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(815,655</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(815,655</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Plus interest accretion</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">736,851</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">658,334</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total carrying value</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">14,921,196</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">20,660,753</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">14,842,679</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">19,029,076</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Less current portion</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">14,921,196</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">20,660,753</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total carrying value, <font style="WHITE-SPACE: nowrap">non-current</font> portion</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">14,842,679</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">19,029,076</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The above assumes, as provided under the Athyrium Credit Agreement, the loan will be repaid immediately out of the proceeds from the lump sum service fees which is expected to be received on or about February&#xA0;15, 2019.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The carrying value of the borrowings approximates its fair value. The fair value is estimated by discounting future cash flows at the currently offered rates for borrowings of similar remaining maturities.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="4%">&#xA0;</td> <td valign="top" width="4%" align="left">(a)</td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">The warrants issued in December 2013 had a fair value of US$815,655 as of September 30, 2018 and December&#xA0;31, 2017, and are included in equity.</p> </td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> The tax effect allocated to each component of other comprehensive loss is as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="59%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b><font style="WHITE-SPACE: nowrap">Before-Tax&#xA0;Amount</font></b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"><b>Tax&#xA0;(Expense)/</b></p> <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"><b>Benefit</b></p> </td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b><font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">Net-of-Tax</font></font><br /> Amount</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> <b><u>Nine Months Ended September&#xA0;30, 2018</u></b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Foreign currency translation reserve</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">36,525</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">36,525</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Reclassification for gains realised in net income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Other comprehensive loss</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">36,525</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">36,525</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> <b><u>Nine Months Ended September&#xA0;30, 2017</u></b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Foreign currency translation reserve</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,497</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,497</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Reclassification for gains realised in net income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Other comprehensive loss</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,497</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,497</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Stock option activity during the current period is as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number&#xA0;of&#xA0;shares</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted&#xA0;average<br /> exercise price</b><br /> <b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Balance at December&#xA0;31, 2017</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">22,003,215</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.63</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Granted</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.00</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Exercised</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(503,334</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.00</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Lapsed</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(5,124,431</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.70</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Balance at September&#xA0;30, 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">16,375,450</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.63</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> The assumptions for these grants were:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>Grant Date</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b><font style="WHITE-SPACE: nowrap">Oct-17</font></b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b><font style="WHITE-SPACE: nowrap">Oct-17</font></b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b><font style="WHITE-SPACE: nowrap">Oct-17</font></b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b><font style="WHITE-SPACE: nowrap">Feb-17</font></b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Exercise Price (A$)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.50</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.60</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.80</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.50</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Share Price at Grant Date (A$)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.38</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.38</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.38</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.39</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Volatility</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">68</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">68</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">68</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">69</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Expected Life (years)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Risk Free Interest Rate</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.36</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.36</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.36</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.47</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Fair Value of Option (A$)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.15</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.13</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.11</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.13</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> </table> </div> UBI <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Stock-based Compensation</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> We measure stock-based compensation at grant date, based on the estimated fair value of the award, and recognize the cost as an expense on a straight-line basis over the vesting period of the award. We estimate the fair value of stock options using the Trinomial Lattice model. We also grant our employees Restricted Stock Units (&#x201C;RSUs&#x201D;) and Zero Priced Employee Options (&#x201C;ZEPOs&#x201D;). RSUs are stock awards granted to employees that entitle the holder to shares of common stock as the award vests. ZEPOs are stock options granted to employees that entitle the holder to shares of common stock as the award vests. The value of RSUs are determined and fixed on the grant date based on the Company&#x2019;s stock price. The exercise price of ZEPOs is nil.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> We record deferred tax assets for awards that will result in deductions on our income tax returns, based on the amount of compensation cost recognized and our statutory tax rate in the jurisdiction in which we will receive a deduction. Differences between the deferred tax assets recognized for financial reporting purposes and the actual tax deduction reported in our income tax return are recorded in expense or in capital in excess of par value if the tax deduction exceeds the deferred tax assets or to the extent that previously recognized credits to <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">paid-in-capital</font></font> are still available if the tax deduction is less than the deferred tax asset.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>(a) Stock Option Plan</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> In 2004, the Company adopted an employee option plan (&#x201C;Plan&#x201D;). Options may be granted pursuant to the Plan to any person considered by the board to be employed by the Group on a permanent basis (whether full time, part time or on a long term casual basis). Each option gives the holder the right to subscribe for one share of common stock. The total number of options that may be issued under the Plan is such maximum amount permitted by law and the Listing Rules of the ASX. The exercise price and any exercise conditions are determined by the board at the time of grant of the options. Any exercise conditions must be satisfied before the options vest and become capable of exercise. The options lapse on such date determined by the board at the time of grant or earlier in accordance with the Plan. Options granted to date have had a term up to 10 years and generally vest in equal tranches over three years.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> An option holder is not permitted to participate in a bonus issue or new issue of securities in respect of an option held prior to the issue of shares to the option holder pursuant to the exercise of an option. If the Company changes the number of issued shares through, or as a result of, any consolidation, subdivision, or similar reconstruction of the issued capital of the Company, the total number of options and the exercise price of the options (as applicable) will likewise be adjusted.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> In accordance with ASC 718, the fair value of the option grants was estimated on the date of each grant using the Trinomial Lattice model. The assumptions for these grants were:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>Grant Date</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b><font style="WHITE-SPACE: nowrap">Oct-17</font></b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b><font style="WHITE-SPACE: nowrap">Oct-17</font></b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b><font style="WHITE-SPACE: nowrap">Oct-17</font></b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b><font style="WHITE-SPACE: nowrap">Feb-17</font></b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Exercise Price (A$)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.50</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.60</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.80</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.50</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Share Price at Grant Date (A$)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.38</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.38</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.38</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.39</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Volatility</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">68</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">68</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">68</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">69</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Expected Life (years)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Risk Free Interest Rate</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.36</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.36</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.36</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.47</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Fair Value of Option (A$)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.15</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.13</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.11</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.13</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Stock option activity during the current period is as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number&#xA0;of&#xA0;shares</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted&#xA0;average<br /> exercise price</b><br /> <b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Balance at December&#xA0;31, 2017</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">22,003,215</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.63</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Granted</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.00</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Exercised</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(503,334</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.00</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Lapsed</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(5,124,431</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.70</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Balance at September&#xA0;30, 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">16,375,450</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.63</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The number of options exercisable as at September 30, 2018 and 2017 was 7,208,775 and 10,963,629, respectively. The total stock compensation expense recognized in the consolidated condensed statements of comprehensive income was A$51,182 and A$154,218 for the three months ended September 30, 2018 and 2017, respectively and A$228,224 and A$354,243 for the nine months ended September 30, 2018 and 2017, respectively.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> As of September 30, 2018, there was A$674,671 of unrecognized compensation expense related to unvested share-based compensation arrangements under the Employee Option Plan. This expense is expected to be recognized over the vesting years as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"><b>Fiscal Year</b></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">94,357</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2019</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">321,558</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2020</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">258,756</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">674,671</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The aggregate intrinsic value for all options outstanding as at September 30, 2018 and 2017 was zero.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>(b) Restricted Share Plan</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Our Employee Share Plan was adopted by the Board of Directors in 2009. The Employee Share Plan permits our Board to grant shares of our common stock to our employees and directors (although our Board has determined not to issue equity to <font style="WHITE-SPACE: nowrap">non-executive</font> directors). The number of shares able to be granted is limited to the amount permitted to be granted at law, the ASX Listing Rules and by the limits on our authorized share capital in our certificate of incorporation. All our employees are eligible for shares under the Employee Share Plan. The Company has in the past issued A$1,000 worth of restricted shares of common stock to employees of the Company but no more frequently than annually. The restricted shares have the same terms of issue as our existing shares of common stock but are not able to be traded until the earlier of three years from the date on which the shares are issued or the date the relevant employee ceases to be an employee of the Company or any of its associated group of companies.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 6px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt"> No restricted shares have been issued by the Company since January&#xA0;1, 2017.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Restricted stock awards activity during the current period is as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number&#xA0;of&#xA0;shares</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted&#xA0;average<br /> issue price</b><br /> <b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Balance at December&#xA0;31, 2017</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">492,749</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.31</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Granted</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.00</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Release of restricted shares</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(287,087</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.27</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Balance at September&#xA0;30, 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">205,662</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.31</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 177096693 176620235 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of the consolidated financial statements requires management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Significant items subject to such estimates and assumptions include the recognition of revenue, carrying amount of property, plant and equipment, deferred income taxes, asset retirement obligations, liabilities related to employee benefits, warrants and research and development tax incentive income. Actual results could differ from those estimates.</p> </div> 20000000 202899 20000000 228224 2836614 2048602 53420 500000 P12M P3M P7Y P3Y P2Y P3M <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b><i>Warrants</i></b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Pursuant to the Credit Agreement, UBI issued to the Lenders warrants entitling the holder to purchase up to an aggregate total of 4.5&#xA0;million shares of UBI&#x2019;s common stock in the form of CDIs at a price of A$1.00 per share (the &#x201C;Exercise Price&#x201D;), which represents a 117% premium over the closing price of UBI&#x2019;s common stock on December&#xA0;19, 2013. The warrants are immediately exercisable and have a term of seven years.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The warrants may be exercised at any time until December&#xA0;19, 2020, in whole or in part in minimum multiples of 500,000 shares of common stock. The holder of the warrants can pay the Exercise Price in cash or it has the right to pay all or a portion of the Exercise Price by making a cashless exercise, therefore reducing the number of shares of common stock the holder would otherwise be issued.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The warrant is subject to adjustments in the event of certain issuances by UBI, such as bonus issues, pro rata (rights) issues and reorganizations (e.g., consolidation, subdivision).</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The Company assessed that the warrants are not liabilities within scope of ASC <font style="white-space:nowrap"><font style="white-space:nowrap">480-10-25.</font></font> The warrants are legally detachable from the loan and separately exercisable and as such meet the definition of a freestanding derivative instrument pursuant to ASC 815.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> However, the scope exception in accordance with ASC <font style="white-space:nowrap"><font style="white-space:nowrap"><font style="white-space:nowrap">815-10-15-74</font></font></font> applies to warrants and it meets the requirements of ASC 815 that would be classified in stockholders&#x2019; equity. Therefore, the warrants were initially accounted for within stockholders&#x2019; equity, and subsequent changes in fair value will not be recorded. The fair value of the warrant was estimated using the Trinomial Lattice model.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The debt issuance costs were recorded as deferred issuance costs and are amortized as interest expense, using the effective interest method, over the term of the loan pursuant to ASC <font style="white-space:nowrap"><font style="white-space:nowrap"><font style="white-space:nowrap">835-30-35-2.</font></font></font></p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Research and development tax incentive income</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Research and development tax incentive income is recognized when there is reasonable assurance that the income will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The research and development tax incentive is one of the key elements of the Australian Government&#x2019;s support for Australia&#x2019;s innovation system and is supported by legislative law primarily in the form of the Australian Income Tax Assessment Act 1997 as long as eligibility criteria are met. Generally speaking, entities which are an R&amp;D entity involved in eligible R&amp;D activities may claim research and development tax incentive income as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="4%">&#xA0;</td> <td valign="top" width="4%" align="left">(1)</td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">as a 43.5% refundable tax offset if aggregate turnover (which generally means an entity&#x2019;s total income that it derives in the ordinary course of carrying on a business, subject to certain exclusions) of the entity is less than A$20&#xA0;million, or</p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="4%">&#xA0;</td> <td valign="top" width="4%" align="left">(2)</td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">as a 38.5% <font style="WHITE-SPACE: nowrap">non-refundable</font> tax offset if aggregate turnover of the entity is more than A$20&#xA0;million.</p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> In accordance with SEC Regulation <font style="WHITE-SPACE: nowrap">S-X</font> Article <font style="WHITE-SPACE: nowrap">5-03,</font> the Company&#x2019;s research and development tax incentive income has been recognized as <font style="WHITE-SPACE: nowrap">non-operating</font> income as it is not indicative of the core operating activities or revenue producing goals of the Company.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> Management has assessed the Company&#x2019;s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the tax incentive regime described above. At each period end management estimates the refundable tax offset available to the Company based on available information at the time. This estimate is also reviewed by external tax advisors on an annual basis.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> In the nine months ended September 30, 2018 and 2017, the aggregate turnover of the Company had exceeded A$20&#xA0;million and accordingly it was not eligible for a refundable tax offset. The Company was however eligible for the <font style="WHITE-SPACE: nowrap">non-refundable</font> tax offset. The eligible R&amp;D activities and expenditures are able to be claimed as part of the current year income tax computation and any amounts included as a tax asset will be subject to recognition rules under ASC 740 &#x201C;Income Taxes&#x201D;.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Australian Goods and Services Tax (GST) and Canadian Harmonized Sales Tax (HST)</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Revenues, expenses and assets are recognized net of the amount of associated GST and HST, unless the GST and HST incurred is not recoverable from the taxation authority. In this case it is recognized as part of the cost of acquisition of the asset or as part of the expense. Receivables and payables are stated inclusive of the amount of GST and HST receivable or payable. The net amount of GST and HST recoverable from, or payable to, the taxation authority is included with other receivables or payables in the consolidated condensed balance sheets.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Government grants</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> UBS was awarded a grant from the Commonwealth of Australia under the Next Generation Manufacturing Investment Programme up to a maximum grant amount of A$575,000 payable over a three year period commencing from January&#xA0;1, 2017. The grants are paid upon achievement of <font style="WHITE-SPACE: nowrap">pre-agreed</font> milestones. The milestones generally relate to UBS placing purchase orders, commissioning upgrades and validating the equipment. Amongst other reasons, the Commonwealth of Australia may terminate the grant agreement for breach of the agreement by UBS or for failure to undertake the required programme. Under these circumstances, the Commonwealth of Australia may require UBS to repay some or the entire grant. The Company continues to undertake the project funded by the Commonwealth of Australia.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> An amount of A$271,318 and A$89,500 were received under this grant in November 2017 and June 2018, respectively. In the event UBS had achieved milestones and received grant payments, it believes that the likelihood of being required to repay grant funding is remote because the Company continues to comply with the grant agreement.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Research and development expenses for the respective periods are as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="60%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Three Months Ended<br /> September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine Months Ended<br /> September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Research and development expenses</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,759,664</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,197,146</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">9,452,609</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7,626,210</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated condensed balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br /> September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Year Ended<br /> December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Cash and cash equivalents</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">28,531,432</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">26,259,918</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Restricted cash - current assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,915,949</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">15,309</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Restricted cash - <font style="WHITE-SPACE: nowrap">non-current</font> assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">320,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,220,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">31,767,381</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">29,495,227</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b><i>Patent and License Costs</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Legal and maintenance fees incurred for patent application costs have been charged to expense and reported in general and administrative expense.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Concentration of Credit Risk and Other Risks and Uncertainties</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Cash and cash equivalents and accounts receivable consist of financial instruments that potentially subject the Company to concentration of credit risk to the extent of the amount recorded on the consolidated condensed balance sheets. The Company&#x2019;s cash and cash equivalents are primarily invested with one of Australia&#x2019;s largest banks. The Company is exposed to credit risk in the event of default by the banks holding the cash or cash equivalents to the extent of the amount recorded on the consolidated condensed balance sheets. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company has not identified any collectability issues with respect to receivables.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b><i>Other Liabilities</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Other liabilities are broken down as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br /> September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Year Ended<br /> December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> <b>Current liabilites</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Marketing support payment</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,836,614</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,626,413</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,836,614</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,626,413</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Marketing Support Payment</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> During 2009, LifeScan chose not to proceed with the registration of the then current product but to proceed with an enhanced product, called OneTouch Verio<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">&#xAE;</sup>, and acknowledged that there would be a delay as a result. As a result of this change, LifeScan agreed to pay additional amounts per strip manufactured by the Company in 2010 and 2011 up to a specified volume limit (&#x201C;manufacturing initiation payments&#x201D;). At the same time, the Company agreed to pay LifeScan a marketing support payment in each of the two years following the first calendar year in which 1&#xA0;billion strips are sold by LifeScan equal to 40% of the total manufacturing initiation payments made. The first calendar year in which 1&#xA0;billion strips were sold by LifeScan was during the 2016 financial year. These amounts will be paid to LifeScan once supporting documentation has been provided to us. The total amount of marketing support payments to be paid to LifeScan in US$ once all the documentation is received is US$2,048,602 (equivalent to A$2,836,614).</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Clinical Trial Expenses</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Clinical trial costs are a component of research and development expenses. These expenses include fees paid to participating hospitals and other service providers, which conduct certain testing activities on behalf of the Company. Depending on the timing of payments to the service providers and the level of service provided, the Company records prepaid or accrued expenses relating to these costs.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> These prepaid or accrued expenses are based on estimates of the work performed under service agreements.</p> </div> 0.435 0.385 1 5124431 0.00 0.70 P3Y 0 0.00 503334 P10Y 0 0.00 287087 0.27 2017-01-01 P3Y 2013-12-19 2019-07-01 600000 2500000 P7Y 1.00 0.13 0.15 0.30 2019-07 1055534 1131319 644508 59593955 21716 P10Y 0.05 0.02 P3Y P12M 0.01 7 228224 0 0 -50 0 0 -36525 0 0 0 0 50 503334 0 41391958 0 0 P6Y 0.0247 0.13 0.69 300000 200000 271318 89500 369630 300000 P5Y 0.0236 0.13 0.68 P5Y 0.0236 0.11 0.68 P5Y 0.0236 0.15 0.68 0 2359443 P8Y 0.34 212377 0.21 1000000000 685613 -1185176 1253004 61873 636000 -0.01 -0.01 61873 1624974 -1180725 0 5092602 1922 15772 -609890 -1180725 -4451 0 -4451 5663437 -570835 3197146 6345606 176410144 176410144 205317 154218 12394 998674 1764855 254330 4580751 734946 41834205 403828 183395 451481 0.24 0.24 183395 1360040 41865596 0 46831197 0 175643 -385666 41865596 -31391 -9758 -31391 4579935 42251262 2759664 47235025 177329518 176859637 8750 51182 18500 186515 227649 217313 47007376 0001279695 us-gaap:ServiceMember 2018-07-01 2018-09-30 0001279695 us-gaap:ProductMember 2018-07-01 2018-09-30 0001279695 2018-07-01 2018-09-30 0001279695 us-gaap:ServiceMember 2017-07-01 2017-09-30 0001279695 us-gaap:ProductMember 2017-07-01 2017-09-30 0001279695 2017-07-01 2017-09-30 0001279695 2016-01-01 2016-12-31 0001279695 us-gaap:InternalRevenueServiceIRSMemberus-gaap:ScenarioPlanMember 2018-01-01 2018-12-31 0001279695 us-gaap:InternalRevenueServiceIRSMember 2017-01-01 2017-12-31 0001279695 2017-01-01 2017-12-31 0001279695 ubi:GrantDateOneMember 2017-10-01 2017-10-31 0001279695 ubi:GrantDateThirdMember 2017-10-01 2017-10-31 0001279695 ubi:GrantDateSecondMember 2017-10-01 2017-10-31 0001279695 2015-08-01 2015-08-31 0001279695 ubi:ElantisPremiumFundingLtdMember 2017-09-01 2017-09-30 0001279695 ubi:UniversalBiosensorsPtyLtdMember 2018-06-01 2018-06-30 0001279695 ubi:UniversalBiosensorsPtyLtdMember 2017-11-01 2017-11-30 0001279695 ubi:AthyriumCreditAgreementMember 2015-01-01 2015-01-30 0001279695 2015-01-31 2015-02-28 0001279695 ubi:GrantDateFourthMember 2017-02-01 2017-02-28 0001279695 us-gaap:RetainedEarningsMember 2018-01-01 2018-09-30 0001279695 us-gaap:CommonStockMember 2018-01-01 2018-09-30 0001279695 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-09-30 0001279695 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-09-30 0001279695 us-gaap:CollaborativeArrangementMember 2018-01-01 2018-09-30 0001279695 srt:MinimumMemberubi:DeferredProfitSharingPlanMember 2018-01-01 2018-09-30 0001279695 srt:MinimumMember 2018-01-01 2018-09-30 0001279695 srt:MaximumMemberubi:DeferredProfitSharingPlanMember 2018-01-01 2018-09-30 0001279695 srt:MaximumMemberubi:RegisteredRetirementSavingsPlanMember 2018-01-01 2018-09-30 0001279695 srt:MaximumMember 2018-01-01 2018-09-30 0001279695 ubi:ViburnumFundsPtyLtdMember 2018-01-01 2018-09-30 0001279695 us-gaap:ServiceMember 2018-01-01 2018-09-30 0001279695 us-gaap:ProductMember 2018-01-01 2018-09-30 0001279695 ubi:FinancialCovenantMemberubi:RestrictedCashNoncurrentAssetMember 2018-01-01 2018-09-30 0001279695 ubi:AthyriumCreditAgreementMember 2018-01-01 2018-09-30 0001279695 ubi:UniversalBiosensorsPtyLtdMember 2018-01-01 2018-09-30 0001279695 us-gaap:RestrictedStockMember 2018-01-01 2018-09-30 0001279695 srt:MaximumMemberus-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001279695 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001279695 2018-01-01 2018-09-30 0001279695 us-gaap:RetainedEarningsMember 2017-01-01 2017-09-30 0001279695 us-gaap:CommonStockMember 2017-01-01 2017-09-30 0001279695 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-09-30 0001279695 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-09-30 0001279695 us-gaap:ServiceMember 2017-01-01 2017-09-30 0001279695 us-gaap:ProductMember 2017-01-01 2017-09-30 0001279695 2017-01-01 2017-09-30 0001279695 srt:MinimumMemberubi:SpeedxMember 2011-09-10 2011-09-30 0001279695 srt:MaximumMemberubi:SpeedxMember 2011-09-10 2011-09-30 0001279695 ubi:SpeedxMember 2011-09-10 2011-09-30 0001279695 ubi:AthyriumCreditAgreementMemberubi:AmendmentMember 2017-12-29 2017-12-29 0001279695 ubi:AthyriumCreditAgreementMember 2013-12-19 2013-12-19 0001279695 us-gaap:RetainedEarningsMember 2018-09-30 0001279695 us-gaap:CommonStockMember 2018-09-30 0001279695 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0001279695 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001279695 us-gaap:CollaborativeArrangementMember 2018-09-30 0001279695 ubi:FinancialCovenantMember 2018-09-30 0001279695 ubi:CollateralMember 2018-09-30 0001279695 ubi:ViburnumFundsPtyLtdMember 2018-09-30 0001279695 ubi:ElantisPremiumFundingLtdMember 2018-09-30 0001279695 ubi:AthyriumCreditAgreementMemberubi:AmendmentMember 2018-09-30 0001279695 ubi:AthyriumCreditAgreementMember 2018-09-30 0001279695 ubi:UniversalBiosensorsPtyLtdMembersrt:MaximumMember 2018-09-30 0001279695 ubi:CollateralMemberubi:CommercialLeasesMemberubi:RestrictedCashNoncurrentAssetMember 2018-09-30 0001279695 ubi:CollateralMemberubi:HrlCreditCardMemberubi:RestrictedCashCurrentAssetMember 2018-09-30 0001279695 ubi:CollateralMemberus-gaap:CreditCardMemberubi:RestrictedCashNoncurrentAssetMember 2018-09-30 0001279695 us-gaap:RestrictedStockMember 2018-09-30 0001279695 us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember 2018-09-30 0001279695 us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember 2018-09-30 0001279695 us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember 2018-09-30 0001279695 us-gaap:EmployeeStockOptionMember 2018-09-30 0001279695 2018-09-30 0001279695 us-gaap:RetainedEarningsMember 2017-09-30 0001279695 us-gaap:CommonStockMember 2017-09-30 0001279695 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-09-30 0001279695 us-gaap:AdditionalPaidInCapitalMember 2017-09-30 0001279695 us-gaap:EmployeeStockOptionMember 2017-09-30 0001279695 2017-09-30 0001279695 2018-10-30 0001279695 us-gaap:RetainedEarningsMember 2017-12-31 0001279695 us-gaap:CommonStockMember 2017-12-31 0001279695 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001279695 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001279695 ubi:FinancialCovenantMember 2017-12-31 0001279695 ubi:CollateralMember 2017-12-31 0001279695 us-gaap:InternalRevenueServiceIRSMember 2017-12-31 0001279695 ubi:HemostasisReferenceLaboratoryINCMemberus-gaap:CanadaRevenueAgencyMember 2017-12-31 0001279695 us-gaap:RestrictedStockMember 2017-12-31 0001279695 us-gaap:EmployeeStockOptionMember 2017-12-31 0001279695 2017-12-31 0001279695 ubi:GrantDateOneMember 2017-10-31 0001279695 ubi:GrantDateThirdMember 2017-10-31 0001279695 ubi:GrantDateSecondMember 2017-10-31 0001279695 ubi:GrantDateFourthMember 2017-02-28 0001279695 us-gaap:RetainedEarningsMember 2016-12-31 0001279695 us-gaap:CommonStockMember 2016-12-31 0001279695 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0001279695 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001279695 us-gaap:InternalRevenueServiceIRSMember 2016-12-31 0001279695 ubi:ElantisPremiumFundingLtdMember 2016-12-31 0001279695 ubi:HemostasisReferenceLaboratoryINCMemberus-gaap:CanadaRevenueAgencyMember 2016-12-31 0001279695 2016-12-31 0001279695 ubi:AthyriumCreditAgreementMember 2013-12-31 0001279695 ubi:AthyriumCreditAgreementMember 2013-12-19 0001279695 2013-12-19 0001279695 us-gaap:CollaborativeArrangementMember 2011-09-09 iso4217:AUD iso4217:USD iso4217:AUD shares shares pure iso4217:CAD iso4217:USD shares ubi:Strips ubi:Milestone ubi:Payments EX-101.SCH 6 ubi-20180930.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Consolidated Condensed Balance Sheets (Unaudited) link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Consolidated Condensed Balance Sheets (Unaudited) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Consolidated Condensed Statements of Comprehensive Income/(Loss) (Unaudited) link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Consolidated Condensed Statements of Changes in Stockholders' Equity and Comprehensive Income/(Loss) (Unaudited) link:calculationLink link:presentationLink link:definitionLink 107 - Statement - Consolidated Condensed Statements of Cash Flows (Unaudited) link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Organization of the Company link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Interim Financial Statements link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Borrowings link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Warrants link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Restricted Cash link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Summary of Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Borrowings (Tables) link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Restricted Cash (Tables) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Basis of Presentation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Summary of Significant Accounting Policies - Inventory, Net (Detail) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Summary of Significant Accounting Policies - Summary of Receivables (Detail) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Summary of Significant Accounting Policies - Other Liabilities (Detail) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Summary of Significant Accounting Policies - Research and Development Expenses (Detail) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Summary of Significant Accounting Policies - Assumptions for Option Grants Issued (Detail) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Summary of Significant Accounting Policies - Stock Option Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Summary of Significant Accounting Policies - Unrecognized Compensation Expense Related to Unvested Share-Based Compensation Arrangements Expected to be Recognized (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Summary of Significant Accounting Policies - Restricted Stock Awards Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Summary of Significant Accounting Policies - Effects of Allocated Tax to Each Component of Other Comprehensive Loss (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Related Party Transactions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Borrowings - Future Maturities, Interest and Other Payments under Company's Long Term Secured Loan Pursuant to Credit Agreement (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Borrowings - Future Maturities, Interest and Other Payments under Company's Long Term Secured Loan Pursuant to Credit Agreement (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Borrowings - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Warrants - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Restricted Cash - Reconciliation of Cash and Cash Equivalent and Restricted Cash (Detail) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Restricted Cash - Restricted Cash Maintained by the Company in the Form of Term Deposits (Detail) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Restricted Cash - Restricted Cash Maintained by the Company in the Form of Term Deposits (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - Restricted Cash - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 140 - Disclosure - Borrowings - Future Maturities, Interest and Other Payments under Company's Long Term Secured Loan Pursuant to Credit Agreement (Detail) (Alternate 1) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 ubi-20180930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 ubi-20180930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 ubi-20180930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 10 ubi-20180930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.10.0.1
Document and Entity Information - shares
9 Months Ended
Sep. 30, 2018
Oct. 30, 2018
Document And Entity Information [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Sep. 30, 2018  
Document Fiscal Year Focus 2018  
Document Fiscal Period Focus Q3  
Trading Symbol UBI  
Entity Registrant Name UNIVERSAL BIOSENSORS INC  
Entity Central Index Key 0001279695  
Current Fiscal Year End Date --12-31  
Entity Filer Category Non-accelerated Filer  
Entity Common Stock, Shares Outstanding   177,001,884
Entity Emerging Growth Company true  
Entity Small Business true  
Entity Ex Transition Period false  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Condensed Balance Sheets (Unaudited)
Sep. 30, 2018
AUD ($)
Dec. 31, 2017
AUD ($)
Current assets:    
Cash and cash equivalents $ 28,531,432 $ 26,259,918
Inventories, net 481,282 662,132
Accounts receivable 4,902,417 4,397,268
Prepayments 665,312 887,303
Restricted cash 2,915,949 15,309
Other current assets 43,331,479 860,254
Total current assets 80,827,871 33,082,184
Non-current assets:    
Property, plant and equipment 37,359,123 37,224,442
Less accumulated depreciation (28,790,321) (27,264,680)
Property, plant and equipment - net 8,568,802 9,959,762
Restricted cash 320,000 3,220,000
Total non-current assets 8,888,802 13,179,762
Total assets 89,716,673 46,261,946
Current liabilities:    
Accounts payable 472,930 329,586
Accrued expenses 1,643,828 1,472,692
Short term secured loan 20,660,753 0
Other liabilities 2,836,614 2,626,413
Deferred revenue 2,356,583 2,356,583
Employee entitlements liabilities 1,278,714 1,550,182
Total current liabilities 29,249,422 8,335,456
Non-current liabilities:    
Asset retirement obligations 2,600,000 2,600,000
Employee entitlements liabilities 50,538 64,358
Long term secured loan 0 19,029,076
Deferred revenue 3,463,737 3,463,737
Total non-current liabilities 6,114,275 25,157,171
Total liabilities 35,363,697 33,492,627
Commitments and contingencies 0 0
Stockholders' equity:    
Preferred stock, US$0.01 par value. Authorized 1,000,000 shares; issued and outstanding nil at September 30, 2018 (nil at December 31, 2017)
Common stock, US$0.0001 par value. Authorized 300,000,000 shares; issued and outstanding 177,001,884 shares at September 30, 2018 (176,498,550 at December 31, 2017) 17,700 17,650
Additional paid-in capital 93,678,895 93,450,721
Accumulated deficit (80,397,343) (79,632,626)
Current year income/(loss) 41,391,958 (764,717)
Accumulated other comprehensive loss (338,234) (301,709)
Total stockholders' equity 54,352,976 12,769,319
Total liabilities and stockholders' equity $ 89,716,673 $ 46,261,946
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Sep. 30, 2018
Dec. 31, 2017
Statement of Financial Position [Abstract]    
Preferred stock, par value $ 0.01 $ 0.01
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 300,000,000 300,000,000
Common stock, shares issued 177,001,884 176,498,550
Common stock, shares outstanding 177,001,884 176,498,550
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Condensed Statements of Comprehensive Income/(Loss) (Unaudited) - AUD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Revenue        
Total revenue $ 47,235,025 $ 6,345,606 $ 60,725,274 $ 20,672,957
Operating costs & expenses        
Total cost of goods sold & services 403,828 1,253,004 1,700,042 3,650,943
Contribution from products & services 46,831,197 5,092,602 59,025,232 17,022,014
Other operating costs & expenses        
Product support 8,750 205,317 202,899 537,010
Depreciation 451,481 636,000 1,519,375 1,485,014
Research and development 2,759,664 3,197,146 9,452,609 7,626,210
General and administrative 1,360,040 1,624,974 5,110,134 4,855,136
Total operating costs & expenses 4,579,935 5,663,437 16,285,017 14,503,370
Profit/(loss) from operations 42,251,262 (570,835) 42,740,215 2,518,644
Other income/(expense)        
Interest income 175,643 15,772 365,542 74,625
Interest expense 0 (1,922) 0 (8,649)
Financing costs (734,946) (685,613) (2,118,069) (2,089,328)
Exchange gain 183,395 61,873 412,768 703,420
Other (9,758) 0 (8,498) 119,932
Total other income/(expense) (385,666) (609,890) (1,348,257) (1,200,000)
Net income/(loss) before tax 41,865,596 (1,180,725) 41,391,958 1,318,644
Income tax benefit/(expense) 0 0 0 0
Net income/( loss) $ 41,865,596 $ (1,180,725) $ 41,391,958 $ 1,318,644
Earnings per share        
Basic net income/(loss) per share $ 0.24 $ (0.01) $ 0.23 $ 0.01
Average weighted number of shares-basic 176,859,637 176,410,144 176,620,235 176,395,711
Diluted net income/(loss) per share $ 0.24 $ (0.01) $ 0.23 $ 0.01
Average weighted number of shares-diluted 177,329,518 176,410,144 177,096,693 177,602,842
Other comprehensive gain/(loss), net of tax:        
Foreign currency translation reserve $ (31,391) $ (4,451) $ (36,525) $ (5,497)
Other comprehensive gain/(loss) (31,391) (4,451) (36,525) (5,497)
Comprehensive gain/(loss) 41,834,205 (1,185,176) 41,355,433 1,313,147
Product [Member]        
Revenue        
Total revenue 227,649 1,764,855 1,131,319 4,062,470
Operating costs & expenses        
Total cost of goods sold & services 186,515 998,674 1,055,534 2,913,808
Service [Member]        
Revenue        
Total revenue 47,007,376 4,580,751 59,593,955 16,610,487
Operating costs & expenses        
Total cost of goods sold & services $ 217,313 $ 254,330 $ 644,508 $ 737,135
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Condensed Statements of Changes in Stockholders' Equity and Comprehensive Income/(Loss) (Unaudited) - AUD ($)
Total
Ordinary Shares [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Accumulated Other Comprehensive Loss [Member]
Beginning Balance at Dec. 31, 2016 $ 13,254,275 $ 17,639 $ 93,167,465 $ (79,632,626) $ (298,203)
Beginning Balance, Shares at Dec. 31, 2016   176,386,884      
Net income 1,318,644 $ 0 0 1,318,644 0
Exercise of stock options issued to employees 766 $ 4 762 0 0
Exercise of stock options issued to employees, Shares   44,999      
Other comprehensive loss (5,497) $ 0 0 0 (5,497)
Stock option expense 354,243 0 354,243 0 0
Ending Balance at Sep. 30, 2017 14,922,431 $ 17,643 93,522,470 (78,313,982) (303,700)
Ending Balance, Shares at Sep. 30, 2017   176,431,883      
Beginning Balance at Dec. 31, 2017 12,769,319 $ 17,650 93,450,721 (80,397,343) (301,709)
Beginning Balance, Shares at Dec. 31, 2017   176,498,550      
Net income 41,391,958 $ 0 0 41,391,958 0
Exercise of stock options issued to employees 0 $ 50 (50) 0 0
Exercise of stock options issued to employees, Shares   503,334      
Other comprehensive loss (36,525) $ 0 0 0 (36,525)
Stock option expense 228,224 0 228,224 0 0
Ending Balance at Sep. 30, 2018 $ 54,352,976 $ 17,700 $ 93,678,895 $ (39,005,385) $ (338,234)
Ending Balance, Shares at Sep. 30, 2018   177,001,884      
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Condensed Statements of Cash Flows (Unaudited) - AUD ($)
9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Cash flows from operating activities:    
Net income $ 41,391,958 $ 1,318,644
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 1,680,323 1,929,451
Share based payments expense 228,224 354,243
Loss on fixed assets disposal 8,498 2,409
Unrealized foreign exchange gains (442,639) (159,889)
Financing costs-amortization of warrants 104,096 158,672
Change in assets and liabilities:    
Inventory 180,850 196,982
Accounts receivables (505,149) (949,175)
Prepaid expenses and other current assets (42,249,234) 90,616
Deferred revenue 0 (546,655)
Employee entitlements (321,814) 105,655
Accounts payable and accrued expenses 789,318 (314,914)
Net cash provided by operating activities 864,431 2,186,039
Cash flows from investing activities:    
Proceeds from sale of property, plant and equipment 2,582 0
Purchases of property, plant and equipment (308,669) (997,503)
Net cash used in investing activities (306,087) (997,503)
Cash flows from financing activities:    
Repayment of borrowings (256,410) (334,811)
Proceeds from stock options exercised 0 767
Net cash used in financing activities (256,410) (334,044)
Net increase in cash, cash equivalents and restricted cash 301,934 854,492
Cash, cash equivalents and restricted cash at beginning of period 29,495,227 23,622,322
Effect of exchange rate fluctuations on the balances of cash held in foreign currencies 1,970,220 (1,409,047)
Cash, cash equivalents and restricted cash at end of period $ 31,767,381 $ 23,067,767
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
Organization of the Company
9 Months Ended
Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization of the Company

Organization of the Company

We are a specialist medical diagnostics company focused primarily on the research, development and manufacture of in vitro diagnostic test devices for consumer and professional point-of-care use. In addition, we own, manage and operate a hemostasis laboratory.

Key aspects of our strategy for increasing shareholder value include:

 

   

executing on our existing business activities, including undertaking research and development activities for our customers and partners, manufacturing products (test strips and analyzers) and providing development and support services including providing laboratory services, to our customers and partners;

 

   

extending and demonstrating the broader application of our technology and seeking to enter into collaborative, strategic or distribution arrangements with other life sciences companies or other industry participants with respect to specific tests or specific fields;

 

   

participating in healthcare markets across the globe; and

 

   

identifying and pursuing related opportunities for growth.

Our plan of operations over the remainder of the fiscal year ending December 2018 is to:

 

   

manufacture products;

 

   

undertake research and development work;

 

   

provide the necessary post-market support for our customers and partners;

 

   

provide laboratory services for our customers and partners;

 

   

demonstrate the broader application of our technology platform for markets with significant commercial potential; and

 

   

seek to enter into collaborative, strategic or distribution arrangements with other life sciences companies or other industry participants with respect to the development and commercialization of specific tests or specific fields.

The Company’s first global strategic partnership was established with LifeScan, Inc. (“LifeScan”) in diabetes care. We have developed a blood glucose product with LifeScan (“OneTouch Verio®”) which is now available in countries that represent over 90% of the world self-monitoring blood glucose market. Unless otherwise noted, references to “LifeScan” in this document are references collectively or individually to LifeScan, Inc., and/or LifeScan Europe, a division of Cilag GmbH International, both affiliates of Johnson and Johnson. During the current quarter, LifeScan gave notice and exercised its right to “convert” its obligation to pay quarterly service fees to Universal Biosensors.

We are working with Siemens Healthcare Diagnostics, Inc. (“Siemens”) in relation to a range of products for the point-of-care coagulation testing market, pursuant to a Collaboration Agreement with Siemens (“Collaboration Agreement”). The first such product developed with Siemens, the Xprecia Stride™ Coagulation Analyzer, is now available in the United States, Europe, the Middle East, Africa, Asia Pacific, Latin America and Canada. Under the terms of a supply agreement with Siemens (“Supply Agreement”), UBS is the manufacturer of test strips for this product and further tests still in development for Siemens.

In addition, UBS is engaged in point-of-care coagulation product development for the consumer, home testing market which could be distributed globally on its own account.

XML 18 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
Interim Financial Statements
9 Months Ended
Sep. 30, 2018
Quarterly Financial Information Disclosure [Abstract]  
Interim Financial Statements

Interim Financial Statements

The accompanying unaudited consolidated condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and with the instructions to Form 10-Q and Article 10 of Regulation S-X for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the nine months ended September 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018. The accompanying unaudited consolidated condensed financial statements should be read in conjunction with the financial statements and footnotes thereto as of and for the year ended December 31, 2017, included in the Annual Report on Form 10-K of Universal Biosensors, Inc. filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 23, 2018 (the “Annual Report”).

 

 

The year-end consolidated condensed balance sheets data as at December 31, 2017 was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain prior year amounts in the consolidated condensed financial statements have been reclassified to conform to the current presentation.

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1
Basis of Presentation
9 Months Ended
Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation

Basis of Presentation

The Company’s consolidated condensed financial statements have been prepared assuming the Company will continue as a going concern. We rely largely on our existing cash and cash equivalents balance and operating cash flow to provide for the working capital needs of our operations. We believe we have sufficient cash and cash equivalents to fund our operations for at least the next twelve months. However, in the event our financing needs for the foreseeable future are not able to be met by our existing cash and cash equivalents balance and operating cash flow, we would seek to raise funds through public or private equity offerings, debt financings, and through other means to meet the financing requirements. There is no assurance that funding would be available at acceptable terms, if at all.

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies
9 Months Ended
Sep. 30, 2018
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

Principles of Consolidation

The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries, UBS and HRL. All intercompany balances and transactions have been eliminated on consolidation.

Use of Estimates

The preparation of the consolidated financial statements requires management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Significant items subject to such estimates and assumptions include the recognition of revenue, carrying amount of property, plant and equipment, deferred income taxes, asset retirement obligations, liabilities related to employee benefits, warrants and research and development tax incentive income. Actual results could differ from those estimates.

Cash, Cash Equivalents and Restricted Cash

The Company considers all highly liquid investments purchased with an initial maturity of three months or less to be cash equivalents. For cash and cash equivalents, the carrying amount approximates fair value due to the short maturity of those instruments. The Company maintains cash and restricted cash, which includes tenant security deposits, credit card security deposits and cash collateral for its borrowings. As of September 30, 2018, the Company has not realized any losses in such cash accounts and believes it is not exposed to any significant risk of loss.

Short-Term Investments (Held-to-maturity)

Short-term investments constitute all highly liquid investments with term to maturity from three months to twelve months. The carrying amount of short-term investments is equivalent to their fair value.

Concentration of Credit Risk and Other Risks and Uncertainties

Cash and cash equivalents and accounts receivable consist of financial instruments that potentially subject the Company to concentration of credit risk to the extent of the amount recorded on the consolidated condensed balance sheets. The Company’s cash and cash equivalents are primarily invested with one of Australia’s largest banks. The Company is exposed to credit risk in the event of default by the banks holding the cash or cash equivalents to the extent of the amount recorded on the consolidated condensed balance sheets. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company has not identified any collectability issues with respect to receivables.

 

Derivative Instruments and Hedging Activities

Derivative financial instruments

The Company may use derivative financial instruments to hedge its exposure to foreign exchange arising from operating, investing and financing activities. The Company does not hold or issue derivative financial instruments for trading purposes. However, derivatives that do not qualify for hedge accounting are accounted for as trading instruments.

Derivative financial instruments are recognized initially at fair value. Subsequent to initial recognition, derivative financial instruments are stated at fair value. The gain or loss on remeasurement to fair value is recognized immediately in the income statement. However, where derivatives qualify for hedge accounting, recognition of any resultant gain or loss depends on the nature of the item being hedged.

Cash flow hedges

Exposure to foreign exchange risks arises in the normal course of the Company’s business and it is the Company’s policy to use forward exchange contracts to hedge anticipated sales and purchases in foreign currencies. The amount of forward cover taken is in accordance with approved policy and internal forecasts.

Where a derivative financial instrument is designated as a hedge of the variability in cash flows of a recognized asset or liability, or a highly probable forecast transaction, the effective part of any unrealized gain or loss on the derivative financial instrument is recognized directly in equity. When the forecast transaction subsequently results in the recognition of a non-financial asset or non-financial liability, the associated cumulative gain or loss is removed from equity and included in the initial cost or other carrying amount of the non-financial asset or liability.

For cash flow hedges, other than those covered by the preceding statement, the associated cumulative gain or loss is removed from equity and recognized in the consolidated condensed statements of comprehensive income in the same period or periods during which the hedged forecast transaction affects the consolidated condensed statements of comprehensive income and on the same line item as that hedged forecast transaction. The ineffective part of any gain or loss is recognized immediately in the consolidated condensed statements of comprehensive income.

When a hedging instrument expires or is sold, terminated or exercised, or the Company revokes designation of the hedge relationship but the hedged forecast transaction is still probable to occur, the cumulative gain or loss at that point remains in equity and is recognized in accordance with the above policy when the transaction occurs. If the hedged transaction is no longer expected to take place, then the cumulative unrealized gain or loss recognized in equity is recognized immediately in the consolidated condensed statements of comprehensive income.

Derivative Instruments and Hedging Activities

In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as consider our own and counterparty credit risk. For periods ended September 30, 2018 and December 31, 2017, we did not have any assets or liabilities that utilize Level 3 inputs. The valuation of our foreign exchange derivatives are based on the market approach using observable market inputs, such as forward rates and incorporate non-performance risk (the credit standing of the counterparty when the derivative is in a net asset position, and the credit standing of the Company when the derivative is in a net liability position). Our derivative assets are categorized as Level 2. The fair value methodologies described as Level 2 and 3 inputs are defined elsewhere in these notes to the consolidated condensed financial statements.

 

Fair Value of Financial Instruments

The carrying value of all current assets and current liabilities approximates fair value because of their short-term nature. The estimated fair value of all other amounts has been determined, depending on the nature and complexity of the assets or the liability, by using one or all of the following approaches:

 

   

Market approach – based on market prices and other information from market transactions involving identical or comparable assets or liabilities.

 

   

Cost approach – based on the cost to acquire or construct comparable assets less an allowance for functional and/or economic obsolescence.

 

   

Income approach – based on the present value of a future stream of net cash flows.

These fair value methodologies depend on the following types of inputs:

 

   

Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).

 

   

Quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in markets that are not active or are directly or indirectly observable (Level 2 inputs).

 

   

Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).

Inventory

Inventories are stated at the lower of cost or net realizable value. Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and estimated costs necessary to dispose. Inventories are principally determined under the average cost method which approximates cost. Cost comprises direct materials, direct labour and an appropriate portion of variable and fixed overhead expenditure, the latter being allocated on the basis of normal operating capacity. Cost also includes the transfer from equity of any gains/losses on qualifying cash flow hedges relating to purchases of raw material. Costs of purchased inventory are determined after deducting rebates and discounts.

 

     Nine Months Ended
September 30,
     Year Ended
December 31,
 
     2018      2017  
     A$      A$  

Raw materials

     322,399        380,540  

Work in progress

     158,883        253,483  

Finished goods

     0        28,109  
  

 

 

    

 

 

 
     481,282        662,132  
  

 

 

    

 

 

 

Receivables

Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the best estimate of the amount of probable credit losses in the existing accounts receivable. The allowance is determined based on a review of individual accounts for collectability, generally focusing on those accounts that are past due. The expense to adjust the allowance for doubtful accounts, if any, is recorded within general and administrative expenses in the consolidated condensed statements of comprehensive income. Account balances are charged against the allowance when it is probable the receivable will not be recovered.

 

     Nine Months Ended
September 30,
     Year Ended
December 31,
 
     2018      2017  
     A$      A$  

Accounts receivable

     4,902,417        4,397,268  

Allowance for doubtful debts

     0        0  
  

 

 

    

 

 

 
     4,902,417        4,397,268  
  

 

 

    

 

 

 

Property, Plant, and Equipment—net

Property, plant, and equipment are recorded at acquisition cost, less accumulated depreciation.

Depreciation on plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful life of machinery and equipment is 3 to 10 years. Leasehold improvements are amortized on the straight-line method over the shorter of the remaining lease term or estimated useful life of the asset. Maintenance and repairs are charged to operations as incurred, include normal services, and do not include items of a capital nature.

The Company receives Commonwealth of Australia grant monies under grant agreements to support its development activities (refer section on “Government Grants”), including in connection with the purchase of plant and equipment. Plant and equipment is presented net of the government grant. The grant monies are recognized against the acquisition costs of the related plant and equipment as and when the related assets are purchased.

Impairment of Long-Lived Assets

The Company reviews its capital assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. In performing the review, the Company estimates undiscounted cash flows from products under development that are covered by these patents and licenses. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition is less than the carrying amount of the asset. If the evaluation indicates that the carrying value of an asset is not recoverable from its undiscounted cash flows, an impairment loss is measured by comparing the carrying value of the asset to its fair value, based on discounted cash flows. Impairment of long-lived-assets as at September 30, 2018 was nil (December 31, 2017: nil).

Government grants

UBS was awarded a grant from the Commonwealth of Australia under the Next Generation Manufacturing Investment Programme up to a maximum grant amount of A$575,000 payable over a three year period commencing from January 1, 2017. The grants are paid upon achievement of pre-agreed milestones. The milestones generally relate to UBS placing purchase orders, commissioning upgrades and validating the equipment. Amongst other reasons, the Commonwealth of Australia may terminate the grant agreement for breach of the agreement by UBS or for failure to undertake the required programme. Under these circumstances, the Commonwealth of Australia may require UBS to repay some or the entire grant. The Company continues to undertake the project funded by the Commonwealth of Australia.

An amount of A$271,318 and A$89,500 were received under this grant in November 2017 and June 2018, respectively. In the event UBS had achieved milestones and received grant payments, it believes that the likelihood of being required to repay grant funding is remote because the Company continues to comply with the grant agreement.

 

Other Liabilities

Other liabilities are broken down as follows:

 

     Nine Months Ended
September 30,
     Year Ended
December 31,
 
     2018      2017  
     A$      A$  

Current liabilites

     

Marketing support payment

     2,836,614        2,626,413  
  

 

 

    

 

 

 
     2,836,614        2,626,413  
  

 

 

    

 

 

 

Marketing Support Payment

During 2009, LifeScan chose not to proceed with the registration of the then current product but to proceed with an enhanced product, called OneTouch Verio®, and acknowledged that there would be a delay as a result. As a result of this change, LifeScan agreed to pay additional amounts per strip manufactured by the Company in 2010 and 2011 up to a specified volume limit (“manufacturing initiation payments”). At the same time, the Company agreed to pay LifeScan a marketing support payment in each of the two years following the first calendar year in which 1 billion strips are sold by LifeScan equal to 40% of the total manufacturing initiation payments made. The first calendar year in which 1 billion strips were sold by LifeScan was during the 2016 financial year. These amounts will be paid to LifeScan once supporting documentation has been provided to us. The total amount of marketing support payments to be paid to LifeScan in US$ once all the documentation is received is US$2,048,602 (equivalent to A$2,836,614).

Research and Development

Research and development expenses consist of costs incurred to further the Group’s research and product development activities and include salaries and related employee benefits, costs associated with clinical trial and preclinical development, regulatory activities, research-related overhead expenses, costs associated with the manufacture of clinical trial material, costs associated with developing a commercial manufacturing process, costs for consultants and related contract research, facility costs and depreciation. Research and development costs are expensed as incurred.

Research and development expenses for the respective periods are as follows:

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2018      2017      2018      2017  
     A$      A$      A$      A$  

Research and development expenses

     2,759,664        3,197,146        9,452,609        7,626,210  
  

 

 

    

 

 

    

 

 

    

 

 

 

Income Taxes

The Company applies ASC 740—Income Taxes which establishes financial accounting and reporting standards for the effects of income taxes that result from a company’s activities during the current and preceding years. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Where it is more likely than not that some portion or all of the deferred tax assets will not be realized, the deferred tax assets are reduced by a valuation allowance. The valuation allowance is sufficient to reduce the deferred tax assets to the amount that is more likely than not to be realized.

 

The recent U.S. Federal Tax Reform has established a mandatory repatriation of foreign accumulated undistributed earnings and profits (the “E&Ps”) for U.S. companies’ subsidiaries. In the past, none of these E&Ps’ were repatriated since such E&Ps’ were considered to be reinvested indefinitely in the foreign location. The E&Ps’ provisions are applicable to our Company commencing with our fiscal year 2018, however the E&Ps’ mandatory repatriation provisions establishes measurement dates for various computations. In our Company’s case this date is December 31, 2017. The Company’s estimated tax for the mandatory repatriation is estimated to be nil. However, the final tax due must be assessed with our December 31, 2018 closing figures. Any such tax liability may be paid over a period of eight years starting on February 28, 2019. As of the issuance date of this report, the U.S. Securities and Exchange Commission and the Financial Accounting Standards Board have issued some preliminary guidance, but have not issued final rules on how the effects of the U.S. Federal Tax Reform will be required to be reported for financial statements purposes.

At December 31, 2017 the Company has A$10,993,737 (A$22,616,230 at December 31, 2016) of accumulated tax losses available for carry forward against future earnings, which under Australian tax laws do not expire but may not be available under certain circumstances. The Company also has A$11,048,336 (A$5,800,672 at December 31, 2016) of non-refundable R&D tax offset as at December 31, 2017. The R&D Tax offset is a non-refundable tax offset, which assists to reduce a company’s tax liability. Once the liability has been reduced to zero, any excess offset may be carried forward into future income years. UBI has U.S. tax losses available for carry forward against future earnings of US$1,011,321 as of December 31, 2017 and 2016. Pursuant to the U.S. Federal Tax Reform, the effective tax rate of UBI has been reduced from 34% to 21%. The deferred tax benefit based on this new rate for UBI is US$212,377. HRL has Canadian tax losses available for carry forward against future earnings of CAD$668,043 and CAD$95,096 as at December 31, 2017 and 2016, respectively.

We are subject to income taxes in the United States, Canada and Australia. Tax returns up to and including the 2017 financial year have been filed in all these jurisdictions.

Asset Retirement Obligations

Asset retirement obligations (“ARO”) are legal obligations associated with the retirement and removal of long-lived assets. ASC 410 – Asset Retirement and Environmental Obligations requires entities to record the fair value of a liability for an asset retirement obligation when it is incurred. When the liability is initially recorded, the Company capitalizes the cost by increasing the carrying amounts of the related property, plant and equipment. Over time, the liability increases for the change in its present value, while the capitalized cost depreciates over the useful life of the asset. The Company derecognizes ARO liabilities when the related obligations are settled.

The ARO is in relation to our premises where in accordance with the terms of the lease, the lessee has to restore part of the building upon vacating the premises.

ARO for the years ended September 30, 2018 and December 31, 2017 was A$2,600,000.

Australian Goods and Services Tax (GST) and Canadian Harmonized Sales Tax (HST)

Revenues, expenses and assets are recognized net of the amount of associated GST and HST, unless the GST and HST incurred is not recoverable from the taxation authority. In this case it is recognized as part of the cost of acquisition of the asset or as part of the expense. Receivables and payables are stated inclusive of the amount of GST and HST receivable or payable. The net amount of GST and HST recoverable from, or payable to, the taxation authority is included with other receivables or payables in the consolidated condensed balance sheets.

Revenue Recognition

We recognize revenue from all sources based on the provisions of the U.S. SEC’s Staff Accounting Bulletin No. 104 and ASC 605 Revenue Recognition.

The Company’s revenue represents revenue from sales of products, provision of services and collaborative research and development agreements.

We recognize revenue from sales of products at the time title of goods passes to the buyer and the buyer assumes the risks and rewards of ownership, assuming all other revenue recognition criteria have been met. Generally, this is at the time products are shipped to the customer.

 

Revenue from services is recognized when a persuasive evidence of an arrangement exists, services have been rendered, the price is fixed or determinable, and collectability is reasonably assured. Revenue recognition principles are assessed for each new contractual arrangement and the appropriate accounting is determined for each service.

On September 21, 2018 LifeScan exercised its right to convert its obligation to pay quarterly service fees to us. We expect the lump sum service fees to be paid to Universal Biosensors on or before February 15, 2019. We estimate the lump sum service fee using the most expected value approach based on (i) actual quarterly service fees received this financial year, (ii) estimating the quarterly service fees for the remainder of the year based on the trend seen in prior years, and (iii) multiplying the total quarterly service fees expected to be received this financial year by two and converting the same into AUD using the period end exchange rate. We assessed if any amount of the lump sum service fees were attributable to the remaining obligation under the Master Services and Supply Agreement that states that LifeScan could require us to provide manufacturing services at our Rowville facility to recommence production of glucose strips. We conclude that this obligation has no fair value attributable to it due to (i) high set-up costs to recommence manufacturing, (ii) the required lead time to gain regulatory compliance, and (iii) the fact there is deemed to be no commercial rationale for LifeScan to request us to recommence glucose-strip manufacturing on the basis of current information. As such, the lump sum service fee revenue has been fully recognized this quarter and no revenue has been deferred.

Where our agreements contain multiple elements, or deliverables, such as the manufacture and sale of products, provision of services or research and development activities, they are assessed to determine whether separate delivery of the individual elements of such arrangements comprises more than one unit of accounting. Where an arrangement can be divided into separate units of accounting (each unit constituting a separate earnings process), the arrangement consideration is allocated amongst those varying units based on the relative selling price of the separate units of accounting and the applicable revenue recognition criteria applied to the separate units. Selling prices are determined using fair value as determined by either vendor specific objective evidence or third party evidence of the selling price, when available, or the Company’s best estimate of selling price when fair value is not available for a given unit of accounting.

Under ASC 605-25, the delivered item(s) are separate units of accounting, provided (i) the delivered item(s) have value to a customer on a stand-alone basis, and (ii) if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item(s) is considered probable and substantially in our control. Where the arrangement cannot be divided into separate units, the individual deliverables are combined as a single unit of accounting and the total arrangement consideration is recognized across other deliverables in the arrangement or over the estimated collaboration period. Payments under these arrangements typically include one or more of the following: non-refundable, upfront payments; funding of research and/or development efforts; and milestone payments.

We typically generate milestone payments from our customers pursuant to the various agreements we have with them. Non-refundable milestone payments which represent the achievement of a significant technical/regulatory hurdle in the research and development process pursuant to collaborative agreements, and are deemed to be substantive, are recognized as revenue upon the achievement of the specified milestone. If the non-refundable milestone payment is not substantive or stand-alone value, the non-refundable milestone payment is deferred and recognized as revenue either over the estimated performance period stipulated in the agreement or across other deliverables in the arrangement.

Management has concluded that the core operations of the Company are expected to be research and development activities, commercial manufacture of approved medical or testing devices and the provision of services. The Company’s ultimate goal is to utilize the underlying technology and skill base for the development of marketable products that the Company will manufacture. The Company considers revenue from the sales of products, revenue from services and the income received from milestone payments indicative of its core operating activities or revenue producing goals of the Company, and as such have accounted for this income as “revenues”.

Master Services and Supply Agreement

In October 2007, the Company and LifeScan entered into a Master Services and Supply Agreement, under which the Company would provide certain services to LifeScan in the field of blood glucose monitoring and act as a non-exclusive manufacturer of blood glucose test strips. The Master Services and Supply Agreement was subsequently amended and restated in May 2009. The Company has concluded the Master Services and Supply Agreement should be accounted for as three separate units of accounting: 1) research and development to assist LifeScan in receiving regulatory clearance to sell the blood glucose product (milestone payment), 2) contract manufacturing of the blood glucose test strips (contract manufacturing) which ceased in December 2013, and 3) ongoing services and efforts to enhance the product (product enhancement).

 

All consideration within the Master Services and Supply Agreement is contingent. The Company concluded the undelivered items were not priced at a significant incremental discount to the delivered items and revenue for each deliverable will be recognized as each contingency is met and the consideration becomes fixed and determinable. The milestone payment was considered to be a substantive payment and the entire amount has been recognized as revenue when the regulatory approval was received. Revenues for contract manufacturing and ongoing efforts to enhance the product are recognized as revenue from products or revenue from services, respectively, when the four basic criteria for revenue recognition are met.

Collaboration Agreement

On September 9, 2011 the Company entered into a Collaboration Agreement with Siemens to develop coagulation related products for hospital point-of-care and ambulatory care coagulation markets. In addition to an up-front, non-refundable payment of A$2,961,245 (equivalent to US$3 million), the Collaboration Agreement (as amended) contains a further seven payments from Siemens upon the achievement of certain defined milestones. These seven milestones, to a large extent, relate to feasibility, regulatory submissions and the launch of the products to be developed. The Company has concluded that the up-front payment is not a separate unit of accounting and recorded the amount as deferred revenue to be recognized as revenue across other deliverables in the arrangement with Siemens based upon the Company’s best estimate of selling price. The deliverables related to each of the seven milestones are considered substantive and are not priced at a significant incremental discount to the other deliverables. As the achievement of the seven milestones is contingent upon a future event, the revenue for each deliverable will be recognized as the contingencies are met and the consideration becomes fixed and determinable.

Of the seven milestones, the Company has delivered on four as of September 30, 2018. The last milestone delivered was in July 2015.

Interest income

Interest income is recognized as it accrues, taking into account the effective yield on the cash and cash equivalents.

Research and development tax incentive income

Research and development tax incentive income is recognized when there is reasonable assurance that the income will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured.

The research and development tax incentive is one of the key elements of the Australian Government’s support for Australia’s innovation system and is supported by legislative law primarily in the form of the Australian Income Tax Assessment Act 1997 as long as eligibility criteria are met. Generally speaking, entities which are an R&D entity involved in eligible R&D activities may claim research and development tax incentive income as follows:

 

  (1)

as a 43.5% refundable tax offset if aggregate turnover (which generally means an entity’s total income that it derives in the ordinary course of carrying on a business, subject to certain exclusions) of the entity is less than A$20 million, or

 

  (2)

as a 38.5% non-refundable tax offset if aggregate turnover of the entity is more than A$20 million.

In accordance with SEC Regulation S-X Article 5-03, the Company’s research and development tax incentive income has been recognized as non-operating income as it is not indicative of the core operating activities or revenue producing goals of the Company.

 

Management has assessed the Company’s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the tax incentive regime described above. At each period end management estimates the refundable tax offset available to the Company based on available information at the time. This estimate is also reviewed by external tax advisors on an annual basis.

In the nine months ended September 30, 2018 and 2017, the aggregate turnover of the Company had exceeded A$20 million and accordingly it was not eligible for a refundable tax offset. The Company was however eligible for the non-refundable tax offset. The eligible R&D activities and expenditures are able to be claimed as part of the current year income tax computation and any amounts included as a tax asset will be subject to recognition rules under ASC 740 “Income Taxes”.

Foreign Currency

Functional and reporting currency

Items included in the financial statements of each of the Group’s entities are measured using the currency of the primary economic environment in which the entity operates (“the functional currency”). The functional currency of UBI and UBS is AUD or A$ for all years presented. The functional currency of HRL is CAD$.

The consolidated condensed financial statements are presented using a reporting currency of Australian dollars.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in the consolidated condensed statements of comprehensive income.

The Company has recorded foreign currency transaction gains of A$183,395 and A$61,873 for the three months ended September 30, 2018 and 2017, respectively and A$412,768 and A$703,420 for the nine months ended September 30, 2018 and 2017, respectively.

The results and financial position of all the Group entities that have a functional currency different from the reporting currency are translated into the reporting currency as follows:

 

   

assets and liabilities for each balance sheet item reported are translated at the closing rate at the date of that balance sheet;

 

   

income and expenses for each income statement item reported are translated at average exchange rates (unless this is not a reasonable approximation of the effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions); and

 

   

all resulting exchange differences are recognized as a separate component of equity.

On consolidation, exchange differences arising from the translation of any net investment in foreign entities are taken to the Accumulated Other Comprehensive Income.

Commitments and Contingencies

Liabilities for loss contingencies, arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. These were nil as at September 30, 2018. Purchase commitments contracted for as at September 30, 2018 is A$1,538,429 (December 31, 2017 : A$2,359,443).

 

Patent and License Costs

Legal and maintenance fees incurred for patent application costs have been charged to expense and reported in general and administrative expense.

Clinical Trial Expenses

Clinical trial costs are a component of research and development expenses. These expenses include fees paid to participating hospitals and other service providers, which conduct certain testing activities on behalf of the Company. Depending on the timing of payments to the service providers and the level of service provided, the Company records prepaid or accrued expenses relating to these costs.

These prepaid or accrued expenses are based on estimates of the work performed under service agreements.

Leased Assets

All of the Company’s leases for the periods ending September 30, 2018 and December 31, 2017 are considered operating leases. The costs of operating leases are charged to the consolidated condensed statements of comprehensive income on a straight-line basis over the lease term.

Stock-based Compensation

We measure stock-based compensation at grant date, based on the estimated fair value of the award, and recognize the cost as an expense on a straight-line basis over the vesting period of the award. We estimate the fair value of stock options using the Trinomial Lattice model. We also grant our employees Restricted Stock Units (“RSUs”) and Zero Priced Employee Options (“ZEPOs”). RSUs are stock awards granted to employees that entitle the holder to shares of common stock as the award vests. ZEPOs are stock options granted to employees that entitle the holder to shares of common stock as the award vests. The value of RSUs are determined and fixed on the grant date based on the Company’s stock price. The exercise price of ZEPOs is nil.

We record deferred tax assets for awards that will result in deductions on our income tax returns, based on the amount of compensation cost recognized and our statutory tax rate in the jurisdiction in which we will receive a deduction. Differences between the deferred tax assets recognized for financial reporting purposes and the actual tax deduction reported in our income tax return are recorded in expense or in capital in excess of par value if the tax deduction exceeds the deferred tax assets or to the extent that previously recognized credits to paid-in-capital are still available if the tax deduction is less than the deferred tax asset.

(a) Stock Option Plan

In 2004, the Company adopted an employee option plan (“Plan”). Options may be granted pursuant to the Plan to any person considered by the board to be employed by the Group on a permanent basis (whether full time, part time or on a long term casual basis). Each option gives the holder the right to subscribe for one share of common stock. The total number of options that may be issued under the Plan is such maximum amount permitted by law and the Listing Rules of the ASX. The exercise price and any exercise conditions are determined by the board at the time of grant of the options. Any exercise conditions must be satisfied before the options vest and become capable of exercise. The options lapse on such date determined by the board at the time of grant or earlier in accordance with the Plan. Options granted to date have had a term up to 10 years and generally vest in equal tranches over three years.

An option holder is not permitted to participate in a bonus issue or new issue of securities in respect of an option held prior to the issue of shares to the option holder pursuant to the exercise of an option. If the Company changes the number of issued shares through, or as a result of, any consolidation, subdivision, or similar reconstruction of the issued capital of the Company, the total number of options and the exercise price of the options (as applicable) will likewise be adjusted.

 

In accordance with ASC 718, the fair value of the option grants was estimated on the date of each grant using the Trinomial Lattice model. The assumptions for these grants were:

 

     Grant Date  
     Oct-17     Oct-17     Oct-17     Feb-17  

Exercise Price (A$)

     0.50       0.60       0.80       0.50  

Share Price at Grant Date (A$)

     0.38       0.38       0.38       0.39  

Volatility

     68     68     68     69

Expected Life (years)

     5       5       5       6  

Risk Free Interest Rate

     2.36     2.36     2.36     2.47

Fair Value of Option (A$)

     0.15       0.13       0.11       0.13  

Stock option activity during the current period is as follows:

 

     Number of shares      Weighted average
exercise price

A$
 

Balance at December 31, 2017

     22,003,215        0.63  

Granted

     0        0.00  

Exercised

     (503,334      0.00  

Lapsed

     (5,124,431      0.70  
  

 

 

    

 

 

 

Balance at September 30, 2018

     16,375,450        0.63  
  

 

 

    

 

 

 

The number of options exercisable as at September 30, 2018 and 2017 was 7,208,775 and 10,963,629, respectively. The total stock compensation expense recognized in the consolidated condensed statements of comprehensive income was A$51,182 and A$154,218 for the three months ended September 30, 2018 and 2017, respectively and A$228,224 and A$354,243 for the nine months ended September 30, 2018 and 2017, respectively.

As of September 30, 2018, there was A$674,671 of unrecognized compensation expense related to unvested share-based compensation arrangements under the Employee Option Plan. This expense is expected to be recognized over the vesting years as follows:

 

Fiscal Year    A$  

2018

     94,357  

2019

     321,558  

2020

     258,756  
  

 

 

 
     674,671  
  

 

 

 

The aggregate intrinsic value for all options outstanding as at September 30, 2018 and 2017 was zero.

(b) Restricted Share Plan

Our Employee Share Plan was adopted by the Board of Directors in 2009. The Employee Share Plan permits our Board to grant shares of our common stock to our employees and directors (although our Board has determined not to issue equity to non-executive directors). The number of shares able to be granted is limited to the amount permitted to be granted at law, the ASX Listing Rules and by the limits on our authorized share capital in our certificate of incorporation. All our employees are eligible for shares under the Employee Share Plan. The Company has in the past issued A$1,000 worth of restricted shares of common stock to employees of the Company but no more frequently than annually. The restricted shares have the same terms of issue as our existing shares of common stock but are not able to be traded until the earlier of three years from the date on which the shares are issued or the date the relevant employee ceases to be an employee of the Company or any of its associated group of companies.

 

No restricted shares have been issued by the Company since January 1, 2017.

Restricted stock awards activity during the current period is as follows:

 

     Number of shares      Weighted average
issue price

A$
 

Balance at December 31, 2017

     492,749        0.31  

Granted

     0        0.00  

Release of restricted shares

     (287,087      0.27  
  

 

 

    

 

 

 

Balance at September 30, 2018

     205,662        0.31  
  

 

 

    

 

 

 

Employee Benefit Costs

The Company contributes 9.5% of each employee’s salary to standard defined contribution superannuation funds on behalf of all UBS employees. Superannuation is a compulsory savings program whereby employers are required to pay a portion of an employee’s remuneration to an approved superannuation fund that the employee is typically not able to access until they have reached the statutory retirement age. Whilst the Company has a third party default superannuation fund, it permits UBS employees to choose an approved and registered superannuation fund into which the contributions are paid. Contributions are charged to the consolidated condensed statements of comprehensive income as they become payable.

Registered Retirement Savings Plan and Deferred Sharing Profit Plan

The Company provides eligible HRL employees a retirement plan. The retirement plan includes a Registered Retirement Savings Plan (“RRSP”) and Deferred Profit Sharing Plan (“DPSP”). The RRSP is voluntary and the employee contributions are matched by the Company up to a maximum of 5% based on their continuous years of service and placed into the DPSP. The Company contributes 1% to 2% of the employee’s base earnings towards the DPSP. The DPSP contributions are vested immediately.

Benefit Plan

The Company provides eligible HRL employees a Benefit Plan to its employees. In general, the Benefit Plan includes extended health care, dental care, basic life insurance, basic accidental death and dismemberment, and disability insurance.

Net Income/(Loss) per Share and Anti-dilutive Securities

Basic and diluted net income/(loss) per share is presented in conformity with ASC 260 – Earnings per Share. Basic and diluted net income/(loss) per share has been computed using the weighted-average number of common shares outstanding during the period. Diluted net income/(loss) per share is calculated by adjusting the basic net income/(loss) per share by assuming all dilutive potential ordinary shares are converted.

Total Comprehensive Income/(Loss)

The Company follows ASC 220 – Comprehensive Income. Comprehensive income/(loss) is defined as the total change in shareholders’ equity during the period other than from transactions with shareholders, and for the Company, includes net income/(loss).

 

The tax effect allocated to each component of other comprehensive loss is as follows:

 

     Before-Tax Amount     

Tax (Expense)/

Benefit

     Net-of-Tax
Amount
 
     A$      A$      A$  

Nine Months Ended September 30, 2018

        

Foreign currency translation reserve

     36,525        0        36,525  

Reclassification for gains realised in net income

     0        0        0  
  

 

 

    

 

 

    

 

 

 

Other comprehensive loss

     36,525        0        36,525  
  

 

 

    

 

 

    

 

 

 

Nine Months Ended September 30, 2017

        

Foreign currency translation reserve

     5,497        0        5,497  

Reclassification for gains realised in net income

     0        0        0  
  

 

 

    

 

 

    

 

 

 

Other comprehensive loss

     5,497        0        5,497  
  

 

 

    

 

 

    

 

 

 

Business combinations

Business combinations are accounted for using the acquisition method of accounting. Acquisition cost is measured as the aggregate of the fair value at the date of acquisition of the assets given, equity instruments issued or liabilities incurred or assumed. Acquisition related costs are expensed as incurred (except for those costs arising on the issue of equity instruments which are recognized directly in equity). Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured at fair value on the acquisition date. Goodwill is measured as the excess of the acquisition cost, the amount of any non-controlling interest and the fair value of any previous UBI equity interest in the acquiree, over the fair value of the identifiable net assets acquired.

Reclassification

Certain prior year amounts have been reclassified to conform to the current year presentation.

Recent Accounting Pronouncements

(a) Recent issued accounting standards not yet adopted

ASU No.2016-02, “Leases’

On February 25, 2016, the FASB issued ASU 2016-02, its new standard on accounting for leases. ASU 2016-02 introduces a lessee model that brings most leases on the balance sheet and eliminates the requirement in current U.S. GAAP for an entity to use bright-line tests in determining lease classification. The standard also requires lessors to increase the transparency of their exposure to changes in value of their residual assets and how they manage that exposure.

The new guidance will be effective for public business entities for annual periods beginning after December 15, 2018, and interim periods therein. Early adoption is permitted. The Company is currently evaluating the impact the adoption of ASU 2016-02 will have on the Company’s consolidated financial statements.

ASU No.2014-09, “Revenue from Contracts with Customers’

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (Topic 606), which provides companies with a single revenue recognition model for recognizing revenue from contracts with customers. The core principle of the new standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. There are two permitted transition methods under the new standard, the full retrospective method or the modified retrospective method. The new standard is effective for annual reporting periods beginning after December 15, 2017. The Company has deferred the adoption of this standard as is allowable for an Emerging Growth Company.

UBI has selected the modified retrospective method where the effect of applying the standard will be recognized at the date of initial application, without restating previous years. The Company is currently evaluating the impact the adoption of ASU 2014-09 will have on the Company’s consolidated financial statements.

ASU No. 2017-12, “Targeted Improvements to Accounting for Hedging Activities”

On August 28, 2017, the FASB issued ASU 2017-12, which amends the hedge accounting recognition and presentation requirements in ASC 815.2. The FASB’s objectives in issuing the ASU are to (1) improve the transparency and understandability of information conveyed to financial statement users about an entity’s risk management activities by better aligning the entity’s financial reporting for hedging relationships with those risk management activities and (2) reduce the complexity of and simplify the application of hedge accounting by preparers.

For public business entities, the ASU is effective for fiscal years beginning after December 15, 2018, and interim periods therein; however, early adoption by all entities is permitted upon its issuance. The Company is currently evaluating the impact the adoption of ASU 2014-09 will have on the Company’s consolidated financial statements.

(b) Recently adopted accounting pronouncements

ASU No.2016-18, “Restricted Cash’

On November 17, 2016, the FASB issued ASU 2016-18, which amends ASC 230 to add or clarify guidance on the classification and presentation of restricted cash in the statement of cash flows. For public business entities, the guidance is effective for fiscal years beginning after December 15, 2017, including interim periods therein. For all other entities, it is effective for fiscal years beginning after December 15, 2018, and interim periods thereafter. Early adoption is permitted for all entities. The Company has adopted this guidance from January 1, 2018 and it has not had a material impact on the Company’s consolidated financial statements.

ASU No.2016-15, “Classification of Certain Cash Receipts and Cash Payments”

On August 26, 2016, the FASB issued ASU 2016-15, which amends the guidance in ASC 230 to eliminate diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The guidance in the ASU is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted for all entities. The Company has adopted this guidance and it has not had a material impact on the Company’s consolidated financial statements.

ASU No.2016-16, “Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory’

On October 24, 2016, the FASB issued ASU 2016-16, which removes the prohibition in ASC 740 against the immediate recognition of the current and deferred income tax effects of intra-entity transfers of assets other than inventory. This ASU is effective for annual periods beginning after December 15, 2017, and interim periods within those annual periods. Early adoption is permitted for all entities as of the beginning of a fiscal year for which neither the annual or interim financial statements have been issued. Entities should apply the ASU’s amendments on a modified retrospective basis, recognizing the effects in retained earnings as of the beginning of the year of adoption. The Company has adopted this guidance and it has not had a material impact on the Company’s consolidated financial statements.

ASU No.2017-01, “Business Combination: Clarifying the Definition of a Business’

On January 5, 2017, the FASB issued ASU 2017-01 to clarify the definition of a business in ASC 805. The amendments in the ASU are intended to make application of the guidance more consistent and cost-efficient. The ASU is effective for annual periods beginning after December 15, 2017, including interim periods therein. The ASU must be applied prospectively on or after the effective date, and no disclosures for a change in accounting principle are required at transition. Early adoption is permitted for transactions (i.e., acquisitions or dispositions) that occurred before the issuance date or effective date of the standard. The Company has adopted this guidance and it has not had a material impact on the Company’s consolidated financial statements.

 

ASU No.2017-09, “Compensation – Stock Compensation: Scope of Modification Accounting’

On May 10, 2017, the FASB issued ASU 2017-09, which amends the scope of modification accounting for share-based payment arrangements. The ASU provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting under ASC 718. This ASU is effective for annual reporting periods, including interim periods within those annual reporting periods, beginning after December 15, 2017. Early adoption is permitted. The Company has adopted this guidance and it has not had a material impact on the Company’s consolidated financial statements.

ASU No. 2018-05, “Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118.”

On March 13, 2018, the FASB issued ASU 2018-05. This Financial Reporting Alert contains responses to frequently asked questions about how an entity should account for the tax effects of the new tax reform legislation in accordance with ASC 740, Income Taxes. This ASU is effective upon issuance and the adoption of this guidance has not had a material impact on the Company’s consolidated financial statements.

ASU No. 2018-09, “Codification Improvements”

The FASB issued ASU 2018-09 on July 16, 2018. The ASU’s amendments “clarify, correct errors in, or make minor improvements to the Codification.” This ASU is effective upon issuance and the adoption of this guidance has not had a material impact on the Company’s consolidated financial statements.

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1
Related Party Transactions
9 Months Ended
Sep. 30, 2018
Related Party Transactions [Abstract]  
Related Party Transactions

Related Party Transactions

Details of related party transactions material to the operations of the Group other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business, are set out below:

In September 2011, we entered into a non-exclusive license agreement with SpeeDx Pty Ltd (“SpeeDx”) pursuant to which SpeeDx granted us a license to use its proprietary MNAzyme technology in the field of molecular diagnostics. Under the agreement we make milestone payments totaling A$500,000 to SpeeDx if certain specified targets are achieved, and royalty payments ranging from 5% to 15% of that portion of our sales and licensing revenues arising from SpeeDx technology or products incorporating SpeeDx technology.

The license agreement and the obligation to pay royalties continues until SpeeDx’s patent rights have expired, lapsed, are found to be invalid or are rejected. The agreement will terminate by mutual agreement or by one party for breach or insolvency of the other. SpeeDx may also terminate the license agreement if the research and development on a first licensed product is not completed by UBS within 7 years (subject to certain exceptions), and UBS may terminate if it determines that it does not wish to proceed with further commercialization of SpeeDx’s technology.

Mr. Denver is a director of SpeeDx and up until August 7, 2017 was a director of the Company. Mr. Denver continued to provide services to the Company in an advisory capacity between October 1, 2017 and June 30, 2018.

Mr. Coleman is a Non-Executive Chairman of the Company and Executive Chairman of Viburnum Funds Pty Ltd. Viburnum Funds Pty Ltd, as an investment manager for its associated funds holds a beneficial interest and voting power over approximately 18% of our shares.

An employee of Viburnum Funds Pty Ltd has on occasions been seconded to Universal Biosensors to assist the Company on strategic matters. During this period Viburnum Funds Pty Ltd continue to pay all the salary entitlements of the seconded person. Universal Biosensors is solely responsible for the reimbursement of certain expenditure such as travel and rental whilst the employee is on secondment. The total expenditure reimbursed by the Company to Viburnum Funds Pty Ltd as at September 30, 2018 was A$21,716.

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1
Borrowings
9 Months Ended
Sep. 30, 2018
Debt Disclosure [Abstract]  
Borrowings

Borrowings

Future maturities, interest and other payments under the Company’s long term secured loan pursuant to the credit agreement (described below) as of September 30, 2018 and December 31, 2017 are as follows:

 

     September 30, 2018      December 31, 2017  
     US$      A$      US$      A$  

2018

     442,750           1,956,563     

2019

     15,221,375           15,875,875     
  

 

 

       

 

 

    

Total minimum payments

     15,664,125           17,832,438     

Less amount representing interest and other fees

     (664,125         (2,832,438   
  

 

 

       

 

 

    

Gross balance of long term debt

     15,000,000           15,000,000     

Less fair value of warrants recorded within loan (a)

     (815,655         (815,655   

Plus interest accretion

     736,851           658,334     
  

 

 

       

 

 

    

Total carrying value

     14,921,196        20,660,753        14,842,679        19,029,076  
  

 

 

    

 

 

    

 

 

    

 

 

 

Less current portion

     14,921,196        20,660,753        0        0  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total carrying value, non-current portion

     0        0        14,842,679        19,029,076  
  

 

 

    

 

 

    

 

 

    

 

 

 

The above assumes, as provided under the Athyrium Credit Agreement, the loan will be repaid immediately out of the proceeds from the lump sum service fees which is expected to be received on or about February 15, 2019.

The carrying value of the borrowings approximates its fair value. The fair value is estimated by discounting future cash flows at the currently offered rates for borrowings of similar remaining maturities.

 

  (a)

The warrants issued in December 2013 had a fair value of US$815,655 as of September 30, 2018 and December 31, 2017, and are included in equity.

Athyrium Credit Agreement

On December 19, 2013 (“Closing Date”), UBI and its wholly owned subsidiary, UBS (together UBI and UBS, the “Transaction Parties”) entered into a credit agreement with Athyrium Opportunities Fund (A) LP (“Athyrium A”), as administrative agent (the “Administrative Agent”) and as a lender, and Athyrium Opportunities Fund (B) LP (“Athyrium B”) as a lender (Athyrium A and Athyrium B together with any other lenders party thereto from time to time, the “Lenders”) for a secured term loan of up to US$25 million, which was amended on January 30, 2015 (“Credit Agreement”). Of this amount, US$15 million had been drawn at December 31, 2013 with a further US$10 million available to be drawn down on or before July 31, 2015, if UBS satisfied certain conditions precedent relating to product revenues.

The credit agreement was amended again on December 29, 2017 (“Amendment”). Subject to the terms of the Amendment, the Amendment modifies the Credit Agreement to (i) extend the maturity date to July 1, 2019 (“Maturity Date”), (ii) add the Borrower’s wholly owned subsidiary, Hemostasis Reference Laboratory, Inc. (“HRL”), as a guarantor of the Borrower’s obligations under the Credit Agreement and (iii) subject to the prior written consent of the Lenders in their sole discretion, permit UBI to repurchase shares in an aggregate amount up to US$2,000,000 within 12 months after the date Lenders provide any such consent.

The term loan bears interest at 10.5% per annum payable in cash quarterly in arrears over the term, and as otherwise described in the Credit Agreement. A default interest rate of 13% per annum shall apply during the existence of a default under the Credit Agreement. Other than as summarized below, UBS is not required to make payments of principal for amounts outstanding under the term loan until maturity, July 1, 2019. The term loan under the Credit Agreement is secured by substantially all of UBI, UBS’ and HRL’s assets. UBI and HRL (together with any future subsidiaries) guarantees all of UBS’s obligations under the term loan.

 

Voluntary prepayments of the term loans were not permitted prior to the second anniversary of the Closing Date, except in the event of a change of control of a Transaction Party. After the second anniversary, UBS can make voluntary repayments in minimum principal amounts of US$2,500,000 together with interest, plus the premium described below. UBS must make mandatory prepayments in certain prescribed circumstances, including in the event of raising additional debt financing, a sale or transfer of assets other than in certain circumstances and in the event of other specified extraordinary receipts. Extraordinary receipts include cash received or paid other than in the ordinary course of business, such as tax refunds (other than GST and R&D tax rebates), LifeScan lump sum fee payments and Siemens termination fees. In such events, UBS must prepay to the Lenders 100% of the net cash proceeds received up to the outstanding principal amount of the loans drawn down, together with all accrued and unpaid interest thereon and all other obligations. In the event of any prepayment after the second anniversary of the Closing Date with respect to any obligations under the Credit Agreement, UBS must pay a prepayment premium commencing at 15% of the principal of such prepayment due and payable on the applicable date and reducing pro-rata on a monthly basis until the Maturity Date.

Unless the facility is otherwise terminated earlier pursuant to the terms of the Credit Agreement, UBS (as the borrower) is required to repay the outstanding principal amount of the loans drawn down, together with all accrued and unpaid interest thereon and all other obligations on Maturity Date.

UBS paid a non-refundable fee of US$625,000 to the Lenders on the Closing Date (being 2.5% of the aggregate credit facility) and non-refundable fees of US$200,000 to the Lenders in connection with each of the January 2015 and December 2017 amendments to the Credit Agreement. A 2% commitment fee based on any available unused borrowing commitment was paid by UBS under the Credit Agreement until July 31, 2015. The Lenders are also entitled to receive 30% of the net proceeds of milestone payments paid under the Collaboration Agreement by and among UBS, UBI and Siemens, up to a maximum of US$600,000 in the aggregate of which US$300,000 was paid in February 2015 and the balance of US$300,000 was paid in August 2015 (upon receipt of two further milestone payments). UBS has also agreed to pay certain taxes arising in connection with the Credit Agreement and other Loan Documents, including withholding taxes. UBS has also agreed to pay certain reasonable out-of-pocket expenses incurred by the Lenders in connection with the loan documents including the January 2015 and December 2017 amendments, or as may be incurred in connection with the enforcement or protection of their rights.

The Credit Agreement also contains certain covenants, including among other things, covenants: (i) relating to the delivery of financial and other information and certificates, notices of defaults, litigation and other material events; payment of taxes and other obligations; maintenance of insurance; (ii) which limit or restrict the incurrence of liens; the making of investments; the incurrence of certain indebtedness; mergers, dispositions, liquidations, or consolidations and significant asset sales; restricted payments; transactions with affiliates other than on normal and arms-length terms; burdensome agreements; prepayment of other indebtedness; ownership of subsidiaries; and (iii) which require UBS to maintain restricted cash of not less than US$2,000,000 in a specified bank account at any time.

As further described below, pursuant to the Credit Agreement, UBI issued to the Lenders warrants entitling the holder to purchase up to an aggregate total of 4.5 million shares of UBI’s common stock in the form of CDIs at a price of A$1.00 per share (the “Exercise Price”), which represents a 117% premium over the closing price of UBI’s common stock on December 19, 2013. The warrants are immediately exercisable and have a term of seven years.

Other

In December 2016, UBS entered into an arrangement with Elantis Premium Funding Ltd to fund the Group’s 2017 insurance premium. The total amount financed was A$369,630 at inception and the short-term borrowing was fully repaid in September 2017. Interest was charged at a fixed rate of 2.60% per annum. The short-term borrowing was secured by the insurance premium refund. The Group’s 2018 insurance premium was funded from its operating cash flows.

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1
Warrants
9 Months Ended
Sep. 30, 2018
Text Block [Abstract]  
Warrants

Warrants

Pursuant to the Credit Agreement, UBI issued to the Lenders warrants entitling the holder to purchase up to an aggregate total of 4.5 million shares of UBI’s common stock in the form of CDIs at a price of A$1.00 per share (the “Exercise Price”), which represents a 117% premium over the closing price of UBI’s common stock on December 19, 2013. The warrants are immediately exercisable and have a term of seven years.

The warrants may be exercised at any time until December 19, 2020, in whole or in part in minimum multiples of 500,000 shares of common stock. The holder of the warrants can pay the Exercise Price in cash or it has the right to pay all or a portion of the Exercise Price by making a cashless exercise, therefore reducing the number of shares of common stock the holder would otherwise be issued.

The warrant is subject to adjustments in the event of certain issuances by UBI, such as bonus issues, pro rata (rights) issues and reorganizations (e.g., consolidation, subdivision).

The Company assessed that the warrants are not liabilities within scope of ASC 480-10-25. The warrants are legally detachable from the loan and separately exercisable and as such meet the definition of a freestanding derivative instrument pursuant to ASC 815.

However, the scope exception in accordance with ASC 815-10-15-74 applies to warrants and it meets the requirements of ASC 815 that would be classified in stockholders’ equity. Therefore, the warrants were initially accounted for within stockholders’ equity, and subsequent changes in fair value will not be recorded. The fair value of the warrant was estimated using the Trinomial Lattice model.

The debt issuance costs were recorded as deferred issuance costs and are amortized as interest expense, using the effective interest method, over the term of the loan pursuant to ASC 835-30-35-2.

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1
Restricted Cash
9 Months Ended
Sep. 30, 2018
Cash and Cash Equivalents [Abstract]  
Restricted Cash

Restricted Cash

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated condensed balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows.

 

     Nine Months Ended
September 30,
     Year Ended
December 31,
 
     2018      2017  
     A$      A$  

Cash and cash equivalents

     28,531,432        26,259,918  

Restricted cash - current assets

     2,915,949        15,309  

Restricted cash - non-current assets

     320,000        3,220,000  
  

 

 

    

 

 

 
     31,767,381        29,495,227  
  

 

 

    

 

 

 

 

Restricted cash maintained by the Company in the form of term deposits is as follows:

 

     Nine Months Ended
September 30,
     Year Ended
December 31,
 
     2018      2017  
     A$      A$  

Collateral for facilities (a) - current assets

     15,949        15,309  

Collateral for facilities (b) - non-current assets

     320,000        320,000  

Financial covenant pursuant to the credit agreement (c) - current assets

     2,900,000        0  

Financial covenant pursuant to the credit agreement (c) - non-current assets

     0        2,900,000  
  

 

 

    

 

 

 
     3,235,949        3,235,309  
  

 

 

    

 

 

 

 

(a)

Represents bank guarantee of CDN$15,000 as security deposit on HRL’s credit card

(b)

Represents bank guarantee of A$250,000 for commercial lease of UBS’ premises and security deposit on Company’s credit cards of A$70,000

(c)

Represents amounts pledged as collateral for financing arrangements as contractually required by the Lenders. The restriction will lapse when the related debt is paid off in July 2019 or earlier as provided pursuant to the Credit Agreement

Interest earned on the restricted cash for the three months ended September 30, 2018 and 2017 were A$18,500 and A$12,394, respectively and for the nine months ended September 30, 2018 and 2017 were A$53,420 and A$50,423, respectively.

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies (Policies)
9 Months Ended
Sep. 30, 2018
Accounting Policies [Abstract]  
Principles of Consolidation

Principles of Consolidation

The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries, UBS and HRL. All intercompany balances and transactions have been eliminated on consolidation.

Use of Estimates

Use of Estimates

The preparation of the consolidated financial statements requires management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Significant items subject to such estimates and assumptions include the recognition of revenue, carrying amount of property, plant and equipment, deferred income taxes, asset retirement obligations, liabilities related to employee benefits, warrants and research and development tax incentive income. Actual results could differ from those estimates.

Cash, Cash Equivalents and Restricted Cash

Cash, Cash Equivalents and Restricted Cash

The Company considers all highly liquid investments purchased with an initial maturity of three months or less to be cash equivalents. For cash and cash equivalents, the carrying amount approximates fair value due to the short maturity of those instruments. The Company maintains cash and restricted cash, which includes tenant security deposits, credit card security deposits and cash collateral for its borrowings. As of September 30, 2018, the Company has not realized any losses in such cash accounts and believes it is not exposed to any significant risk of loss.

Short-Term Investments (Held-to-maturity)

Short-Term Investments (Held-to-maturity)

Short-term investments constitute all highly liquid investments with term to maturity from three months to twelve months. The carrying amount of short-term investments is equivalent to their fair value.

Concentration of Credit Risk and Other Risks and Uncertainties

Concentration of Credit Risk and Other Risks and Uncertainties

Cash and cash equivalents and accounts receivable consist of financial instruments that potentially subject the Company to concentration of credit risk to the extent of the amount recorded on the consolidated condensed balance sheets. The Company’s cash and cash equivalents are primarily invested with one of Australia’s largest banks. The Company is exposed to credit risk in the event of default by the banks holding the cash or cash equivalents to the extent of the amount recorded on the consolidated condensed balance sheets. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company has not identified any collectability issues with respect to receivables.

Derivative Instruments and Hedging Activities

Derivative Instruments and Hedging Activities

Derivative financial instruments

The Company may use derivative financial instruments to hedge its exposure to foreign exchange arising from operating, investing and financing activities. The Company does not hold or issue derivative financial instruments for trading purposes. However, derivatives that do not qualify for hedge accounting are accounted for as trading instruments.

Derivative financial instruments are recognized initially at fair value. Subsequent to initial recognition, derivative financial instruments are stated at fair value. The gain or loss on remeasurement to fair value is recognized immediately in the income statement. However, where derivatives qualify for hedge accounting, recognition of any resultant gain or loss depends on the nature of the item being hedged.

Cash flow hedges

Exposure to foreign exchange risks arises in the normal course of the Company’s business and it is the Company’s policy to use forward exchange contracts to hedge anticipated sales and purchases in foreign currencies. The amount of forward cover taken is in accordance with approved policy and internal forecasts.

Where a derivative financial instrument is designated as a hedge of the variability in cash flows of a recognized asset or liability, or a highly probable forecast transaction, the effective part of any unrealized gain or loss on the derivative financial instrument is recognized directly in equity. When the forecast transaction subsequently results in the recognition of a non-financial asset or non-financial liability, the associated cumulative gain or loss is removed from equity and included in the initial cost or other carrying amount of the non-financial asset or liability.

For cash flow hedges, other than those covered by the preceding statement, the associated cumulative gain or loss is removed from equity and recognized in the consolidated condensed statements of comprehensive income in the same period or periods during which the hedged forecast transaction affects the consolidated condensed statements of comprehensive income and on the same line item as that hedged forecast transaction. The ineffective part of any gain or loss is recognized immediately in the consolidated condensed statements of comprehensive income.

When a hedging instrument expires or is sold, terminated or exercised, or the Company revokes designation of the hedge relationship but the hedged forecast transaction is still probable to occur, the cumulative gain or loss at that point remains in equity and is recognized in accordance with the above policy when the transaction occurs. If the hedged transaction is no longer expected to take place, then the cumulative unrealized gain or loss recognized in equity is recognized immediately in the consolidated condensed statements of comprehensive income.

Derivative Instruments and Hedging Activities

In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as consider our own and counterparty credit risk. For periods ended September 30, 2018 and December 31, 2017, we did not have any assets or liabilities that utilize Level 3 inputs. The valuation of our foreign exchange derivatives are based on the market approach using observable market inputs, such as forward rates and incorporate non-performance risk (the credit standing of the counterparty when the derivative is in a net asset position, and the credit standing of the Company when the derivative is in a net liability position). Our derivative assets are categorized as Level 2. The fair value methodologies described as Level 2 and 3 inputs are defined elsewhere in these notes to the consolidated condensed financial statements.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The carrying value of all current assets and current liabilities approximates fair value because of their short-term nature. The estimated fair value of all other amounts has been determined, depending on the nature and complexity of the assets or the liability, by using one or all of the following approaches:

 

   

Market approach – based on market prices and other information from market transactions involving identical or comparable assets or liabilities.

 

   

Cost approach – based on the cost to acquire or construct comparable assets less an allowance for functional and/or economic obsolescence.

 

   

Income approach – based on the present value of a future stream of net cash flows.

These fair value methodologies depend on the following types of inputs:

 

   

Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).

 

   

Quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in markets that are not active or are directly or indirectly observable (Level 2 inputs).

 

   

Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).

Inventory

Inventory

Inventories are stated at the lower of cost or net realizable value. Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and estimated costs necessary to dispose. Inventories are principally determined under the average cost method which approximates cost. Cost comprises direct materials, direct labour and an appropriate portion of variable and fixed overhead expenditure, the latter being allocated on the basis of normal operating capacity. Cost also includes the transfer from equity of any gains/losses on qualifying cash flow hedges relating to purchases of raw material. Costs of purchased inventory are determined after deducting rebates and discounts.

 

     Nine Months Ended
September 30,
     Year Ended
December 31,
 
     2018      2017  
     A$      A$  

Raw materials

     322,399        380,540  

Work in progress

     158,883        253,483  

Finished goods

     0        28,109  
  

 

 

    

 

 

 
     481,282        662,132  
  

 

 

    

 

 

 
Receivables

Receivables

Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the best estimate of the amount of probable credit losses in the existing accounts receivable. The allowance is determined based on a review of individual accounts for collectability, generally focusing on those accounts that are past due. The expense to adjust the allowance for doubtful accounts, if any, is recorded within general and administrative expenses in the consolidated condensed statements of comprehensive income. Account balances are charged against the allowance when it is probable the receivable will not be recovered.

 

     Nine Months Ended
September 30,
     Year Ended
December 31,
 
     2018      2017  
     A$      A$  

Accounts receivable

     4,902,417        4,397,268  

Allowance for doubtful debts

     0        0  
  

 

 

    

 

 

 
     4,902,417        4,397,268  
  

 

 

    

 

 

 
Property, Plant, and Equipment-net

Property, Plant, and Equipment—net

Property, plant, and equipment are recorded at acquisition cost, less accumulated depreciation.

Depreciation on plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful life of machinery and equipment is 3 to 10 years. Leasehold improvements are amortized on the straight-line method over the shorter of the remaining lease term or estimated useful life of the asset. Maintenance and repairs are charged to operations as incurred, include normal services, and do not include items of a capital nature.

The Company receives Commonwealth of Australia grant monies under grant agreements to support its development activities (refer section on “Government Grants”), including in connection with the purchase of plant and equipment. Plant and equipment is presented net of the government grant. The grant monies are recognized against the acquisition costs of the related plant and equipment as and when the related assets are purchased.

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

The Company reviews its capital assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. In performing the review, the Company estimates undiscounted cash flows from products under development that are covered by these patents and licenses. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition is less than the carrying amount of the asset. If the evaluation indicates that the carrying value of an asset is not recoverable from its undiscounted cash flows, an impairment loss is measured by comparing the carrying value of the asset to its fair value, based on discounted cash flows. Impairment of long-lived-assets as at September 30, 2018 was nil (December 31, 2017: nil).

Government grants

Government grants

UBS was awarded a grant from the Commonwealth of Australia under the Next Generation Manufacturing Investment Programme up to a maximum grant amount of A$575,000 payable over a three year period commencing from January 1, 2017. The grants are paid upon achievement of pre-agreed milestones. The milestones generally relate to UBS placing purchase orders, commissioning upgrades and validating the equipment. Amongst other reasons, the Commonwealth of Australia may terminate the grant agreement for breach of the agreement by UBS or for failure to undertake the required programme. Under these circumstances, the Commonwealth of Australia may require UBS to repay some or the entire grant. The Company continues to undertake the project funded by the Commonwealth of Australia.

An amount of A$271,318 and A$89,500 were received under this grant in November 2017 and June 2018, respectively. In the event UBS had achieved milestones and received grant payments, it believes that the likelihood of being required to repay grant funding is remote because the Company continues to comply with the grant agreement.

Other Liabilities

Other Liabilities

Other liabilities are broken down as follows:

 

     Nine Months Ended
September 30,
     Year Ended
December 31,
 
     2018      2017  
     A$      A$  

Current liabilites

     

Marketing support payment

     2,836,614        2,626,413  
  

 

 

    

 

 

 
     2,836,614        2,626,413  
  

 

 

    

 

 

 

Marketing Support Payment

During 2009, LifeScan chose not to proceed with the registration of the then current product but to proceed with an enhanced product, called OneTouch Verio®, and acknowledged that there would be a delay as a result. As a result of this change, LifeScan agreed to pay additional amounts per strip manufactured by the Company in 2010 and 2011 up to a specified volume limit (“manufacturing initiation payments”). At the same time, the Company agreed to pay LifeScan a marketing support payment in each of the two years following the first calendar year in which 1 billion strips are sold by LifeScan equal to 40% of the total manufacturing initiation payments made. The first calendar year in which 1 billion strips were sold by LifeScan was during the 2016 financial year. These amounts will be paid to LifeScan once supporting documentation has been provided to us. The total amount of marketing support payments to be paid to LifeScan in US$ once all the documentation is received is US$2,048,602 (equivalent to A$2,836,614).

Research and Development

Research and Development

Research and development expenses consist of costs incurred to further the Group’s research and product development activities and include salaries and related employee benefits, costs associated with clinical trial and preclinical development, regulatory activities, research-related overhead expenses, costs associated with the manufacture of clinical trial material, costs associated with developing a commercial manufacturing process, costs for consultants and related contract research, facility costs and depreciation. Research and development costs are expensed as incurred.

Research and development expenses for the respective periods are as follows:

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2018      2017      2018      2017  
     A$      A$      A$      A$  

Research and development expenses

     2,759,664        3,197,146        9,452,609        7,626,210  
  

 

 

    

 

 

    

 

 

    

 

 

 
Income Taxes

Income Taxes

The Company applies ASC 740—Income Taxes which establishes financial accounting and reporting standards for the effects of income taxes that result from a company’s activities during the current and preceding years. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Where it is more likely than not that some portion or all of the deferred tax assets will not be realized, the deferred tax assets are reduced by a valuation allowance. The valuation allowance is sufficient to reduce the deferred tax assets to the amount that is more likely than not to be realized.

 

The recent U.S. Federal Tax Reform has established a mandatory repatriation of foreign accumulated undistributed earnings and profits (the “E&Ps”) for U.S. companies’ subsidiaries. In the past, none of these E&Ps’ were repatriated since such E&Ps’ were considered to be reinvested indefinitely in the foreign location. The E&Ps’ provisions are applicable to our Company commencing with our fiscal year 2018, however the E&Ps’ mandatory repatriation provisions establishes measurement dates for various computations. In our Company’s case this date is December 31, 2017. The Company’s estimated tax for the mandatory repatriation is estimated to be nil. However, the final tax due must be assessed with our December 31, 2018 closing figures. Any such tax liability may be paid over a period of eight years starting on February 28, 2019. As of the issuance date of this report, the U.S. Securities and Exchange Commission and the Financial Accounting Standards Board have issued some preliminary guidance, but have not issued final rules on how the effects of the U.S. Federal Tax Reform will be required to be reported for financial statements purposes.

At December 31, 2017 the Company has A$10,993,737 (A$22,616,230 at December 31, 2016) of accumulated tax losses available for carry forward against future earnings, which under Australian tax laws do not expire but may not be available under certain circumstances. The Company also has A$11,048,336 (A$5,800,672 at December 31, 2016) of non-refundable R&D tax offset as at December 31, 2017. The R&D Tax offset is a non-refundable tax offset, which assists to reduce a company’s tax liability. Once the liability has been reduced to zero, any excess offset may be carried forward into future income years. UBI has U.S. tax losses available for carry forward against future earnings of US$1,011,321 as of December 31, 2017 and 2016. Pursuant to the U.S. Federal Tax Reform, the effective tax rate of UBI has been reduced from 34% to 21%. The deferred tax benefit based on this new rate for UBI is US$212,377. HRL has Canadian tax losses available for carry forward against future earnings of CAD$668,043 and CAD$95,096 as at December 31, 2017 and 2016, respectively.

We are subject to income taxes in the United States, Canada and Australia. Tax returns up to and including the 2017 financial year have been filed in all these jurisdictions.

Asset Retirement Obligations

Asset Retirement Obligations

Asset retirement obligations (“ARO”) are legal obligations associated with the retirement and removal of long-lived assets. ASC 410 – Asset Retirement and Environmental Obligations requires entities to record the fair value of a liability for an asset retirement obligation when it is incurred. When the liability is initially recorded, the Company capitalizes the cost by increasing the carrying amounts of the related property, plant and equipment. Over time, the liability increases for the change in its present value, while the capitalized cost depreciates over the useful life of the asset. The Company derecognizes ARO liabilities when the related obligations are settled.

The ARO is in relation to our premises where in accordance with the terms of the lease, the lessee has to restore part of the building upon vacating the premises.

ARO for the years ended September 30, 2018 and December 31, 2017 was A$2,600,000.

Australian Goods and Services Tax (GST) and Canadian Harmonized Sales Tax (HST)

Australian Goods and Services Tax (GST) and Canadian Harmonized Sales Tax (HST)

Revenues, expenses and assets are recognized net of the amount of associated GST and HST, unless the GST and HST incurred is not recoverable from the taxation authority. In this case it is recognized as part of the cost of acquisition of the asset or as part of the expense. Receivables and payables are stated inclusive of the amount of GST and HST receivable or payable. The net amount of GST and HST recoverable from, or payable to, the taxation authority is included with other receivables or payables in the consolidated condensed balance sheets.

Revenue Recognition

Revenue Recognition

We recognize revenue from all sources based on the provisions of the U.S. SEC’s Staff Accounting Bulletin No. 104 and ASC 605 Revenue Recognition.

The Company’s revenue represents revenue from sales of products, provision of services and collaborative research and development agreements.

We recognize revenue from sales of products at the time title of goods passes to the buyer and the buyer assumes the risks and rewards of ownership, assuming all other revenue recognition criteria have been met. Generally, this is at the time products are shipped to the customer.

 

Revenue from services is recognized when a persuasive evidence of an arrangement exists, services have been rendered, the price is fixed or determinable, and collectability is reasonably assured. Revenue recognition principles are assessed for each new contractual arrangement and the appropriate accounting is determined for each service.

On September 21, 2018 LifeScan exercised its right to convert its obligation to pay quarterly service fees to us. We expect the lump sum service fees to be paid to Universal Biosensors on or before February 15, 2019. We estimate the lump sum service fee using the most expected value approach based on (i) actual quarterly service fees received this financial year, (ii) estimating the quarterly service fees for the remainder of the year based on the trend seen in prior years, and (iii) multiplying the total quarterly service fees expected to be received this financial year by two and converting the same into AUD using the period end exchange rate. We assessed if any amount of the lump sum service fees were attributable to the remaining obligation under the Master Services and Supply Agreement that states that LifeScan could require us to provide manufacturing services at our Rowville facility to recommence production of glucose strips. We conclude that this obligation has no fair value attributable to it due to (i) high set-up costs to recommence manufacturing, (ii) the required lead time to gain regulatory compliance, and (iii) the fact there is deemed to be no commercial rationale for LifeScan to request us to recommence glucose-strip manufacturing on the basis of current information. As such, the lump sum service fee revenue has been fully recognized this quarter and no revenue has been deferred.

Where our agreements contain multiple elements, or deliverables, such as the manufacture and sale of products, provision of services or research and development activities, they are assessed to determine whether separate delivery of the individual elements of such arrangements comprises more than one unit of accounting. Where an arrangement can be divided into separate units of accounting (each unit constituting a separate earnings process), the arrangement consideration is allocated amongst those varying units based on the relative selling price of the separate units of accounting and the applicable revenue recognition criteria applied to the separate units. Selling prices are determined using fair value as determined by either vendor specific objective evidence or third party evidence of the selling price, when available, or the Company’s best estimate of selling price when fair value is not available for a given unit of accounting.

Under ASC 605-25, the delivered item(s) are separate units of accounting, provided (i) the delivered item(s) have value to a customer on a stand-alone basis, and (ii) if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item(s) is considered probable and substantially in our control. Where the arrangement cannot be divided into separate units, the individual deliverables are combined as a single unit of accounting and the total arrangement consideration is recognized across other deliverables in the arrangement or over the estimated collaboration period. Payments under these arrangements typically include one or more of the following: non-refundable, upfront payments; funding of research and/or development efforts; and milestone payments.

We typically generate milestone payments from our customers pursuant to the various agreements we have with them. Non-refundable milestone payments which represent the achievement of a significant technical/regulatory hurdle in the research and development process pursuant to collaborative agreements, and are deemed to be substantive, are recognized as revenue upon the achievement of the specified milestone. If the non-refundable milestone payment is not substantive or stand-alone value, the non-refundable milestone payment is deferred and recognized as revenue either over the estimated performance period stipulated in the agreement or across other deliverables in the arrangement.

Management has concluded that the core operations of the Company are expected to be research and development activities, commercial manufacture of approved medical or testing devices and the provision of services. The Company’s ultimate goal is to utilize the underlying technology and skill base for the development of marketable products that the Company will manufacture. The Company considers revenue from the sales of products, revenue from services and the income received from milestone payments indicative of its core operating activities or revenue producing goals of the Company, and as such have accounted for this income as “revenues”.

Master Services and Supply Agreement

In October 2007, the Company and LifeScan entered into a Master Services and Supply Agreement, under which the Company would provide certain services to LifeScan in the field of blood glucose monitoring and act as a non-exclusive manufacturer of blood glucose test strips. The Master Services and Supply Agreement was subsequently amended and restated in May 2009. The Company has concluded the Master Services and Supply Agreement should be accounted for as three separate units of accounting: 1) research and development to assist LifeScan in receiving regulatory clearance to sell the blood glucose product (milestone payment), 2) contract manufacturing of the blood glucose test strips (contract manufacturing) which ceased in December 2013, and 3) ongoing services and efforts to enhance the product (product enhancement).

 

All consideration within the Master Services and Supply Agreement is contingent. The Company concluded the undelivered items were not priced at a significant incremental discount to the delivered items and revenue for each deliverable will be recognized as each contingency is met and the consideration becomes fixed and determinable. The milestone payment was considered to be a substantive payment and the entire amount has been recognized as revenue when the regulatory approval was received. Revenues for contract manufacturing and ongoing efforts to enhance the product are recognized as revenue from products or revenue from services, respectively, when the four basic criteria for revenue recognition are met.

Collaboration Agreement

On September 9, 2011 the Company entered into a Collaboration Agreement with Siemens to develop coagulation related products for hospital point-of-care and ambulatory care coagulation markets. In addition to an up-front, non-refundable payment of A$2,961,245 (equivalent to US$3 million), the Collaboration Agreement (as amended) contains a further seven payments from Siemens upon the achievement of certain defined milestones. These seven milestones, to a large extent, relate to feasibility, regulatory submissions and the launch of the products to be developed. The Company has concluded that the up-front payment is not a separate unit of accounting and recorded the amount as deferred revenue to be recognized as revenue across other deliverables in the arrangement with Siemens based upon the Company’s best estimate of selling price. The deliverables related to each of the seven milestones are considered substantive and are not priced at a significant incremental discount to the other deliverables. As the achievement of the seven milestones is contingent upon a future event, the revenue for each deliverable will be recognized as the contingencies are met and the consideration becomes fixed and determinable.

Of the seven milestones, the Company has delivered on four as of September 30, 2018. The last milestone delivered was in July 2015.

Interest income

Interest income

Interest income is recognized as it accrues, taking into account the effective yield on the cash and cash equivalents.

Research and development tax incentive income

Research and development tax incentive income

Research and development tax incentive income is recognized when there is reasonable assurance that the income will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured.

The research and development tax incentive is one of the key elements of the Australian Government’s support for Australia’s innovation system and is supported by legislative law primarily in the form of the Australian Income Tax Assessment Act 1997 as long as eligibility criteria are met. Generally speaking, entities which are an R&D entity involved in eligible R&D activities may claim research and development tax incentive income as follows:

 

  (1)

as a 43.5% refundable tax offset if aggregate turnover (which generally means an entity’s total income that it derives in the ordinary course of carrying on a business, subject to certain exclusions) of the entity is less than A$20 million, or

 

  (2)

as a 38.5% non-refundable tax offset if aggregate turnover of the entity is more than A$20 million.

In accordance with SEC Regulation S-X Article 5-03, the Company’s research and development tax incentive income has been recognized as non-operating income as it is not indicative of the core operating activities or revenue producing goals of the Company.

 

Management has assessed the Company’s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the tax incentive regime described above. At each period end management estimates the refundable tax offset available to the Company based on available information at the time. This estimate is also reviewed by external tax advisors on an annual basis.

In the nine months ended September 30, 2018 and 2017, the aggregate turnover of the Company had exceeded A$20 million and accordingly it was not eligible for a refundable tax offset. The Company was however eligible for the non-refundable tax offset. The eligible R&D activities and expenditures are able to be claimed as part of the current year income tax computation and any amounts included as a tax asset will be subject to recognition rules under ASC 740 “Income Taxes”.

Foreign Currency

Foreign Currency

Functional and reporting currency

Items included in the financial statements of each of the Group’s entities are measured using the currency of the primary economic environment in which the entity operates (“the functional currency”). The functional currency of UBI and UBS is AUD or A$ for all years presented. The functional currency of HRL is CAD$.

The consolidated condensed financial statements are presented using a reporting currency of Australian dollars.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in the consolidated condensed statements of comprehensive income.

The Company has recorded foreign currency transaction gains of A$183,395 and A$61,873 for the three months ended September 30, 2018 and 2017, respectively and A$412,768 and A$703,420 for the nine months ended September 30, 2018 and 2017, respectively.

The results and financial position of all the Group entities that have a functional currency different from the reporting currency are translated into the reporting currency as follows:

 

   

assets and liabilities for each balance sheet item reported are translated at the closing rate at the date of that balance sheet;

 

   

income and expenses for each income statement item reported are translated at average exchange rates (unless this is not a reasonable approximation of the effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions); and

 

   

all resulting exchange differences are recognized as a separate component of equity.

On consolidation, exchange differences arising from the translation of any net investment in foreign entities are taken to the Accumulated Other Comprehensive Income.

Commitments and Contingencies

Commitments and Contingencies

Liabilities for loss contingencies, arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. These were nil as at September 30, 2018. Purchase commitments contracted for as at September 30, 2018 is A$1,538,429 (December 31, 2017 : A$2,359,443).

Patent and License Costs

Patent and License Costs

Legal and maintenance fees incurred for patent application costs have been charged to expense and reported in general and administrative expense.

Clinical Trial Expenses

Clinical Trial Expenses

Clinical trial costs are a component of research and development expenses. These expenses include fees paid to participating hospitals and other service providers, which conduct certain testing activities on behalf of the Company. Depending on the timing of payments to the service providers and the level of service provided, the Company records prepaid or accrued expenses relating to these costs.

These prepaid or accrued expenses are based on estimates of the work performed under service agreements.

Leased Assets

Leased Assets

All of the Company’s leases for the periods ending September 30, 2018 and December 31, 2017 are considered operating leases. The costs of operating leases are charged to the consolidated condensed statements of comprehensive income on a straight-line basis over the lease term.

Stock-based Compensation

Stock-based Compensation

We measure stock-based compensation at grant date, based on the estimated fair value of the award, and recognize the cost as an expense on a straight-line basis over the vesting period of the award. We estimate the fair value of stock options using the Trinomial Lattice model. We also grant our employees Restricted Stock Units (“RSUs”) and Zero Priced Employee Options (“ZEPOs”). RSUs are stock awards granted to employees that entitle the holder to shares of common stock as the award vests. ZEPOs are stock options granted to employees that entitle the holder to shares of common stock as the award vests. The value of RSUs are determined and fixed on the grant date based on the Company’s stock price. The exercise price of ZEPOs is nil.

We record deferred tax assets for awards that will result in deductions on our income tax returns, based on the amount of compensation cost recognized and our statutory tax rate in the jurisdiction in which we will receive a deduction. Differences between the deferred tax assets recognized for financial reporting purposes and the actual tax deduction reported in our income tax return are recorded in expense or in capital in excess of par value if the tax deduction exceeds the deferred tax assets or to the extent that previously recognized credits to paid-in-capital are still available if the tax deduction is less than the deferred tax asset.

(a) Stock Option Plan

In 2004, the Company adopted an employee option plan (“Plan”). Options may be granted pursuant to the Plan to any person considered by the board to be employed by the Group on a permanent basis (whether full time, part time or on a long term casual basis). Each option gives the holder the right to subscribe for one share of common stock. The total number of options that may be issued under the Plan is such maximum amount permitted by law and the Listing Rules of the ASX. The exercise price and any exercise conditions are determined by the board at the time of grant of the options. Any exercise conditions must be satisfied before the options vest and become capable of exercise. The options lapse on such date determined by the board at the time of grant or earlier in accordance with the Plan. Options granted to date have had a term up to 10 years and generally vest in equal tranches over three years.

An option holder is not permitted to participate in a bonus issue or new issue of securities in respect of an option held prior to the issue of shares to the option holder pursuant to the exercise of an option. If the Company changes the number of issued shares through, or as a result of, any consolidation, subdivision, or similar reconstruction of the issued capital of the Company, the total number of options and the exercise price of the options (as applicable) will likewise be adjusted.

 

In accordance with ASC 718, the fair value of the option grants was estimated on the date of each grant using the Trinomial Lattice model. The assumptions for these grants were:

 

     Grant Date  
     Oct-17     Oct-17     Oct-17     Feb-17  

Exercise Price (A$)

     0.50       0.60       0.80       0.50  

Share Price at Grant Date (A$)

     0.38       0.38       0.38       0.39  

Volatility

     68     68     68     69

Expected Life (years)

     5       5       5       6  

Risk Free Interest Rate

     2.36     2.36     2.36     2.47

Fair Value of Option (A$)

     0.15       0.13       0.11       0.13  

Stock option activity during the current period is as follows:

 

     Number of shares      Weighted average
exercise price

A$
 

Balance at December 31, 2017

     22,003,215        0.63  

Granted

     0        0.00  

Exercised

     (503,334      0.00  

Lapsed

     (5,124,431      0.70  
  

 

 

    

 

 

 

Balance at September 30, 2018

     16,375,450        0.63  
  

 

 

    

 

 

 

The number of options exercisable as at September 30, 2018 and 2017 was 7,208,775 and 10,963,629, respectively. The total stock compensation expense recognized in the consolidated condensed statements of comprehensive income was A$51,182 and A$154,218 for the three months ended September 30, 2018 and 2017, respectively and A$228,224 and A$354,243 for the nine months ended September 30, 2018 and 2017, respectively.

As of September 30, 2018, there was A$674,671 of unrecognized compensation expense related to unvested share-based compensation arrangements under the Employee Option Plan. This expense is expected to be recognized over the vesting years as follows:

 

Fiscal Year    A$  

2018

     94,357  

2019

     321,558  

2020

     258,756  
  

 

 

 
     674,671  
  

 

 

 

The aggregate intrinsic value for all options outstanding as at September 30, 2018 and 2017 was zero.

(b) Restricted Share Plan

Our Employee Share Plan was adopted by the Board of Directors in 2009. The Employee Share Plan permits our Board to grant shares of our common stock to our employees and directors (although our Board has determined not to issue equity to non-executive directors). The number of shares able to be granted is limited to the amount permitted to be granted at law, the ASX Listing Rules and by the limits on our authorized share capital in our certificate of incorporation. All our employees are eligible for shares under the Employee Share Plan. The Company has in the past issued A$1,000 worth of restricted shares of common stock to employees of the Company but no more frequently than annually. The restricted shares have the same terms of issue as our existing shares of common stock but are not able to be traded until the earlier of three years from the date on which the shares are issued or the date the relevant employee ceases to be an employee of the Company or any of its associated group of companies.

 

No restricted shares have been issued by the Company since January 1, 2017.

Restricted stock awards activity during the current period is as follows:

 

     Number of shares      Weighted average
issue price

A$
 

Balance at December 31, 2017

     492,749        0.31  

Granted

     0        0.00  

Release of restricted shares

     (287,087      0.27  
  

 

 

    

 

 

 

Balance at September 30, 2018

     205,662        0.31  
  

 

 

    

 

 

 
Employee Benefit Costs

Employee Benefit Costs

The Company contributes 9.5% of each employee’s salary to standard defined contribution superannuation funds on behalf of all UBS employees. Superannuation is a compulsory savings program whereby employers are required to pay a portion of an employee’s remuneration to an approved superannuation fund that the employee is typically not able to access until they have reached the statutory retirement age. Whilst the Company has a third party default superannuation fund, it permits UBS employees to choose an approved and registered superannuation fund into which the contributions are paid. Contributions are charged to the consolidated condensed statements of comprehensive income as they become payable.

Registered Retirement Savings Plan and Deferred Sharing Profit Plan

Registered Retirement Savings Plan and Deferred Sharing Profit Plan

The Company provides eligible HRL employees a retirement plan. The retirement plan includes a Registered Retirement Savings Plan (“RRSP”) and Deferred Profit Sharing Plan (“DPSP”). The RRSP is voluntary and the employee contributions are matched by the Company up to a maximum of 5% based on their continuous years of service and placed into the DPSP. The Company contributes 1% to 2% of the employee’s base earnings towards the DPSP. The DPSP contributions are vested immediately.

Benefit Plan

Benefit Plan

The Company provides eligible HRL employees a Benefit Plan to its employees. In general, the Benefit Plan includes extended health care, dental care, basic life insurance, basic accidental death and dismemberment, and disability insurance.

Net Income/(Loss) per Share and Anti-dilutive Securities

Net Income/(Loss) per Share and Anti-dilutive Securities

Basic and diluted net income/(loss) per share is presented in conformity with ASC 260 – Earnings per Share. Basic and diluted net income/(loss) per share has been computed using the weighted-average number of common shares outstanding during the period. Diluted net income/(loss) per share is calculated by adjusting the basic net income/(loss) per share by assuming all dilutive potential ordinary shares are converted.

Total Comprehensive Income

Total Comprehensive Income/(Loss)

The Company follows ASC 220 – Comprehensive Income. Comprehensive income/(loss) is defined as the total change in shareholders’ equity during the period other than from transactions with shareholders, and for the Company, includes net income/(loss).

 

The tax effect allocated to each component of other comprehensive loss is as follows:

 

     Before-Tax Amount     

Tax (Expense)/

Benefit

     Net-of-Tax
Amount
 
     A$      A$      A$  

Nine Months Ended September 30, 2018

        

Foreign currency translation reserve

     36,525        0        36,525  

Reclassification for gains realised in net income

     0        0        0  
  

 

 

    

 

 

    

 

 

 

Other comprehensive loss

     36,525        0        36,525  
  

 

 

    

 

 

    

 

 

 

Nine Months Ended September 30, 2017

        

Foreign currency translation reserve

     5,497        0        5,497  

Reclassification for gains realised in net income

     0        0        0  
  

 

 

    

 

 

    

 

 

 

Other comprehensive loss

     5,497        0        5,497  
  

 

 

    

 

 

    

 

 

 
Business combinations

Business combinations

Business combinations are accounted for using the acquisition method of accounting. Acquisition cost is measured as the aggregate of the fair value at the date of acquisition of the assets given, equity instruments issued or liabilities incurred or assumed. Acquisition related costs are expensed as incurred (except for those costs arising on the issue of equity instruments which are recognized directly in equity). Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured at fair value on the acquisition date. Goodwill is measured as the excess of the acquisition cost, the amount of any non-controlling interest and the fair value of any previous UBI equity interest in the acquiree, over the fair value of the identifiable net assets acquired.

Reclassification

Reclassification

Certain prior year amounts have been reclassified to conform to the current year presentation.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

(a) Recent issued accounting standards not yet adopted

ASU No.2016-02, “Leases’

On February 25, 2016, the FASB issued ASU 2016-02, its new standard on accounting for leases. ASU 2016-02 introduces a lessee model that brings most leases on the balance sheet and eliminates the requirement in current U.S. GAAP for an entity to use bright-line tests in determining lease classification. The standard also requires lessors to increase the transparency of their exposure to changes in value of their residual assets and how they manage that exposure.

The new guidance will be effective for public business entities for annual periods beginning after December 15, 2018, and interim periods therein. Early adoption is permitted. The Company is currently evaluating the impact the adoption of ASU 2016-02 will have on the Company’s consolidated financial statements.

ASU No.2014-09, “Revenue from Contracts with Customers’

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (Topic 606), which provides companies with a single revenue recognition model for recognizing revenue from contracts with customers. The core principle of the new standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. There are two permitted transition methods under the new standard, the full retrospective method or the modified retrospective method. The new standard is effective for annual reporting periods beginning after December 15, 2017. The Company has deferred the adoption of this standard as is allowable for an Emerging Growth Company.

UBI has selected the modified retrospective method where the effect of applying the standard will be recognized at the date of initial application, without restating previous years. The Company is currently evaluating the impact the adoption of ASU 2014-09 will have on the Company’s consolidated financial statements.

ASU No. 2017-12, “Targeted Improvements to Accounting for Hedging Activities”

On August 28, 2017, the FASB issued ASU 2017-12, which amends the hedge accounting recognition and presentation requirements in ASC 815.2. The FASB’s objectives in issuing the ASU are to (1) improve the transparency and understandability of information conveyed to financial statement users about an entity’s risk management activities by better aligning the entity’s financial reporting for hedging relationships with those risk management activities and (2) reduce the complexity of and simplify the application of hedge accounting by preparers.

For public business entities, the ASU is effective for fiscal years beginning after December 15, 2018, and interim periods therein; however, early adoption by all entities is permitted upon its issuance. The Company is currently evaluating the impact the adoption of ASU 2014-09 will have on the Company’s consolidated financial statements.

(b) Recently adopted accounting pronouncements

ASU No.2016-18, “Restricted Cash’

On November 17, 2016, the FASB issued ASU 2016-18, which amends ASC 230 to add or clarify guidance on the classification and presentation of restricted cash in the statement of cash flows. For public business entities, the guidance is effective for fiscal years beginning after December 15, 2017, including interim periods therein. For all other entities, it is effective for fiscal years beginning after December 15, 2018, and interim periods thereafter. Early adoption is permitted for all entities. The Company has adopted this guidance from January 1, 2018 and it has not had a material impact on the Company’s consolidated financial statements.

ASU No.2016-15, “Classification of Certain Cash Receipts and Cash Payments”

On August 26, 2016, the FASB issued ASU 2016-15, which amends the guidance in ASC 230 to eliminate diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The guidance in the ASU is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted for all entities. The Company has adopted this guidance and it has not had a material impact on the Company’s consolidated financial statements.

ASU No.2016-16, “Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory’

On October 24, 2016, the FASB issued ASU 2016-16, which removes the prohibition in ASC 740 against the immediate recognition of the current and deferred income tax effects of intra-entity transfers of assets other than inventory. This ASU is effective for annual periods beginning after December 15, 2017, and interim periods within those annual periods. Early adoption is permitted for all entities as of the beginning of a fiscal year for which neither the annual or interim financial statements have been issued. Entities should apply the ASU’s amendments on a modified retrospective basis, recognizing the effects in retained earnings as of the beginning of the year of adoption. The Company has adopted this guidance and it has not had a material impact on the Company’s consolidated financial statements.

ASU No.2017-01, “Business Combination: Clarifying the Definition of a Business’

On January 5, 2017, the FASB issued ASU 2017-01 to clarify the definition of a business in ASC 805. The amendments in the ASU are intended to make application of the guidance more consistent and cost-efficient. The ASU is effective for annual periods beginning after December 15, 2017, including interim periods therein. The ASU must be applied prospectively on or after the effective date, and no disclosures for a change in accounting principle are required at transition. Early adoption is permitted for transactions (i.e., acquisitions or dispositions) that occurred before the issuance date or effective date of the standard. The Company has adopted this guidance and it has not had a material impact on the Company’s consolidated financial statements.

 

ASU No.2017-09, “Compensation – Stock Compensation: Scope of Modification Accounting’

On May 10, 2017, the FASB issued ASU 2017-09, which amends the scope of modification accounting for share-based payment arrangements. The ASU provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting under ASC 718. This ASU is effective for annual reporting periods, including interim periods within those annual reporting periods, beginning after December 15, 2017. Early adoption is permitted. The Company has adopted this guidance and it has not had a material impact on the Company’s consolidated financial statements.

ASU No. 2018-05, “Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118.”

On March 13, 2018, the FASB issued ASU 2018-05. This Financial Reporting Alert contains responses to frequently asked questions about how an entity should account for the tax effects of the new tax reform legislation in accordance with ASC 740, Income Taxes. This ASU is effective upon issuance and the adoption of this guidance has not had a material impact on the Company’s consolidated financial statements.

ASU No. 2018-09, “Codification Improvements”

The FASB issued ASU 2018-09 on July 16, 2018. The ASU’s amendments “clarify, correct errors in, or make minor improvements to the Codification.” This ASU is effective upon issuance and the adoption of this guidance has not had a material impact on the Company’s consolidated financial statements.

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2018
Accounting Policies [Abstract]  
Inventory, Net

Costs of purchased inventory are determined after deducting rebates and discounts.

 

     Nine Months Ended
September 30,
     Year Ended
December 31,
 
     2018      2017  
     A$      A$  

Raw materials

     322,399        380,540  

Work in progress

     158,883        253,483  

Finished goods

     0        28,109  
  

 

 

    

 

 

 
     481,282        662,132  
  

 

 

    

 

 

 
Summary of Receivables

Account balances are charged against the allowance when it is probable the receivable will not be recovered.

 

     Nine Months Ended
September 30,
     Year Ended
December 31,
 
     2018      2017  
     A$      A$  

Accounts receivable

     4,902,417        4,397,268  

Allowance for doubtful debts

     0        0  
  

 

 

    

 

 

 
     4,902,417        4,397,268  
  

 

 

    

 

 

 
Other Liabilities

Other liabilities are broken down as follows:

 

     Nine Months Ended
September 30,
     Year Ended
December 31,
 
     2018      2017  
     A$      A$  

Current liabilites

     

Marketing support payment

     2,836,614        2,626,413  
  

 

 

    

 

 

 
     2,836,614        2,626,413  
  

 

 

    

 

 

 
Research and Development Expenses

Research and development expenses for the respective periods are as follows:

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2018      2017      2018      2017  
     A$      A$      A$      A$  

Research and development expenses

     2,759,664        3,197,146        9,452,609        7,626,210  
  

 

 

    

 

 

    

 

 

    

 

 

 
Assumptions for Option Grants Issued

The assumptions for these grants were:

 

     Grant Date  
     Oct-17     Oct-17     Oct-17     Feb-17  

Exercise Price (A$)

     0.50       0.60       0.80       0.50  

Share Price at Grant Date (A$)

     0.38       0.38       0.38       0.39  

Volatility

     68     68     68     69

Expected Life (years)

     5       5       5       6  

Risk Free Interest Rate

     2.36     2.36     2.36     2.47

Fair Value of Option (A$)

     0.15       0.13       0.11       0.13  
Stock Option Activity

Stock option activity during the current period is as follows:

 

     Number of shares      Weighted average
exercise price

A$
 

Balance at December 31, 2017

     22,003,215        0.63  

Granted

     0        0.00  

Exercised

     (503,334      0.00  

Lapsed

     (5,124,431      0.70  
  

 

 

    

 

 

 

Balance at September 30, 2018

     16,375,450        0.63  
  

 

 

    

 

 

 
Unrecognized Compensation Expense Related to Unvested Share-Based Compensation Arrangements Expected to be Recognized

This expense is expected to be recognized over the vesting years as follows:

 

Fiscal Year    A$  

2018

     94,357  

2019

     321,558  

2020

     258,756  
  

 

 

 
     674,671  
  

 

 

 
Restricted Stock Awards Activity

Restricted stock awards activity during the current period is as follows:

 

     Number of shares      Weighted average
issue price

A$
 

Balance at December 31, 2017

     492,749        0.31  

Granted

     0        0.00  

Release of restricted shares

     (287,087      0.27  
  

 

 

    

 

 

 

Balance at September 30, 2018

     205,662        0.31  
  

 

 

    

 

 

 
Effects of Allocated Tax to Each Component of Other Comprehensive Loss

The tax effect allocated to each component of other comprehensive loss is as follows:

 

     Before-Tax Amount     

Tax (Expense)/

Benefit

     Net-of-Tax
Amount
 
     A$      A$      A$  

Nine Months Ended September 30, 2018

        

Foreign currency translation reserve

     36,525        0        36,525  

Reclassification for gains realised in net income

     0        0        0  
  

 

 

    

 

 

    

 

 

 

Other comprehensive loss

     36,525        0        36,525  
  

 

 

    

 

 

    

 

 

 

Nine Months Ended September 30, 2017

        

Foreign currency translation reserve

     5,497        0        5,497  

Reclassification for gains realised in net income

     0        0        0  
  

 

 

    

 

 

    

 

 

 

Other comprehensive loss

     5,497        0        5,497  
  

 

 

    

 

 

    

 

 

 
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1
Borrowings (Tables)
9 Months Ended
Sep. 30, 2018
Debt Disclosure [Abstract]  
Future Maturities, Interest and Other Payments under Company's Long Term Secured Loan Pursuant to Credit Agreement

Future maturities, interest and other payments under the Company’s long term secured loan pursuant to the credit agreement (described below) as of September 30, 2018 and December 31, 2017 are as follows:

 

     September 30, 2018      December 31, 2017  
     US$      A$      US$      A$  

2018

     442,750           1,956,563     

2019

     15,221,375           15,875,875     
  

 

 

       

 

 

    

Total minimum payments

     15,664,125           17,832,438     

Less amount representing interest and other fees

     (664,125         (2,832,438   
  

 

 

       

 

 

    

Gross balance of long term debt

     15,000,000           15,000,000     

Less fair value of warrants recorded within loan (a)

     (815,655         (815,655   

Plus interest accretion

     736,851           658,334     
  

 

 

       

 

 

    

Total carrying value

     14,921,196        20,660,753        14,842,679        19,029,076  
  

 

 

    

 

 

    

 

 

    

 

 

 

Less current portion

     14,921,196        20,660,753        0        0  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total carrying value, non-current portion

     0        0        14,842,679        19,029,076  
  

 

 

    

 

 

    

 

 

    

 

 

 

The above assumes, as provided under the Athyrium Credit Agreement, the loan will be repaid immediately out of the proceeds from the lump sum service fees which is expected to be received on or about February 15, 2019.

The carrying value of the borrowings approximates its fair value. The fair value is estimated by discounting future cash flows at the currently offered rates for borrowings of similar remaining maturities.

 

  (a)

The warrants issued in December 2013 had a fair value of US$815,655 as of September 30, 2018 and December 31, 2017, and are included in equity.

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1
Restricted Cash (Tables)
9 Months Ended
Sep. 30, 2018
Cash and Cash Equivalents [Abstract]  
Reconciliation of Cash and Cash Equivalent and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated condensed balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows.

 

     Nine Months Ended
September 30,
     Year Ended
December 31,
 
     2018      2017  
     A$      A$  

Cash and cash equivalents

     28,531,432        26,259,918  

Restricted cash - current assets

     2,915,949        15,309  

Restricted cash - non-current assets

     320,000        3,220,000  
  

 

 

    

 

 

 
     31,767,381        29,495,227  
  

 

 

    

 

 

 
Restricted Cash Maintained by the Company in the Form of Term Deposits

Restricted cash maintained by the Company in the form of term deposits is as follows:

 

     Nine Months Ended
September 30,
     Year Ended
December 31,
 
     2018      2017  
     A$      A$  

Collateral for facilities (a) - current assets

     15,949        15,309  

Collateral for facilities (b) - non-current assets

     320,000        320,000  

Financial covenant pursuant to the credit agreement (c) - current assets

     2,900,000        0  

Financial covenant pursuant to the credit agreement (c) - non-current assets

     0        2,900,000  
  

 

 

    

 

 

 
     3,235,949        3,235,309  
  

 

 

    

 

 

 

 

(a)

Represents bank guarantee of CDN$15,000 as security deposit on HRL’s credit card

(b)

Represents bank guarantee of A$250,000 for commercial lease of UBS’ premises and security deposit on Company’s credit cards of A$70,000

(c)

Represents amounts pledged as collateral for financing arrangements as contractually required by the Lenders. The restriction will lapse when the related debt is paid off in July 2019 or earlier as provided pursuant to the Credit Agreement

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1
Basis of Presentation - Additional Information (Detail)
9 Months Ended
Sep. 30, 2018
Minimum [Member]  
Basis Of Presentation [Line Items]  
Sufficient cash and cash equivalents to fund our operations 12 months
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies - Additional Information (Detail)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jun. 30, 2018
AUD ($)
Nov. 30, 2017
AUD ($)
Sep. 30, 2018
AUD ($)
Strips
Milestone
shares
Sep. 30, 2017
AUD ($)
shares
Sep. 30, 2018
AUD ($)
Strips
Milestone
Payments
shares
Sep. 30, 2018
USD ($)
Payments
shares
Sep. 30, 2017
AUD ($)
shares
Dec. 31, 2018
Dec. 31, 2017
AUD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2016
AUD ($)
Strips
Dec. 31, 2017
USD ($)
Dec. 31, 2017
CAD ($)
Dec. 31, 2016
USD ($)
Dec. 31, 2016
CAD ($)
Sep. 09, 2011
AUD ($)
Sep. 09, 2011
USD ($)
Summary Of Significant Accounting Policies [Line Items]                                  
Minimum maturity period of highly liquid investments purchase         3 months 3 months                      
Short-term investments maturity period, minimum         3 months 3 months                      
Short-term investments maturity period, maximum         12 months 12 months                      
Impairment of long-lived assets held-for-use         $ 0       $ 0                
Percentage of manufacturing initial payment     40.00%   40.00%                        
Duration of payment of marketing support payment on achieving target sales         2 years 2 years                      
Target strips to be sold for payment of marketing support payment | Strips     1,000,000,000   1,000,000,000                        
Total amount of expected marketing support payments         $ 2,836,614 $ 2,048,602                      
Number of strips sold | Strips                     1,000,000,000            
Income tax liabilities expected payment period                 8 years 8 years              
Estimated tax on mandatory repatriation                                
Accumulated tax losses available for carry forward against future earnings                 $ 10,993,737   $ 22,616,230            
Non-refundable R&D tax offset                 11,048,336   $ 5,800,672            
Asset retirement obligation     $ 2,600,000   2,600,000       2,600,000                
Refundable tax offset research and development tax incentive income         20,000,000                        
Non-refundable tax offset research and development tax incentive income         $ 20,000,000   $ 20,000,000                    
Refundable tax offset percentage         43.50% 43.50%                      
Non-refundable tax offset percentage         38.50% 38.50%                      
Foreign currency transaction gains     183,395 $ 61,873 $ 412,768   $ 703,420                    
Commitments and contingencies     $ 0   0       0                
Purchase commitments         $ 1,538,429       $ 2,359,443                
Number of common stock given to each option holder | shares         1 1                      
Number of options exercisable | shares     7,208,775 10,963,629 7,208,775   10,963,629                    
Stock compensation expense recognized     $ 51,182 $ 154,218 $ 228,224   $ 354,243                    
Restricted shares of common stock to employees     1,000   $ 1,000                        
Period of non traded years of existing shares of common stock         3 years 3 years                      
Restricted shares, issued | shares         0 0                      
Employer contribution percentage         9.50% 9.50%                      
Employee Stock Option [Member]                                  
Summary Of Significant Accounting Policies [Line Items]                                  
Vesting period of options granted         3 years 3 years                      
Unrecognized compensation expense related to unvested share-based compensation arrangements     674,671   $ 674,671                        
Aggregate intrinsic value for all options outstanding     $ 0 $ 0 $ 0   $ 0                    
Internal Revenue Service (IRS) [Member]                                  
Summary Of Significant Accounting Policies [Line Items]                                  
Accumulated tax losses available for carry forward against future earnings                       $ 1,011,321   $ 1,011,321      
Effective tax rate                 34.00% 34.00%              
Deferred tax benefit on new rate                   $ 212,377              
Scenario, Plan [Member] | Internal Revenue Service (IRS) [Member]                                  
Summary Of Significant Accounting Policies [Line Items]                                  
Effective tax rate               21.00%                  
Universal Biosensors Pty Ltd [Member]                                  
Summary Of Significant Accounting Policies [Line Items]                                  
Government grants term         3 years 3 years                      
Government grants commencement date         Jan. 01, 2017 Jan. 01, 2017                      
Government grants received $ 89,500 $ 271,318                              
Hemostasis Reference Laboratory Inc [Member] | Canada Revenue Agency [Member]                                  
Summary Of Significant Accounting Policies [Line Items]                                  
Accumulated tax losses available for carry forward against future earnings                         $ 668,043   $ 95,096    
Collaborative Arrangement [Member]                                  
Summary Of Significant Accounting Policies [Line Items]                                  
Non-refundable payment                               $ 2,961,245 $ 3,000,000
Maximum number of payments entity may receive from Siemens | Payments         7 7                      
Number of milestone payments delivered | Milestone     4   4                        
Maximum [Member]                                  
Summary Of Significant Accounting Policies [Line Items]                                  
Estimated useful life of machinery and equipment         10 years 10 years                      
Maximum [Member] | Employee Stock Option [Member]                                  
Summary Of Significant Accounting Policies [Line Items]                                  
Term of options granted         10 years 10 years                      
Maximum [Member] | Universal Biosensors Pty Ltd [Member]                                  
Summary Of Significant Accounting Policies [Line Items]                                  
Government grants receivable     $ 575,000   $ 575,000                        
Maximum [Member] | RRSP [Member]                                  
Summary Of Significant Accounting Policies [Line Items]                                  
Employer matching contribution percentage         5.00% 5.00%                      
Maximum [Member] | DPSP [Member]                                  
Summary Of Significant Accounting Policies [Line Items]                                  
Employer contribution percentage         2.00% 2.00%                      
Minimum [Member]                                  
Summary Of Significant Accounting Policies [Line Items]                                  
Estimated useful life of machinery and equipment         3 years 3 years                      
Minimum [Member] | DPSP [Member]                                  
Summary Of Significant Accounting Policies [Line Items]                                  
Employer contribution percentage         1.00% 1.00%                      
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies - Inventory, Net (Detail) - AUD ($)
Sep. 30, 2018
Dec. 31, 2017
Accounting Policies [Abstract]    
Raw materials $ 322,399 $ 380,540
Work in progress 158,883 253,483
Finished goods 0 28,109
Inventory, Net, Total $ 481,282 $ 662,132
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies - Summary of Receivables (Detail) - AUD ($)
Sep. 30, 2018
Dec. 31, 2017
Accounting Policies [Abstract]    
Accounts receivable $ 4,902,417 $ 4,397,268
Allowance for doubtful debts 0 0
Accounts Receivable, Net, Current, Total $ 4,902,417 $ 4,397,268
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies - Other Liabilities (Detail) - AUD ($)
Sep. 30, 2018
Dec. 31, 2017
Current liabilities    
Marketing support payment $ 2,836,614 $ 2,626,413
Other current liabilities $ 2,836,614 $ 2,626,413
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies - Research and Development Expenses (Detail) - AUD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Accounting Policies [Abstract]        
Research and development expenses $ 2,759,664 $ 3,197,146 $ 9,452,609 $ 7,626,210
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies - Assumptions for Option Grants Issued (Detail) - $ / shares
1 Months Ended
Oct. 31, 2017
Feb. 28, 2017
Oct-17 [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Exercise Price $ 0.50  
Share Price at Grant Date $ 0.38  
Volatility 68.00%  
Expected Life (years) 5 years  
Risk Free Interest Rate 2.36%  
Fair Value of Option $ 0.15  
Oct-17 [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Exercise Price 0.60  
Share Price at Grant Date $ 0.38  
Volatility 68.00%  
Expected Life (years) 5 years  
Risk Free Interest Rate 2.36%  
Fair Value of Option $ 0.13  
Oct-17 [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Exercise Price 0.80  
Share Price at Grant Date $ 0.38  
Volatility 68.00%  
Expected Life (years) 5 years  
Risk Free Interest Rate 2.36%  
Fair Value of Option $ 0.11  
Feb-17 [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Exercise Price   $ 0.50
Share Price at Grant Date   $ 0.39
Volatility   69.00%
Expected Life (years)   6 years
Risk Free Interest Rate   2.47%
Fair Value of Option   $ 0.13
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies - Stock Option Activity (Detail) - Employee Stock Option [Member]
9 Months Ended
Sep. 30, 2018
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Stock Options, Outstanding Number of shares, Beginning Balance | shares 22,003,215
Stock Options, Number of shares, Granted | shares 0
Stock Options, Number of shares, Exercised | shares (503,334)
Stock Options, Number of shares, Lapsed | shares (5,124,431)
Stock Options, Outstanding Number of shares, Ending Balance | shares 16,375,450
Stock Options, Weighted average exercise price, Beginning Balance | $ / shares $ 0.63
Stock Options, Weighted average exercise price, Granted | $ / shares 0.00
Stock Options, Weighted average exercise price, Exercised | $ / shares 0.00
Stock Options, Weighted average exercise price, Lapsed | $ / shares 0.70
Stock Options, Weighted average exercise price, Ending Balance | $ / shares $ 0.63
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies - Unrecognized Compensation Expense Related to Unvested Share-Based Compensation Arrangements Expected to be Recognized (Detail) - Employee Stock Option [Member]
Sep. 30, 2018
AUD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Total $ 674,671
2018 [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Total 94,357
2019 [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Total 321,558
2020 [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Total $ 258,756
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies - Restricted Stock Awards Activity (Detail) - Restricted Stock [Member]
9 Months Ended
Sep. 30, 2018
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Number of shares, Beginning Balance | shares 492,749
Number of shares, Granted | shares 0
Number of shares, Release of restricted shares | shares (287,087)
Number of shares, Ending Balance | shares 205,662
Weighted average issue price, Beginning Balance | $ / shares $ 0.31
Weighted average issue price, Granted | $ / shares 0.00
Weighted average issue price, Release of restricted shares | $ / shares 0.27
Weighted average issue price, Ending Balance | $ / shares $ 0.31
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies - Effects of Allocated Tax to Each Component of Other Comprehensive Loss (Detail) - AUD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Accounting Policies [Abstract]        
Foreign currency translation reserve, before-tax amount     $ 36,525 $ 5,497
Foreign currency translation reserve, reclassification for gains realized in net income, before-tax amount     0 0
Other comprehensive gain/loss, before- tax amount     36,525 5,497
Foreign currency translation reserve, tax (expense)/ benefit     0 0
Foreign currency translation reserve, reclassification for gains realized in net income, tax (expense)/ benefit     0 0
Other comprehensive gain/loss, tax (expense)/ benefit     0 0
Foreign currency translation reserve, net-of-tax amount $ 31,391 $ 4,451 36,525 5,497
Foreign currency translation reserve, Reclassification for gains realized in net income, net-of-tax amount     0 0
Other comprehensive gain/(loss) $ 31,391 $ 4,451 $ 36,525 $ 5,497
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1
Related Party Transactions - Additional Information (Detail) - AUD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2011
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Related Party Transaction [Line Items]          
Agreement of milestone payments   $ 47,235,025 $ 6,345,606 $ 60,725,274 $ 20,672,957
SpeeDx [Member]          
Related Party Transaction [Line Items]          
Agreement of milestone payments $ 500,000        
License agreement termination period 7 years        
SpeeDx [Member] | Minimum [Member]          
Related Party Transaction [Line Items]          
Sales and licensing revenues payments 5.00%        
SpeeDx [Member] | Maximum [Member]          
Related Party Transaction [Line Items]          
Sales and licensing revenues payments 15.00%        
Viburnum Funds Pty Ltd [Member]          
Related Party Transaction [Line Items]          
Ownership shares held in Company which has one of our directors   18.00%   18.00%  
Expenditure reimbursed       $ 21,716  
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1
Borrowings - Future Maturities, Interest and Other Payments under Company's Long Term Secured Loan Pursuant to Credit Agreement (Detail)
Sep. 30, 2018
AUD ($)
Sep. 30, 2018
USD ($)
Dec. 31, 2017
AUD ($)
Dec. 31, 2017
USD ($)
Borrowings        
2018   $ 442,750   $ 1,956,563
2019   15,221,375   15,875,875
Total minimum payments   15,664,125   17,832,438
Less amount representing interest and other fees   (664,125)   (2,832,438)
Gross balance of long term debt   15,000,000   15,000,000
Less fair value of warrants recorded within loan   (815,655)   (815,655)
Plus interest accretion   736,851   658,334
Total carrying value $ 20,660,753 14,921,196 $ 19,029,076 14,842,679
Less current portion 20,660,753 14,921,196 0 0
Total carrying value, non-current portion 0 0 19,029,076 14,842,679
Total carrying value $ 20,660,753 $ 14,921,196 $ 19,029,076 $ 14,842,679
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.10.0.1
Borrowings - Future Maturities, Interest and Other Payments under Company's Long Term Secured Loan Pursuant to Credit Agreement (Parenthetical) (Detail) - USD ($)
Sep. 30, 2018
Dec. 31, 2017
Debt Disclosure [Abstract]    
Fair value included in equity $ 815,655 $ 815,655
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1
Borrowings - Additional Information (Detail)
$ / shares in Units, shares in Millions
1 Months Ended 9 Months Ended
Dec. 29, 2017
Dec. 19, 2013
USD ($)
shares
Sep. 30, 2017
AUD ($)
Aug. 31, 2015
USD ($)
Feb. 28, 2015
USD ($)
Jan. 30, 2015
USD ($)
Sep. 30, 2018
USD ($)
Milestone
Dec. 31, 2017
USD ($)
Dec. 31, 2016
AUD ($)
Dec. 31, 2013
USD ($)
Dec. 19, 2013
$ / shares
Debt Instrument [Line Items]                      
Secured term loan, drawn amount             $ 15,000,000 $ 15,000,000      
Milestone payments paid       $ 300,000 $ 300,000            
Number of common stock entitled by issuing warrants | shares   4.5                  
Exercise price of warrants | $ / shares                     $ 1.00
Percentage of premium over closing price of common stock   117.00%                  
Warrants exercisable period             7 years        
Elantis Premium Funding Ltd [Member]                      
Debt Instrument [Line Items]                      
Interest charged             2.60%        
Total amount financed                 $ 369,630    
Repayment of financed amount     $ 369,630                
Athyrium Credit Agreement [Member]                      
Debt Instrument [Line Items]                      
Athyrium credit agreement, date             Dec. 19, 2013        
Secured term loan, amount   $ 25,000,000                  
Secured term loan, drawn amount                   $ 15,000,000  
Secured term loan, undrawn amount             $ 10,000,000        
Line of credit facility expiration date             Jul. 01, 2019        
Interest charged             10.50%        
Default interest rate under credit agreement             13.00%        
Minimum voluntary repayments             $ 2,500,000        
Percentage of prepayment to lenders on net cash proceeds received             100.00%        
Prepayment premium after second anniversary, percentage             15.00%        
Non-refundable fee paid   $ 625,000       $ 200,000          
Non-refundable fee as percentage of aggregate credit facility   2.50%                  
Percentage of commitment fee paid   2.00%                  
Percentage of milestone payments             30.00%        
Maximum milestone payments to be paid             $ 600,000        
Number of milestone payments | Milestone             2        
Minimum restricted cash required             $ 2,000,000        
Number of common stock entitled by issuing warrants | shares   4.5                  
Exercise price of warrants | $ / shares                     $ 1.00
Percentage of premium over closing price of common stock   117.00%                  
Warrants exercisable period             7 years        
Athyrium Credit Agreement [Member] | Amendment [Member]                      
Debt Instrument [Line Items]                      
Line of credit facility expiration date Jul. 01, 2019                    
Stock repurchase program, authorized amount             $ 2,000,000        
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.10.0.1
Warrants - Additional Information (Detail) - $ / shares
9 Months Ended
Sep. 30, 2018
Dec. 19, 2013
Other Liabilities Disclosure [Abstract]    
Number of common stock entitled by issuing warrants   4,500,000
Exercise price of warrants   $ 1.00
Percentage of premium over closing price of common stock   117.00%
Warrants exercisable period 7 years  
Warrants exercise expiration date Dec. 19, 2020  
Warrants exercise in multiples of shares, minimum 500,000  
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.10.0.1
Restricted Cash - Reconciliation of Cash and Cash Equivalent and Restricted Cash (Detail) - AUD ($)
Sep. 30, 2018
Dec. 31, 2017
Cash and Cash Equivalents [Abstract]    
Cash and cash equivalents $ 28,531,432 $ 26,259,918
Restricted cash - current assets 2,915,949 15,309
Restricted cash - non-current assets 320,000 3,220,000
Total $ 31,767,381 $ 29,495,227
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.10.0.1
Restricted Cash - Restricted Cash Maintained by the Company in the Form of Term Deposits (Detail) - AUD ($)
Sep. 30, 2018
Dec. 31, 2017
Restricted Cash and Cash Equivalents Items [Line Items]    
Restricted cash, current $ 2,915,949 $ 15,309
Restricted cash, noncurrent 320,000 3,220,000
Total 3,235,949 3,235,309
Collateral for Facilities [Member]    
Restricted Cash and Cash Equivalents Items [Line Items]    
Restricted cash, current 15,949 15,309
Restricted cash, noncurrent 320,000 320,000
Financial Covenant Pursuant to the Credit Agreement [Member]    
Restricted Cash and Cash Equivalents Items [Line Items]    
Restricted cash, current 2,900,000 0
Restricted cash, noncurrent $ 0 $ 2,900,000
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.10.0.1
Restricted Cash - Restricted Cash Maintained by the Company in the Form of Term Deposits (Parenthetical) (Detail) - 9 months ended Sep. 30, 2018
AUD ($)
CAD ($)
Financial Covenant Pursuant to the Credit Agreement [Member] | Restricted Cash NonCurrent Asset [Member]    
Restricted Cash and Cash Equivalents Items [Line Items]    
Maturity of debt instrument 2019-07  
Collateral for Facilities [Member] | HRL Credit Card [Member] | Restricted Cash Current Asset [Member]    
Restricted Cash and Cash Equivalents Items [Line Items]    
Security deposit   $ 15,000
Collateral for Facilities [Member] | Commercial Leases [Member] | Restricted Cash NonCurrent Asset [Member]    
Restricted Cash and Cash Equivalents Items [Line Items]    
Security deposit $ 250,000  
Collateral for Facilities [Member] | Credit Card [Member] | Restricted Cash NonCurrent Asset [Member]    
Restricted Cash and Cash Equivalents Items [Line Items]    
Security deposit $ 70,000  
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.10.0.1
Restricted Cash - Additional Information (Detail) - AUD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Cash and Cash Equivalents [Abstract]        
Interest earned on restricted cash $ 18,500 $ 12,394 $ 53,420 $ 50,423
EXCEL 49 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 51 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 53 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 107 280 1 false 39 0 false 10 false false R1.htm 101 - Document - Document and Entity Information Sheet http://universalbiosensors.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 103 - Statement - Consolidated Condensed Balance Sheets (Unaudited) Sheet http://universalbiosensors.com/taxonomy/role/StatementOfFinancialPositionClassified Consolidated Condensed Balance Sheets (Unaudited) Statements 2 false false R3.htm 104 - Statement - Consolidated Condensed Balance Sheets (Unaudited) (Parenthetical) Sheet http://universalbiosensors.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Consolidated Condensed Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 105 - Statement - Consolidated Condensed Statements of Comprehensive Income/(Loss) (Unaudited) Sheet http://universalbiosensors.com/taxonomy/role/StatementOfIncome Consolidated Condensed Statements of Comprehensive Income/(Loss) (Unaudited) Statements 4 false false R5.htm 106 - Statement - Consolidated Condensed Statements of Changes in Stockholders' Equity and Comprehensive Income/(Loss) (Unaudited) Sheet http://universalbiosensors.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome Consolidated Condensed Statements of Changes in Stockholders' Equity and Comprehensive Income/(Loss) (Unaudited) Statements 5 false false R6.htm 107 - Statement - Consolidated Condensed Statements of Cash Flows (Unaudited) Sheet http://universalbiosensors.com/taxonomy/role/StatementOfCashFlowsIndirect Consolidated Condensed Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 108 - Disclosure - Organization of the Company Sheet http://universalbiosensors.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations Organization of the Company Notes 7 false false R8.htm 109 - Disclosure - Interim Financial Statements Sheet http://universalbiosensors.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock Interim Financial Statements Notes 8 false false R9.htm 110 - Disclosure - Basis of Presentation Sheet http://universalbiosensors.com/taxonomy/role/NotesToFinancialStatementsBasisOfAccounting Basis of Presentation Notes 9 false false R10.htm 111 - Disclosure - Summary of Significant Accounting Policies Sheet http://universalbiosensors.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock Summary of Significant Accounting Policies Notes 10 false false R11.htm 112 - Disclosure - Related Party Transactions Sheet http://universalbiosensors.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock Related Party Transactions Notes 11 false false R12.htm 113 - Disclosure - Borrowings Sheet http://universalbiosensors.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock Borrowings Notes 12 false false R13.htm 114 - Disclosure - Warrants Sheet http://universalbiosensors.com/taxonomy/role/NotesToFinancialStatementsWarrantsDisclosureTextBlock Warrants Notes 13 false false R14.htm 115 - Disclosure - Restricted Cash Sheet http://universalbiosensors.com/taxonomy/role/NotesToFinancialStatementsCashAndCashEquivalentsDisclosureTextBlock Restricted Cash Notes 14 false false R15.htm 116 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://universalbiosensors.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies Summary of Significant Accounting Policies (Policies) Policies http://universalbiosensors.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock 15 false false R16.htm 117 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://universalbiosensors.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables Summary of Significant Accounting Policies (Tables) Tables http://universalbiosensors.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock 16 false false R17.htm 118 - Disclosure - Borrowings (Tables) Sheet http://universalbiosensors.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables Borrowings (Tables) Tables http://universalbiosensors.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock 17 false false R18.htm 119 - Disclosure - Restricted Cash (Tables) Sheet http://universalbiosensors.com/taxonomy/role/NotesToFinancialStatementsCashAndCashEquivalentsDisclosureTextBlockTables Restricted Cash (Tables) Tables http://universalbiosensors.com/taxonomy/role/NotesToFinancialStatementsCashAndCashEquivalentsDisclosureTextBlock 18 false false R19.htm 120 - Disclosure - Basis of Presentation - Additional Information (Detail) Sheet http://universalbiosensors.com/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformation Basis of Presentation - Additional Information (Detail) Details 19 false false R20.htm 121 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://universalbiosensors.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation Summary of Significant Accounting Policies - Additional Information (Detail) Details 20 false false R21.htm 122 - Disclosure - Summary of Significant Accounting Policies - Inventory, Net (Detail) Sheet http://universalbiosensors.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryNet Summary of Significant Accounting Policies - Inventory, Net (Detail) Details 21 false false R22.htm 123 - Disclosure - Summary of Significant Accounting Policies - Summary of Receivables (Detail) Sheet http://universalbiosensors.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReceivables Summary of Significant Accounting Policies - Summary of Receivables (Detail) Details 22 false false R23.htm 124 - Disclosure - Summary of Significant Accounting Policies - Other Liabilities (Detail) Sheet http://universalbiosensors.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesOtherLiabilities Summary of Significant Accounting Policies - Other Liabilities (Detail) Details 23 false false R24.htm 125 - Disclosure - Summary of Significant Accounting Policies - Research and Development Expenses (Detail) Sheet http://universalbiosensors.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentExpenses Summary of Significant Accounting Policies - Research and Development Expenses (Detail) Details 24 false false R25.htm 126 - Disclosure - Summary of Significant Accounting Policies - Assumptions for Option Grants Issued (Detail) Sheet http://universalbiosensors.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAssumptionsForOptionGrantsIssued Summary of Significant Accounting Policies - Assumptions for Option Grants Issued (Detail) Details 25 false false R26.htm 127 - Disclosure - Summary of Significant Accounting Policies - Stock Option Activity (Detail) Sheet http://universalbiosensors.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesStockOptionActivity Summary of Significant Accounting Policies - Stock Option Activity (Detail) Details 26 false false R27.htm 128 - Disclosure - Summary of Significant Accounting Policies - Unrecognized Compensation Expense Related to Unvested Share-Based Compensation Arrangements Expected to be Recognized (Detail) Sheet http://universalbiosensors.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesUnrecognizedCompensationExpenseRelatedToUnvestedShareBasedCompensationArrangementsExpectedToBeRecognized Summary of Significant Accounting Policies - Unrecognized Compensation Expense Related to Unvested Share-Based Compensation Arrangements Expected to be Recognized (Detail) Details 27 false false R28.htm 129 - Disclosure - Summary of Significant Accounting Policies - Restricted Stock Awards Activity (Detail) Sheet http://universalbiosensors.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedStockAwardsActivity Summary of Significant Accounting Policies - Restricted Stock Awards Activity (Detail) Details 28 false false R29.htm 130 - Disclosure - Summary of Significant Accounting Policies - Effects of Allocated Tax to Each Component of Other Comprehensive Loss (Detail) Sheet http://universalbiosensors.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEffectsOfAllocatedTaxToEachComponentOfOtherComprehensiveLoss Summary of Significant Accounting Policies - Effects of Allocated Tax to Each Component of Other Comprehensive Loss (Detail) Details 29 false false R30.htm 131 - Disclosure - Related Party Transactions - Additional Information (Detail) Sheet http://universalbiosensors.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation Related Party Transactions - Additional Information (Detail) Details 30 false false R31.htm 132 - Disclosure - Borrowings - Future Maturities, Interest and Other Payments under Company's Long Term Secured Loan Pursuant to Credit Agreement (Detail) Sheet http://universalbiosensors.com/taxonomy/role/DisclosureBorrowingsFutureMaturitiesInterestAndOtherPaymentsUnderCompanysLongTermSecuredLoanPursuantToCreditAgreement Borrowings - Future Maturities, Interest and Other Payments under Company's Long Term Secured Loan Pursuant to Credit Agreement (Detail) Details 31 false false R32.htm 133 - Disclosure - Borrowings - Future Maturities, Interest and Other Payments under Company's Long Term Secured Loan Pursuant to Credit Agreement (Parenthetical) (Detail) Sheet http://universalbiosensors.com/taxonomy/role/DisclosureBorrowingsFutureMaturitiesInterestAndOtherPaymentsUnderCompanysLongTermSecuredLoanPursuantToCreditAgreementParenthetical Borrowings - Future Maturities, Interest and Other Payments under Company's Long Term Secured Loan Pursuant to Credit Agreement (Parenthetical) (Detail) Details 32 false false R33.htm 134 - Disclosure - Borrowings - Additional Information (Detail) Sheet http://universalbiosensors.com/taxonomy/role/DisclosureBorrowingsAdditionalInformation Borrowings - Additional Information (Detail) Details 33 false false R34.htm 135 - Disclosure - Warrants - Additional Information (Detail) Sheet http://universalbiosensors.com/taxonomy/role/DisclosureWarrantsAdditionalInformation Warrants - Additional Information (Detail) Details 34 false false R35.htm 136 - Disclosure - Restricted Cash - Reconciliation of Cash and Cash Equivalent and Restricted Cash (Detail) Sheet http://universalbiosensors.com/taxonomy/role/DisclosureRestrictedCashReconciliationOfCashAndCashEquivalentAndRestrictedCash Restricted Cash - Reconciliation of Cash and Cash Equivalent and Restricted Cash (Detail) Details 35 false false R36.htm 137 - Disclosure - Restricted Cash - Restricted Cash Maintained by the Company in the Form of Term Deposits (Detail) Sheet http://universalbiosensors.com/taxonomy/role/DisclosureRestrictedCashRestrictedCashMaintainedByTheCompanyInTheFormOfTermDeposits Restricted Cash - Restricted Cash Maintained by the Company in the Form of Term Deposits (Detail) Details 36 false false R37.htm 138 - Disclosure - Restricted Cash - Restricted Cash Maintained by the Company in the Form of Term Deposits (Parenthetical) (Detail) Sheet http://universalbiosensors.com/taxonomy/role/DisclosureRestrictedCashRestrictedCashMaintainedByTheCompanyInTheFormOfTermDepositsParenthetical Restricted Cash - Restricted Cash Maintained by the Company in the Form of Term Deposits (Parenthetical) (Detail) Details 37 false false R38.htm 139 - Disclosure - Restricted Cash - Additional Information (Detail) Sheet http://universalbiosensors.com/taxonomy/role/DisclosureRestrictedCashAdditionalInformation Restricted Cash - Additional Information (Detail) Details 38 false false All Reports Book All Reports ubi-20180930.xml ubi-20180930.xsd ubi-20180930_cal.xml ubi-20180930_def.xml ubi-20180930_lab.xml ubi-20180930_pre.xml http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/us-gaap/2018-01-31 true true ZIP 55 0001193125-18-311190-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-18-311190-xbrl.zip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

S6@E 6<'.28V'W"Z,%^*^0.&)?( E1G8^QK"6 M'22%.:PDNU3$!HT?<(0I"KF1[L^"*& QO]#J"6?9 JRZVI90<)]+O N)LK\ MO'().P=+\K7Q$I;=='LG 6U7W")VBB>$9DH$] =F%R_ 65@_03'2Q0A4O/#( MH29H?:#O,;]\4X%XESW:XR#0F0G:*KQ5I>U0GK)-/Z]62]DZ_L3$)F3* MOUH14Q2W03LLO(7(*PBNEK%")1ANZ03DTXF3HI<*=7DKQT=R4H21QM?4Q2YT2%;LM6K7&BZ>2I MJ=3"^5>P*/S$B^^2^1P8)O5V%*4LGLE,*">3C??,.(WIXF1^D-3; MJIX8VB%_G4PJ,F29),*AR'+ON&JJM=97#YC)(P].GB9LB'TE/J1(_WU-XZW? M+U)D K\F!M1N=3B9'=R(!74^O9.YPK4ALCQ]0!HZ<$Y<]P\ -O-Q3/@F0I<=K$(%D]6]?X MKES^L?+BV>K#@*62-QC$W <1H1@Q?([3_U^\9($W^&/*'ZJ^A0%,7QI6Y>OL MEPC;F3,K^>,&B32K-6P@N"04=%R4YH=ZY=>$OVZ.PO0]=2FD1DU8R;C) MR+B.[D"XKB>5U/ZZ9P0,*UO*,JG,CE&TT-8P)YT\MF@@0[A2T/76^"3-= A M?$O7;E-\L@:L7 F;O4X_)D,/C R*FSY_U* !2U?>>AC[8L--8EB9 &S0@G6$ M_,#2M8@5L(L73+V *WF/5D)-ZQDCQDO!TY>6-19%DLM"B=WPSK+8JE1 MZN1M@LVM[NKVE$K'*]*2NKX'OQ4W#.P+5U./&GHN2J[4V95.7N*V)7\:^!6* MK XW9Y7&,UR1GZ6=Z^3UZ-O!UVYH.'F5^G;\4)GF3B:<;\<*TUT4-W/3M^-- MLUTT16[%J^:0P?ZZD_EDVW&E9@]!D7'VJ@7%;'-/D8KVA7'&;*O&S>OJVN;5 MVG:JDR\MM,T5W;:LDT>E=J5\]!D5VYW[L).!Q]??D+!$V+0.+*Y@$GC<;TU'"<;WAH0!?X? >0"55ZPL M7:\B^K_D>=!3[(N3J.)8,D\3IT^:)(?ZFK8NC.GZ>]E+ F[1\T?0R#1 83.F MJRM:Q?,;H9^YP4(\S)H!TM2T?"AW79RDS]!IAM+)"),Q<-V8.QE+,D:NTYG; MA8[<6+R6I0J?C5G)ZE]S'<4A%_WKQ#65;*A1_7./ABA*5:Q@"$/RC"(/7Q)Z M3I*'>)*$ZT36@&K4AMTW\0R&3/^B9U54G5PJ&C.AF8PH%I%NG]9JJDM7GR=R MR8G1'BAU"LF0@;RG&^P@F^E6^P<*1=D(?@%2',)2RA;(PB$+E\CG6RD>@0)_ M57?E,K'*0EEC%'E)8G"'SXCZ MS,7!39.CV/6$+P6>&$CT,B87R)ORT2.1.#*Z?J)5[-AW[-;+]-(@]95^9G6[ M=I>G>J\3M+SXE!D9_G^3]):<;?BP36_N8JWT!U9R]>>"O0>#;8 M\/IL=)OMP=^#(A%9#&!8_9D$OBB^#S%MC<0O=(SV,"':HO +':%.#XXKX[*J MFMMCJJSEKG'D"[PM7$&SGMSC#;A0UZ+=^WN:&-.F-REO9:\Z&76SRL;VC+ M MHWL=9'X#Q;8[Z9:\=^?4'5_=Y&]K=JTB"]9AJ3=_PCG/$\Z/A-U# MWT)64+1@^?E*<=LO]J\(BFX2RA($DXN\OW262"F8VG1(P;-V&;M84Z*9_*OJ%!Y 5SK@[Y4]/C M9V(P!,9-=1SS+9ZA@.M0?D<\ T7/Z=X>O[S9%L3V-T3%!O8E"NBO*$QPL7A( M)%17VJK%)%-*^;WES6>FDT:CC@6F*ZN;QS9EVKYL_U8YXZ3#JX18-X6=/$]9 M-Z!&1I5;-_5O84%41'WKEPQE]/4I-S3E@06SFUL;)(FVBR#NC>_Z\8>_2YH/TW1"O78R[& MPEK38QWT!%<6JZZY6I](C-F89/==HW#Y)B3[Q!UV?#W)KNTBD=6SPFHZ?TD0 MC3$-%\O?2JP=0]>GH&8_=Y/V[-:OX@AF-\G4GA;M.(O-:,^_BW2&QW+O]/617RF+@B !Q+ ( % '5B:2TR,#$X,#DS,%]D968N>&UL M[5U;<^.XE7Y/5?Z#UWG95*W;?9E+NFLZ*5FV>[QEMQQ;/9/LRQ1-0A(S%*F MI-O*K]\#D!1("0!!"A1 MJIFW+:$R_D.0>#<\=/?7I;!R3/"L1^%'T_?O'I] M>H)"-_+\AQ?'-S^K>__O$//_W7V=G)Y?7CR3]<%"#L).ADZKQ$ M8;1K#^?G7KU]?>;/8C5ZYT?(<&CJA MZSO!68SPL^^B^/SD[*P8_Y>,D@\G/[QZ^^[5#Z5O'J(T]#Z__A_Y=;1:HW]^2(Y^6_WSZ3QCR>7 M41BB($#KD^N"JO\YN;T=OSH9!<') VDZ\:'CZQS^<9(T_O,1^IUS?OW[\_I]^66P,=7K)I7B;K^_/LRZQU['^(Z9RWD4M9J0#G1-B" M_'56-#LC'YV]>7OV[LVKE]@[_2N9\"<@!S4XHQ1^2]0I]/(W]Y2I I_EG M"XQF'T_3)_^,/,_7[]^])MW_=!FYZ1*%P!?O*DS\9'T3SB*\I$2?GI!AOSS< M;*A/0Y^L:2=X\J,8A7&$8[KXDGS!GI,.Y](QS_L&-KLETD!\/I!&TAX7 M 'H1!1[07 ?1U_@F]'R, MW$0#F-TQ]R7XTH_=((I3C"ZD N\I^=IP#%AP+.G?O0#*![X:WO//D!K+_#@=^9]]# B0CL M8'D9!M"*;[-7+"B >C@TU5!Q\"XSC=+DB6T]\'>$)_>T3AJ;Q#7S3 M7K333L?!]XDD&_R4$<2."!O]!'A&< !P]H/*% M^H "$%*\:?0%]O(8?J-B%QSTU=8C#(]P3H69F/1T:9\+Z%Z,?2B>'@R/@5TM MP3XAA"Z;T5<'>_&A5ZRE]&HCZ'YN@?%-%E/86W'CDOWX(XDXV;3:=1U(HRCK\#^^#I- MX.\[!WY2*>0F3!#H)4FA)-X[:_IV?PF]C/-.N(YOHW ^17CYB%SH[-U&3GB? MXCB%)SN-QO")GXSF&-%]08.Z=$!B>\GBJAFE3_S6:P#B0>A*A:^90!^47QU, MQ;Z.@,B'U[FQ%B$0^2!T0?&ATV1V'5A4Y!]BHWIV E@6\$&UEX[]5@,5 MW3&E_->=XX<)_(^\B_5T@?*WZR:$WT$A6$YFY!V[1"MB5-5P2NLCQ4+V:-X@ M.Z*K*\9U)KO43[(OI ?H^-OG*$'Q--KX$3;VX/@S.9D0B(4KXKDD@E-;6(WF MZ!C5WU,0!Q$.UIOO2BR=HI?D B3DW_4C59RW8_2Y<9QI"/J![D[1,2:IYM/A M$U6FN+"9WPIN3/>RPVN:O6-.B)1?=L1T^&HTF;QC/ERBI^0@F$43 MF<'7U1*73]A5^H!6=>_[R/&]S3CIT2 ],1>S#47CFH9F3!DDS MZG:['X;6: FJ8VM2L]Y=4DIG.%NBY1/"#)B"6Q,-6:(97#84>\=]EGY*A= 8N9@2<5RDX!%6*,8F6TU>UM-A ;!YP M1V>%>6&;KDQ&G6 1YKX$=.G.G/B)KM\T/IL[SNJ<'%WG*$CBXA-ZF)V]?I/' MZOXI__BWT3+"B?^?W.B9,RV @1.[^!D!5Z?. MBP""K(<9!#',_BF*O!C.\,<\:OXQ"CPA &$'N^@?/<4)=DB\9T,C)0F2I[XJZO#[!J97YP;E@ZGJ900(+W?5S,Z^ [%(3$S1>.3@DWK-[A(O( M$M\5$,MO:PW5)'#-#]($U2U\U=XV(,MI4D12M#9!^2<4(NP$P,>1MX2CFS Q M@2T^#V02(*CK900)AAWC'D8H+D)VD$D94M>0'"UC1$J M0:7)7D#R.A%2Y*M"W-XJZFO.[_I^)M!,"I*H,D9DT4T /Q>%N+U5U-<\B_I^ M1M'4OL.\ED8H%B0"TA,7SE5_'HY3C%'HEKUDP&_Z5Y#GKOTKS3;0&A6\H\EL MXUM!V#VQF0#%28+]IS0A-OAIE!FB6C!(9=0>ZR5UN]>>276VC@\,5-CLPC65;UV7N MYA$1RFG;*VI_>]N0WAW/*WQ0#/^8KE;P@G.MTX)6)EX2:1JCX*61]S¯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end